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Abstract 
With more than 400 million cases a year, Campylobacter jejuni is a leading cause of 
gastroenteritis worldwide. Farm animals, such as cattle poultry and pigs, act as an 
environmental reservoir for the bacterium. Although many studies have been 
performed in order to gain a better understanding of the disease and of the 
environmental lifestyle of the bacterium, much remains to be uncovered. This work 
aim is to understand the role of the plasmid pTet in the bacterium lifestyle: firstly, 
analysing which genes are most represented in the plasmids pTet-like and if a 
difference in genetic set-up between pTet-like plasmids exists and what is its 
significance. Secondly, assessing whether the plasmids pTet-like are associated with 
bacterial characteristics, such as virulence, survival or adaptation to different 
ecological niches.  
Several plasmids have previously been described in C. jejuni: pTet is the most 
widely distributed plasmid amongst the known C. jejuni strains. This plasmid is about 
45 kilobase pairs (kbp) long and 52 open reading frames (ORFs) can be identified in 
its sequence. Before this work, it was known to be found in about 20 % of C. jejuni 
strains, to encode for tetracycline resistance and a conjugative type four secretion 
system and to possess several genes involved in horizontal gene transfer. However, 
the function of this plasmid and the reason why it is so broadly distributed remain 
largely unknown. 
In the first part of this work I screened 4005 genome sequenced strains of C. 
jejuni for the presence of the plasmid. I investigated the genetic make-up of the pTet 
plasmids, sequencing 19 new plasmids and described a core and accessory sets of 
genes in this plasmid family using an innovative approach. I found that the core set 
of genes is predicted to be primarily involved with the maintenance and transfer of 
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the plasmid pTet, while the accessory set of genes are predicted to be associated 
with metabolism, resistance and regulative functions. 
In the second part of this work I produced 11 C. jejuni deletion mutants. I tested 
these mutants for phenotypes associated with environmental survival and host 
invasion such as biofilm production, motility and infection of the model organism 
Galleria mellonella larvae. Two of the mutant strains showed an impaired phenotype, 
when compared to the wild type strain, in motility, production of biofilm and growth in 
MH broth. 
These findings indicate that the pTet plasmids have functions other than 
tetracycline resistance and horizontal transfer, and may help to explain the broad 
distribution of the plasmids in C. jejuni. 
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Campylobacter spp. are the causal agents of Campylobacter enteritis, one of 
the leading causes of gastroenteritis worldwide (Tauxe, 2002). It is responsible for 
400-500 million cases of food poisoning worldwide every year (Ruiz-Palacios, 2007), 
with an estimated cost for England and Wales of £583 million in 2008, according to 
the “UK Research and Innovation Strategy for Campylobacter in the food chain, 
Global Food Security, 2010-2015”. Overall, more than 80% of human cases are 
caused by C. jejuni, around 10% by C. coli, and the remainder by other 
Campylobacter species (e.g. foetus). The infectious dose of Campylobacter is as low 
as 500-800 cells (Young et al., 2007), and common symptoms of the disease include 
diarrhoea containing mucus and blood, acute abdominal pain, vomit, fever, and 
general malaise (Van Vliet and Ketley, 2001). The disease is usually limited to 5-8 
days, but immunocompromised patients can face a persistent infection and, in rare 
cases, death (less than 1 case in 1000). Complications following Campylobacter 
infections are rare but involve severe pancreatitis (De bois, 1989) and in some cases 
Guillain-Barrè syndrome (Nachamkin et al., 1998). 
From a phenotypical and morphological point of view, the bacterium is a Gram 
negative, spirally curved rod, and it was described for the first time by Jones et al., in 
1931. The Campylobacter species are fastidious microorganisms, obligate micro-
aerophilic and thermophilic, requiring complex growth media, a concentration of 
oxygen between 3% and 15%, and a temperature range for growth of 34 to 44 °C 
with an optimum of 42 °C. Moreover, they are unable to ferment carbohydrates. 
Campylobacter cells usually show a polar flagellum at both ends and are highly 
motile (Van Vliet and Ketley 2001). 
The genomes of Campylobacter species are relatively small compared to other 
enteric pathogens species such as Escherichia or Salmonella, between 1.6 and 1.7 
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megabases, and the G+C content is relatively low, around 30% (Van Vliet and 
Ketley, 2001; Chang and Taylor, 1990). The first complete genome sequencing of C. 
jejuni was published in 2000 (Parkhill et al., 2000); since then several studies have 
aimed to understand the genome diversity of the bacterial species, particularly the 
differences between isolates deriving from different sources. In a DNA microarray 
study performed on 111 C. jejuni isolates, six genes belonging to a flagellin 
glycosylation locus were associated with the chicken-associated strains (Champion 
et al., 2005); that study also suggested that the majority of C. jejuni infection may 
derive from non-livestock sources. A comparison amongst C. jejuni isolated from wild 
birds and farm animals highlighted that the genetic differences between strains 
isolated from wild birds was much more pronounced than the strains isolated from a 
“domestic” environment, concluding that the flow between different hosts makes the 
differentiation of strains isolated from farm animals much more complex (Sheppard 
et al., 2011). However, the same study associated the presence of different 
Sequence Types (STs, identified by MLST) in different hosts. In 2013, the first 
genome-wide association study (GWAS) was performed on Campylobacter, and it 
identified a statistical association between genes for the biosynthesis of vitamin B5 
and strains isolated from cattle, rather than other farm animals (Sheppard et al., 
2013). Finally, a study on the entire Campylobacter genus, published in 2014 by 
Iraola et al., showed how different Campylobacter species have emerged, originating 
from a putative non-pathogenic Campylobacter ancestor, which acquired a repertoire 
of virulence genes from other bacteria in order to establish success in a different 
ecological niche (Iraola et al., 2014, Figure 1.1). 
Farm animals such as cattle, poultry, and pigs are known to act as reservoirs 
for Campylobacter species (Young et al., 2007), and they are adapted to survive in 
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the intestine and cecum of warm-blooded birds. Cross contamination usually occurs 
during the slaughter process, during which faeces containing bacteria can 
contaminate meat. Consumption of inadequately cooked meat is one of the major 
sources of infection (Van Vliet and Ketley, 2001). Other sources include infected 
milk, other animal products, and water, where the bacterium has been shown to be 
capable of surviving for prolonged periods of time (Rollins and Colwell, 1986; Sacks 
et al., 1986; Young et al., 2007; Figure 1.2). 
During the infection process, Campylobacter makes use of several different 
virulence factors: an ability to move into the mucus layer that protects the intestine is 
crucial for colonisation (Szymanski et al., 1995), as well as binding and invasion of 
the host cell with the aid of membrane oligo and poly-saccharides (Woolbridge and 
Ketley, 1997) and producing toxins once the invasion is started (Wassenaar, 1997). 
For a successful colonisation, the bacterium needs to acquire iron from the host 
(Field, 1986; Pickett, 1992); it needs to be able to deal with the oxidative stress 
during transmission or the host response, as well as heat stresses due to the 
different temperatures found in human or avian guts (37°C and 42°C respectively) or 
during the transmission via water, meat, or milk. 
This introduction will firstly describe the virulence and survival factors identified 
in C. jejuni to date. Secondly, it will describe the plasmids identified in C. jejuni, with 
a particular focus on pTet and pVir plasmids. Finally, it details the aims and research 
questions of this thesis.  
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Figure 1.1 - Main evolutionary processes in Campylobacter. Species are highlighted in blue 
(genital), red (gastrointestinal), and green (oral). Adapted from Iraola et al., 2014. 
 
 
Figure 1.2 - The sources and outcomes of C. jejuni infection. Environmental reservoirs that can 
lead to human infection by C. jejuni. It colonizes the chicken gastrointestinal tract and is passed 
between chicks through the faecal-oral route. C. jejuni can be associate with protozoans in water 
supplies, such as freshwater amoebae. Unpasteurised milk, contaminated meat and drinking water 
are the primary routes of infection. In humans, C. jejuni invades the intestinal epithelial layer 
provoking inflammation and diarrhoea. Adapted from Young et al., 2007. 
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1.1 Virulence and survival factors of C. jejuni 
1.1.1 Motility 
C. jejuni motility is mediated by flagella composed of a major and a minor 
flagellin (FlaA and FlaB, Nuijten et al., 1990), which are highly conserved proteins 
and about 59 kDa in size. Campylobacter species are characterised by a fast, 
darting motility, and flagella have been recognised as essential elements for 
pathogenesis, as early studies observed the necessity of functional motility for the 
successful colonisation of the intestine of animals and humans (Guerry, 2007; 
Morooka et al., 1985; Nachamkin et al., 1993, Pavlovskis et al., 1991). Gene 
expression for flaA and flaB is mediated by a σ28 and a σ54 dependent promoter 
respectively (Hendrixson and DiRita, 2003). Mutations in the gene flaA result in the 
production of a truncated flagellum, while the mutation of the gene flaB does not 
appear to have an effect on motility and the flagellar structure (Wassenaar et al., 
1991). A kinase/response regulator system FlgSR has been highlighted as a primary 
regulatory system controlling the expression of flagella in C. jejuni (Hendrixson and 
DiRita, 2003). Moreover, flagellar gene expression and biosynthesis are also 
controlled by a phase variation process (Lertsethtakarn et al., 2011). Phase variation 
is a fast and reversible genetic process used by bacteria to influence quickly the 
transcription or the translation of a gene in response to a rapid change in the 
environment (van der Woude and Bäumler, 2004). For instance, a mechanism of 
phase variation may involve the modification of the number of nucleotide repeats in a 
homopolymer present in the gene or in the promoter, leading to a frameshift of the 
coding sequence or in the loss of the promoter “power”. An example of phase 
variation regulation in the flagellar genes has been identified in C. jejuni, where 
25 
 
homopolymeric tracts of adenines or thymines are present in the genes flaS and 
flaR, and whose alteration truncate the genes (Hendrixson, 2006; Hendrixson, 2008). 
Flagella in C. jejuni have been shown to be involved in a series of cellular 
functions important for host colonisation and environment survival other than motility. 
For instance, a functional flagellar system is essential for the export of secreted 
proteins important in pathogenesis (Konkel et al., 2004), such as the Cia proteins, a 
protein family typical of Campylobacter essential for successful cell invasion but that 
is not secreted in the absence of flagellar structures (Konkel et al., 1999). Moreover, 
flagellar structure is considered essential for autoagglutination (AGG), a process 
shared by many bacterial species in which cells aggregate as micro-colonies: it is 
often shown as an initiation of biofilm formation (Misawa et al, 2000; Cole et al., 
2004; Moreira et al., 2006; Golden and Acheson, 2002). AAG has been associated 
with virulence in C. jejuni strain 81-176 (Misawa et al, 2000). 
 
1.1.2 Biofilm formation 
C. jejuni has a strict microaerobic requirement, and it is typically hard to grow 
and maintain in a laboratory environment. It is susceptible to a variety of 
environmental stresses, food processing procedures, and antimicrobial treatments. 
Nevertheless, it is extremely widespread in the environment and its high incidence is 
nearly solely due to the ingestion of living bacterial cells, as the human-to-human 
transmission is extremely rare. This fact was described as the “Campylobacter 
paradox” in 1999 (Solomon and Hoover, 1999). A hypothesis commonly embraced is 
that the bacterium makes the best use of biofilm structures to survive in its known 
environmental reservoirs (Buswell et al., 1998). Biofilms are described as bacterial 
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populations adherent to each other and/or to surfaces and interfaces (Costerton et 
al., 1995). 
C. jejuni was shown to form three different types of biofilms in a monoculture: 
attached to a glass surface, as a pellicle at the gas-liquid interface in a stationary 
culture, and as free cellular aggregate in a liquid culture (Joshua et al., 2006). C. 
jejuni 11168 was shown to be more resistant to environmental stresses when in a 
biofilm structure, compared to planktonic bacteria (Joshua et al., 2006). 
Environmental and growth conditions influence the ability of C. jejuni to form biofilm: 
high nutrient conditions and high osmolarity were shown to inhibit biofilm formation 
(Reeser et al., 2007), while growth in atmospheric oxygen concentration enhanced 
the formation of biofilm (Reuter et al., 2010). Both flagellar structure and quorum 
sensing play a central role in biofilm formation in C. jejuni, as mutants in flaAB and 
luxS genes are significantly impaired during biofilm formation (Reeser et al., 2007). 
 
1.1.3 Adhesion and invasion of host cells 
Campylobacter’s ability to adhere to gastrointestinal epithelial cells is essential 
for host colonisation. The process is believed to be mediated by a series of adhesins 
(Jin et al., 2001). The adhesion to a glycoprotein commonly found in the membrane 
of epithelial cells also triggers the signalling cascade, mediated by Rac1 and Cdc24 
GTPases, which promotes the internalisation of the bacterial cells (Monteville et al., 
2003). The protein CadF mediates the adhesion of Campylobacter cells to 
fibronectin. It is reported that an inactivation of cadF gene results in a reduced ability 
of Campylobacter to adhere and invade INT407 human intestinal epithelial cells 
(Krause-Gruszczynska et al., 2007). Other factors controlling the ability of C. jejuni 
cells to adhere to epithelial cells include: the Campylobacter adhesion protein A 
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(CapA), mutation of which results in a reduced capacity to adhere to and invade 
human epithelial cells (Flanagan et al., 2009); FlpA, a protein that is capable of 
binding fibronectin and is thought to work together with CadF in the 
adhesion/invasion process (Konkel et al., 2010; Eucker and Konkel, 2012); and JlpA, 
which has been suggested to be involved in the adhesion to Hep-2 cells via mutation 
analysis (Jin et al., 2003). The plasmid pVir has also been reported to be involved in 
adherence and invasion, as mutants lacking in the virB11 gene of the type four 
secretion system encoded by that plasmid are significantly impaired both in 
adherence and invasion of INT 407 cells (Bacon et al., 2000). However, subsequent 
studies failed to replicate the result (Dasti et al., 2010).  
The surface lipooligopolysaccharide (LOS) molecule of C. jejuni is composed of 
a lipid A and a core oligosaccharide and was reported to serve in immune system 
evasion, host cells adhesion, and invasion. The sialylation of the LOS is a marker of 
increased invasive potential and immune system evasion (Guerry et al., 2000; 
Louwen et al., 2008). The oligosaccharide encapsulation of C. jejuni cells also 
facilitates adherence and evasion from the host immune system (Karlyshev et al., 
2000). Non-capsulated mutants (e.g. mutants in the gene that encodes the capsular 
polysaccharide transport protein, KspM) show reduced ability to colonise INT407 
human cells and poultry intestine (Bacon et al., 2001, Jones et al., 2004 and Bachtiar 
et al., 2007). Other glycosylation systems encoded by the bacterial genome, such as 
the N-linked glycosylation system encoded by the pgl locus, facilitate the immune 
system evasion and promote the ability to colonise the chicken gastrointestinal tract 
(Hendrixson and DiRita, 2004, Jones et al., 2004 and Karlyshev et al., 2004). 
Finally, flagellar structures are known to be involved in host invasion. The 
secretion function of the flagellar apparatus is pivotal in this process (Poly and 
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Guerry 2008). Mutants in fla and flg genes are reported to have impaired ability to 
invade host cells (Konkel et al., 2004). The products of cia genes (CiaB, CiaC and 
CiaI) are delivered in to the cytoplasm of the host cells through the flagellar secretion 
system, and they have an essential role in the invasion process and in the 
intracellular survival of the bacterium (Konkel et al., 2004; Konkel et al., 1999; 
Buelow et al., 2011). 
 
1.1.4 Production of toxins 
When colonising the host, Campylobacter is known to produce an array of 
different toxins (McFarland and Neill, 1992 and Schulze et al., 1998). The cytolethal 
distending toxin (CDT), produced by many Gram-negative bacteria, is the only one 
studied in detail (Pickett and Whitehouse, 1999). The CDT is composed of three 
subunits (encoded by cdtA, cdtB and cdtC genes).  It is delivered in the cytosol of the 
host’s cell where it blocks the kinase cascade essential for the transition to the G2 
phase of mitosis (Asakura et al., 2008, Pickett and Whitehouse, 1999). The LOS 
molecules trigger complications of the Campylobacter infection, such as the 
neuropathies Guillain–Barré and Miller–Fisher Syndrome (Nachamkin et al., 2002). 
 
1.1.5 Iron uptake 
The significance of iron acquisition and metabolism for successful microbial 
proliferation is displayed by numerous examples from medical and environmental 
biology (Ratledge and Dover, 2000). Campylobacter acquires iron from the host in 
order to establish a successful infection, and it is believed that in order to achieve 
this, the bacterium uses siderophores derived from the existing microflora (Palayada 
et al., 2004). Mutants in genes encoding for membrane ferric receptors (Cj0178, cfrA 
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and cfrB) and ferric uptake regulator (fur gene) all show impaired chicken 
colonisation ability (Palayada et al., 2004; Xu et al, 2010), and in the chicken cecum 
an increased transcription level of a gene encoding for a haemoglobin membrane 
receptor have been observed (Woodall et al., 2005).  
 
1.1.6 Resistance to antibiotics and other antimicrobial molecules  
Campylobacter is able to resist to a high concentration of bile salts, heavy 
metals, and several other antimicrobial agents thanks to the Campylobacter multi 
efflux pump (CME, Lin et al., 2002). This pump is made of a periplasmic protein, an 
efflux transporter, and an outer membrane protein, encoded by the cmeABC operon 
(Lin et al., 2002). The expression of the operon cmeABC is controlled by the 
transcriptional repressor CmeR: mutation of the cmeR gene impaires the ability of C. 
jejuni to colonise chicken (Guo et al., 2008).   
Antibiotic resistance in Campylobacter is often mediated by specific resistance 
genes located on the chromosome or on plasmids (Pratt and Korolik, 2004; 
Chatzipanagiotou et al., 2005; Zhao et al., 2015). The problem of antibiotic 
resistance is recognised as an issue of public health importance (Takkinen et al., 
2003; McDermott et al., 2002; Moore et al., 2006). Even if Campylobacter infections 
are usually self-limiting and not treated in humans other than replacing lost fluids and 
electrolytes, antibiotic treatments are used to treat severe systemic infections of 
Campylobacter spp. (Aarestrup and Engberg, 2001). Several studies comparing the 
evolution of antibiotic resistance in time observed a rapid development of multiple 
antibiotic resistant strains both in the food chain and in clinical isolates (Gallay et al., 
2003; Mazi et al., 2008; Smole Možina et al., 2009). For decades, animal production 
was supplemented with an indiscriminate use of antibiotics (EFSA, 2008; Igimi et al., 
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2008), and strong evidence supports the conclusion that this led to the emergence 
and spread of antibiotic resistance in Campylobacter spp. (Takkinen et al., 2003; 
Smith and Fratamico, 2010). In countries or farming areas where the use of 
antibiotics in animal production is limited, the incidence of antibiotics-resistant 
Campylobacter strains is reduced (Norström et al., 2007; Luangtongkum et al., 
2006). It was shown that a limitation in the use of antimicrobial drugs in animals food 
resulted in a reduction in fluoroquinolone resistance (Gallay et al., 2007, Han et al., 
2009): however Nelson et al., in 2007 and Price et al., 2007, have suggested that the 
antimicrobial resistance may persist in the environment for long periods of time.  
 
1.1.7 Stress tolerance and response  
Following the first genome sequence of C. jejuni (Parkhill et al., 2000), it was 
observed that a homologue of the E. coli stationary phase regulator rpoS (which 
encode for the global regulator RpoS, σ38) was missing, and therefore a range of 
adaptive responses present in other bacteria are not present in C. jejuni. Other σ 
factors are present (FliA - σ28, RpoN - σ54 and RpoD - σ70), and they control the 
expression of a range of genes involved in survival and virulence (Jagannathan et 
al., 2001, Carrillo et al., 2004, Wösten et al., 2004 and Hendrixson, 2006). The 
protein SpoT is extremely important in controlling the cell response in conditions of 
stress: SpoT is an effector molecule of stringent response (guanosine 
tetraphosphate - ppGpp) that negatively regulates the rRNA transcription (acting with 
the RNA polymerase-associated protein DksA), in favour of amino acid biosynthesis, 
moving cellular resources away from growth and division, in favour of cellular 
survival (Gaynor et al., 2005). spoT deletion impairs oxygen tolerance, stationary 
phase survival, invasion and survival in intestinal cells, as well as rifampicin 
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resistance (Gaynor et al., 2005). The DksA protein has also been shown to be 
involved in iron metabolism and host cell invasion (Yun et al., 2008) 
Campylobacter is primarily a foodborne pathogen, and in the food chain it 
encounters several stresses that it must endure. In the slaughter chain, 
Campylobacter is subject to desiccation and oxidative stress. The bacterium is 
particularly sensitive to desiccation and its presence is reduced considerably on beef 
and pork meat, which are air chilled in the slaughtering process, while its survival is 
facilitated on chicken where the wet surface is maintained by the water chilling 
procedure (Humphrey et al., 1995; Oosterom et al., 1983; Butzler and Oosterom, 
1991). C. jejuni endures different oxygen conditions during its life cycle: aerobic 
respiration and the immune response of hosts generate ROSs (Reactive oxygen 
species) including the superoxide anion, hydrogen peroxide, and the hydroxyl radical 
(Atack and Kelly, 2009). Campylobacter can respond to high concentration of ROS 
with an antioxidant defence system which includes a wide range of enzymes and 
antioxidant molecules, such as glutathione, catalase (KatA, Atack and Kelly, 2009), 
alkyl hydroperoxide reductase (AhpC), and other peroxiredoxins (such as the thiol 
peroxidise Tpx and bacterioferritin co-migratory protein Bcp), cytochrome c 
peroxidises (Cj0358 and Cj0020c; Atack and Kelly, 2009), and superoxide dismutase 
(Storz and Imlay, 1999): the increased production of these enzymes results in a 
long-term aerobic adaptation (Klancnik et al., 2009). Superoxide dismutase proteins 
(SOD) protect against the superoxide anions (Palyada et al., 2009): the survival of 
mutants deficient in SOD is impaired in the avian gut due to the presence of oxygen 
and to the ability to invade Caco-2 cells (Garénaux et al., 2008; Purdy et al., 1999; 
Mihaljevic et al., 2007). 
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In the food chain, Campylobacter also encounter starvation stress and may be 
exposed to low pH. In these conditions, the Campylobacter cells were shown to 
enter a viable but non-culturable state (VBNC; Chaveerach et al., 2003), which is 
characterised by a decreased metabolic activity and change in cell shape and in 
which the cell survives to stress condition for a prolonged period of time (Moore, 
2001; Mihaljevic et al., 2007). Different abilities of retaining virulence were observed 
in Campylobacter VBNC cells, with studies that demonstrated a loss of virulence and 
others that demonstrated maintenance of the ability to invade intestinal epithelial 
cells (Byrne et al., 2007, Klancnik et al., 2009). 
C. jejuni has an optimum growth temperature of 41.5 C to 42 C, and cells are 
unable to grow below 30 C (Bolton, 2015). During food processing, bacterial cells 
are exposed to temperatures close to 4 C and over 42 C. Chilled cells remain 
viable and metabolically active for a prolonged period (Hazeleger et al., 1998 and 
Dasti et al., 2010). A heat-shock response has been previously described in 
Campylobacter (Konkel et al., 1998). The differential expression of at least 15 genes, 
the majority of which encode for regulative proteins, was reported when comparing 
the growth of C. jejuni at 37 C and 42 C—the body temperatures of humans and 
chickens respectively (Zhang et al., 2009). The RacR/RacS signal transduction 
system may also have a role in growth at 42 C: it regulates a heat-shock protein 
DnaJ. Mutation of the gene encoding DnaJ severely impairs the ability to colonise 
chicken (Hermans et al., 2011; Konkel et al., 2004; Ziprin et al., 2001). 
C. jejuni is characterised by an extremely high frequency of intragenomic 
recombination, which can alter its phenotypic characteristics, virulence, and ability to 
survive in an array of different adverse conditions (Park, 2005; Ridley et al., 2008). 
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1.2 Plasmids 
Plasmids are circular or linear DNA molecules able to replicate autonomously in 
the host cell (Jackson et al., 2011). They appear in all domains of life and they carry 
genes encoding for a broad variety of functions (Lipps, 2008; Sundin 2007). In 
bacteria, plasmids can spread horizontally via conjugation, and indeed plasmid 
transfer has been defined as “sex in bacteria” (Lederberg and Tatum, 1953). 
Plasmids play a central role in the adaptation and evolution of prokaryotes (Gogarten 
and Townsend, 2005).  
Classically plasmids were classified into five major groups, according to the 
functions they encode (Hardy, 1986):  
(i) Fertility plasmids (F-plasmids) encode tra genes and are responsible for 
the expression of pili and conjugation structures. These plasmids are 
capable of horizontal transfer between bacteria via conjugation. Many of 
the tra genes are necessary for the formation of the conjugative pili, and 
almost all of the genes necessary for the DNA transfer are organised 
into a single operon. Further genes carried by an F-plasmid may encode 
for production of bacteriocins or metabolism of carbon compounds. 
Resistance to antibiotics may be included in an F-plasmid (Hardy, 1986); 
(ii) Resistance plasmids (R-plasmids) possess genes conferring antibiotic 
resistance. The most notable and studied examples are tetracycline and 
chloramphenicol, but genes encoding for many different antibiotic 
resistances are known to be carried by plasmids. More broadly, the 
resistance properties conferred by these plasmids also extend to 
different classes of compounds such as heavy metals or other toxic 
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molecules, to physical stresses such as ultraviolet radiations, and to 
bacteriophages (Martins et al, 2001; Thomas and Summers 2008); 
(iii) Col plasmids encode for genes responsible for the synthesis of 
bacteriocins. These proteins are toxic to other bacteria and are used to 
gain competitive advantage in a particular ecological niche (Hardy 1986); 
(iv) Degradative plasmids carry those genes that confer on the bacterium the 
ability to metabolise particular substances. The classes of compounds 
that are degraded this way are various and may be simple 
carbohydrates, complex carbon compounds (such as toluene, nicotine or 
camphor), halogenated carbon compounds, or proteins (Schmidt et al., 
2001); 
(v) Virulence plasmids carry “virulence genes”, usually organised in 
contiguous pathogenicity islands. Virulence plasmids may encode for: 
toxins, such as the enterotoxins of Escherichia coli or the neurotoxins of 
Clostridium tetani; cell structures to evade host defence, such as the 
capsule of Bacillus anthracis or colonisation antigens produced by E. 
coli; or effectors to obtain nutrients from the host, such as an iron 
transport system in E. coli (Thomas and Summers 2008; Hardy 1986). 
Another way of classifying plasmids is through incompatibility groups. 
Replication of plasmids is typically controlled by a region of about 1-3 kbp, known as 
the basic replicon (which is the shortest piece of the plasmid able to replicate 
independently). The replicon contains the functions to initiate and control the 
replication (such as the origin of replication), and the inhibitor of the replication 
(which can be, a protein factor derived from a bacteriophage or an RNA antisense) 
which controls the copy number per cell typical of every plasmid (Del Solar and 
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Espinoza, 2002). If two plasmids share the same replicon, they belong to the same 
incompatibility group. Two plasmids belonging to different incompatibility groups 
replicate independently and use independent mechanism to control their copy 
number; two plasmids that belong to the same incompatibility group share those 
mechanisms, and also share the total number of copy per cells. They are selected 
randomly for replication inside the cell and, consequently, one of the incompatible 
plasmids ends up diluted in subsequent generations, leaving only one of the two 
incompatible plasmids in the bacterial cell (Bergquist, 1987, Ebersbach et al., 2005). 
Some plasmids can have more than one replicon and belong to more than one 
incompatibility group. Closely related plasmids tend to be incompatible, while 
plasmids that are distantly related tend to be compatible (Thomas, 2014). 
Several examples of the roles of plasmids in pathogenic bacteria have been 
published over the last 50 years. Plant pathogenic bacteria, for example, are known 
often to rely on several different plasmids to express secretion systems for delivering 
toxin molecules, which are themselves expressed by several different plasmids 
(Vivian et al., 2001). For example, Erwinia arboicola pv. gypsophilae carries the hrp 
genes for the expression of the Type Three Secretion System on a large pPATH 
plasmid of about 150 kbp in size (Nizan et al., 1997), and in Ralstonia solanacearum 
these genes are on a pVir megaplasmid (Boucher et al., 1986). Other functions 
specifically linked to virulence are often encoded by plasmids in phytopathogenic 
bacteria. One example is the production of phytohormones, such as the indole-3-
acetic acid (IAA), to affect plant cell proliferation at the infection site (Vivian et al., 
2001); several pathovars of Pseudomonas savastanoi and Erwinia herbicola are 
known to carry the iaaLMH genes for IAA biosynthesis on plasmids, such as pIAA1 
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and pIAA2 (P. savastanoi, Yamada et al., 1986) and pPATH (E. herbicola, Clark et 
al., 1993).   
What is described for plant pathogenic bacteria is also true of bacterial 
pathogens of animals and humans. Clostridium perfringens is known to be 
dependent on its toxin-producing ability to be successful in causing disease (Li et al, 
2013): many of the 16 known toxins produced by the bacterium are encoded by large 
plasmids (Miyamoto et al., 2006, Lepp et al., 2010). In Salmonella enterica, a group 
of virulence plasmids with size between 50 and 100 kbp was described (Rychlik et 
al., 2006). These plasmids are all characterised by the presence of the genes 
spvRABCD (Salmonella virulence genes), which are known to be involved in the 
systemic phase of Salmonella infection and with the destabilisation of the 
macrophage cells cytoskeleton (Wallis et al., 1995; Lesnick et al., 2001). Moreover, 
different serovars of S. enterica carry plasmids encoding additional virulence-
associated genes, such as rck (resistance to complement killing, Hackett et al., 
1987) for evading the host immune response, or pef (plasmid encoding fimbriae, 
Baumler et al., 1996), which contributes to S. typhimurium adhesion to the mouse 
intestinal epithelium. 
Plasmids encode for a variety of genes and functions, but there is an important 
similarity among them that is represented by the circumstances in which they are 
useful for the bacterial host (Top et al., 2000). A part of each plasmid is devoted to 
the “survival” of the plasmid itself: it encodes for genes that promote replication, 
maintenance, and conjugation of the plasmid—genes typically referred as “plasmid-
selfish” or backbone genes. A part of the plasmid encodes for genes that are useful 
to the bacterial host only in particular circumstances, such as genes for the 
adaptation to a particular environment or genes used to initiate the disease in a host. 
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These genes are concentrated on plasmids as a direct consequence of natural 
selection: in conditions where a gene would increase the host fitness, the plasmid 
localisation would allow a more rapid spread both through horizontal and vertical 
transmission, and the chromosomal localisation would be more limited in conferring 
advantage only through vertical transmission (Top et al., 2000; Thomas and 
Summers, 2008). 
 
1.3 Plasmids in C. jejuni 
The presence of several different plasmids is reported in Campylobacter spp. 
With the exception of a few cases—describing the presence and the structure of 
small “cryptic plasmids” in regional isolates (Jesse et al., 2006, Hiett et al., 2013), 
and a handful of mega-plasmids between 80 and 150 kbp long (Gunther et al., 2016; 
Marasini and Fakir, 2016)—the literature is focused on two plasmids: namely, pTet 
and pVir (Bacon et al., 2000, Bacon et al., 2002, Batchelor et al., 2004). 
Both plasmids were described for the first time in C. jejuni strain 81-176, one of 
the better-characterised strains of C. jejuni. It was isolated from a diarrheal outbreak 
associated with raw-milk consumption (Korlath et al., 1985); it causes inflammatory 
diarrhoea in humans and disease in several different experimental models (Black et 
al., 1988, Russell et al., 1989). Moreover, C. jejuni strain 81-176 invades INT407 
cells at particularly high levels (Hu et al., 1999, Bacon et al., 2000, Bacon et al., 
2001, Yao et al., 1994). 
 
1.3.1 Plasmid pVir 
The plasmid pVir in the strain 81-176 is reported to be 37,468 bp and to encode 
for 54 putative ORFs. The G+C content of this plasmid is 26% and just the 83% of 
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the pVir sequence is predicted to be coding: both these numbers are significantly 
lower than the chromosome of the strain 81-176 where the G+C content is 30.6% 
and the percentage of coding sequence is 94% (Bacon et al., 2002). 
Amongst the 54 ORFs, the function of the vast majority is unknown. Seven 
genes encode for homologues of the type four secretion system (T4SS): namely 
virB4, virB7, virB8, virB9, virB10, virB11, virD4, all grouped in an 8.9 kbp long area. 
The type four secretion system is described in a wide number of bacterial species, 
and it is involved in a variety of bacterial cell processes including conjugation, DNA 
translocation, and protein delivery (Bacon et al., 2000). 
Although, the plasmid pVir alone does not confer the ability to invade INT407 
cells, as demonstrated transforming the strain NCTC 11168 with the full pVir 
plasmid, some of the pVir genes were associated with the bacterium’s ability to move 
and to invade INT407 cells in vitro (Bacon et al., 2002). Mutants in genes encoding 
for putative components of the T4SS, genes with orthologs in H. pylori or genes that 
appear to be unique to the campylobacter plasmid show a broad range of reduction 
in INT407 cells invasion, which is difficult to interpret and might be due to the 
presence of a second plasmid in the strain where this mutant were produced (strain 
81-176, which harbours both plasmid pTet and pVir; Bacon et al., 2002). A second 
study tried to replicate this result unsuccessfully (Dasti et al., 2010). More recently, 
the presence of the plasmid pVir was also associated with symptoms in humans: 
patients infected with pVir positive strains were more likely to develop bloody 
diarrhoea (Tracz et al., 2005). However, the distribution of pVir amongst clinical 
strains is exceptionally low; a survey conducted in 2005 reported that just one strain 
out of 56 isolated from symptomatic humans harbouring plasmids contains a plasmid 
related to pVir (Schmidt-Ott et al., 2005). This observation challenges this plasmid 
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family’s importance in C. jejuni virulence, as in that case a higher occurrence in 
clinical isolates would be expected (Friis et al., 2007). Moreover, the higher virulence 
of the strains carrying the pVir plasmid have been strongly criticised: Louwen et al. in 
2006 was not able to replicate the results shown by shown by Tracz et al., in 2005. 
 
1.3.2 Plasmid pTet 
A second plasmid was identified in the strain 81-176 of C. jejuni (Bacon et al., 
2000). Plasmid pTet in the strain 81-176 was determined to be 45,205 bp, 
approximately 20% bigger than pVir, and to encode 49 ORFs. The G+C content in 
this case is 29.1%, just slightly lower than the G+C content of the chromosome. It is 
worth noting that a region with a particularly high G+C content of 40.4% incorporates 
the tetracycline resistance gene, suggesting the incorporation of this region via 
horizontal transfer (Batchelor et al., 2004). 
The majority of the predicted ORFs are of unknown function. A tetO gene was 
identified, known to confer tetracycline resistance, along with several hypothetical 
proteins sharing a high percent of similarity with Helicobacter pylori. Ten genes 
grouped in a region that spans across approximately 12.6 kbp encode for proteins 
that share a high amino acid similarity with the T4SS of some Brucella and 
Actinobacillus species. These genes were demonstrated to be involved in the 
conjugative transfer of the plasmid pTet, which happens to a rate of 10-4 to 10-6 
transconjugant per donor cell (Batchelor et al., 2004). Genes homologous to T4SS 
have been designated as Campylobacter mating genes (cmg). Other genes with 
predicted known functions encoded by pTet are tolA (uptake of colicin A), a 
virulence-associated protein (sharing 42% similarity with Helicobacter pilori), and 
several genes involved in conjugative transfer (Batchelor et al., 2004). 
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Schmidt-Ott et al., in 2005 reported the presence of several pTet-like plasmids, 
which were identified as the “mob” family, in a study involving 56 patients with bloody 
or watery diarrohea. This class of conjugative plasmids conferring tetracycline 
resistance was identified in 53% of clinical isolates. Their study shows that it is 
impossible to cure the “mob” plasmid, except from 81-176 (the only described strain 
that carries both pTet and pVir), in which the loss of pTet does not affect the ability to 
invade INT407 cells. Finally, the study reveals the lack of correlation between 
invasiveness and the presence of a “mob” plasmid: if a strain that is unable to invade 
caco-2 cells acquires a “mob” plasmid, it does not acquire the ability of invading 
caco-2 cells, and vice versa. 
In both the studies described here (Batchelor et al., 2004; Schmidt-Ott et al., 
2005), the conjugation experiments involved the use of DNAse in the suspension 
buffers used to harvest the bacteria and on the plates used to induce the 
conjugation. The DNAse was used to avoid the possibility of natural transformation 
of extracellular DNA. 
A second survey published in 2007 by Friis et al., where sequences of the 
plasmids were considered, reported the high diffusion of pTet-like plasmid across 29 
tetracycline-resistance or plasmid-carrying strains isolated in various geographical 
areas and sources (UK, U.S., and Canada; both from environmental and clinical 
samples). The conservation and diffusion of the pTet-like sequence and structure is 
remarkable: 83% of the analysed strains showed the presence of a full or partial set 
of genes previously annotated on the plasmid pTet. Moreover, not one of the 
analysed strains in that case showed the presence of pVir. The study concludes that 
pTet-like plasmids are stably maintained and broadly diffused in Campylobacter, and 
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its prevalence in Campylobacter population may play an important role in genomic 
plasticity of Campylobacter (De friis et al., 2007). 
Other than the plasmid pTet isolated from the strain 81-176 in 2000 (Bacon et 
al., 2000), plasmids similar to pTet have been isolated from several strains: one 
example is the strain ICDCCJ07001, harbouring the plasmid 07001_pTet (Zhang et 
al., 2010). A mosaic structure is described for the plasmid 07001_pTet in this work. It 
shares homology with 26 pTet genes, and harbours 5 unique genes previously 
undescribed in the plasmid (Zhang et al., 2010). Mosaic plasmids share homologous 
genes with a variety of different bacteria (Batchelor et al., 2004), and it is suggested 
that their origin derives from the acquisition of different DNA regions from different 
bacterial sources (Boyd et al., 1996). 
 
1.3.3 Other plasmids in C. jejuni: small “cryptic” plasmids and mega-
plasmids. 
Plasmids are defined as cryptic when they do not have genes that appear to 
contribute to the phenotype of the bacterium. They are typically very small, carry the 
genes necessary for self-repliction and can be used to develop plasmid vectors for 
molecular manipulation of specific bacteria (Burian et al., 1997; Li-Zhao et al., 2011). 
The first plasmid defined as “cryptic” in C. jejuni was a short plasmid described 
in 2000 (Luo and Zhang): the plasmid pCJ01 was 3212 bp long and exhibited a G+C 
content of 33.5%. Four open reading frames were identified in that plasmid, and at 
the time they did not show any sequence similarity with any of the C. jejuni DNA 
sequences available. It was suggested that the plasmid could be used to produce 
molecular tools for the genetic manipulation of C. jejuni, such as E. coli - C. jejuni 
shuttle vectors (Luo and Zhang, 2000). In 2003, a second cryptic plasmid was 
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described in a human clinical isolate of C. jejuni: the plasmid pCJ419 (Alfredson and 
Korolik, 2003). It was 4013 bp long and its G+C content was lower pCJ01 and the 
chromosome of C. jejuni with a value of 27.1%. The plasmid pCJ419 encodes for 
four ORFs, three of which involved with DNA mobilization and replication (encoding 
for the proteins Mob, RepA and RepB), and one sharing a higly similar with a gene of 
unknown function (cjp23).  The plasmid was successfully used to produce a shuttle 
vector pGU0202 for the transformation of both C. jejuni and E. coli. In 2006, the 
small plasmid pCJ1170 was described in C. jejuni: it was 4381 bp long and shared a 
99.7% identity with the plasmid pCC2228 isolated in the same study from 
Campylobacter coli. It was identified to be a member of a novel incompatibility group 
for plasmids in Campylobacter and it was suggested that it could be used as a base 
for the design of vectors to modify plasmid carrying strains of C. jejuni and C. coli 
(Miller et al., 2006). Finally, in 2013 the plasmid pTIW94, purified from C. jejuni 
strains isolated from wild birds in south-east US, was described (Hiett et al., 2013). It 
was a short 3860 bp plasmid, encoding for five ORFs: two ORFs encoded for the 
repA and repB found on the pCC2228 plasmid (100% and 95%, similarity 
respectively), one ORF was 99% similar to a mob gene identified in C. coli 
previously, and the remaining two ORFs exhibited no significant similarity with any of 
the other DNA sequences present in the GenBank database (Hiett et al., 2013). 
With the advent of novel sequencing and assembly techniques, it has been 
possible to identify new and larger plasmids in several strains of C. jejuni. The first 
example is an 81.08 kbp plasmid isolated from a clinical bacterial isolate from 1994 
showing an increased resistance to UV light (strain RM3194; Gunther et al., 2016). 
The plasmid was identified to encode for an UV-damage repair protein (ImpB), a full 
type six secretion system, and several proteins involved in the plasmid conjugation. 
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These characteristics could associate the plasmid with an increased fitness in 
particular environmental conditions and in virulence. Secondly, a plasmid conferring 
kanamycin and tetracycline resistance was described in the strain 11601MD isolated 
from turkey. The length of this plasmid and its organization showed a high similarity 
with the plasmid pTet (44095 bp, Crespo et al., 2016), and it is the first fully 
characterized plasmid carrying both the gene tet(O) and the aphA-3 for resistance to 
tetracycline and kanamycin. The presence of the two resistance genes on plasmids 
was first shown in 2004 in a partially characterized plasmid (Nirdnoy et al., 2004) and 
further addressed in the study from Zhao et al., 2016, concluding that the two 
resistance genes are often associated. Finally, the genome sequencing of the strains 
OD267 and WP2202, isolated from the liver and the digestive tract of chicken, 
showed the presence of two mega-plasmids and a shorter plasmid (pCJDM67S) 
homologous to pVir (Marasini and Fakir, 2016). In particular, the plasmid 
pCJDM202L, isolated from the strain WP2202 is 119 kbp, encodes for 116 genes 
and has a C+G content of about 30.5%. It was shown to encode for tetracycline 
resistance, cag pathogenicity island genes, and the 14 core genes for the 
conjugative type four secretion system. 
 
1.4 Conclusions  
The plasmid pTet in C. jejuni is found in a high number of known strains. If 
studies that take into account the tetracycline resistance phenotype are considered, 
the number of strains potentially carrying this phenotypic marker is even higher. 
Although the plasmid is reported to be extremely common, the function of the 
majority of pTet genes is unknown. Moreover, no study of the genetic differences 
between the several plasmids similar to pTet that were isolated and sequenced was 
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ever performed. In fact, the literature about the plasmid pTet stops in 2007, when de 
Friis et al., were surprised by the level of conservation and maintenance of the 
plasmids pTet-pCC31-like in Campylobacter populations (pCC31 is a pTet 
homologous plasmid isolated from C. coli, Batchelor et al., 2004). The question that 
concludes that paper from 2007 is indeed still open: why and how are plasmids pTet-
like maintained? 
In this study, a thorough genomic survey for the presence of the plasmid pTet 
will be performed: several plasmid markers were tested via PCR and phenotypically 
on the strain collection of the University of Exeter’s Molecular Pathogenesis 
Laboratory for the identification of new strains carrying the plasmid pTet; the 
presence of the plasmid pTet was assessed in all the C. jejuni strains sequenced to 
date (June 2016). The pTet-like plasmid pan-genome was defined in order to identify 
the genes present in all the pTet-like plasmids sequenced. The core and the 
accessory genes for the pTet-like plasmids will be defined and the putative function 
of those genes will be defined. In order to study the function of a set of genes found 
with different frequencies on the pTet-like plasmids, a series of 12 mutants will be 
produced in one model strain of C. jejuni and their phenotypic difference when 
compared to the wild-type will be tested in conditions linked to environmental survival 
or virulence. 
 
1.5 Aim of this work 
The aim of this work is to identify the importance of the plasmid pTet-like for C. 
jejuni: which genes are most represented in the plasmids pTet-like, whether a 
difference in genetic set-up between pTet-like plasmids exists, and what is its 
significance? This study will also assess whether or not the plasmids pTet-like are 
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associated with different functions, such as virulence, survival in particular 
conditions, or adaptation to different ecological niches.  
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Chapter 2 - Materials and Methods 
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2.1 Bacterial Strains and Growth conditions 
Campylobacter jejuni strains used in this study are held by the Campylobacter 
collection of the Molecular Pathogenesis Laboratory of University of Exeter (Geoffrey 
Pope building, laboratory 401, EX44QD) and have been isolated in Asia (Thailand 
and Pakistan), USA, and the United Kingdom. Table S1 lists the bacterial strains 
present in this collection. Bacterial strains were stored in glycerol (30% v/v) or on 
CryobankTM ceramic beads (Copan Diagnostics Inc.) and maintained at -80 C. 
Campylobacter strains were cultured under the conditions detailed here or in the 
relevant section of Materials and Methods for each phenotypic analysis. All strains 
were streaked in Colombia Blood Agar plates (CBA, CBA Base from Oxoid LTD, 
supplemented with 5% defribinated horse blood, Oxoid LTD) with selective growth 
supplement for Campylobacter (CBA+, Skirrow’s supplement, Oxoid LTD) and 
incubated for 48 hours in microaerophilic conditions at 42 C (83% Nitrogen, 8% 
Oxygen, 5% Carbon Dioxide). Colonies were selected from these plates and 
streaked on CBA+ and incubated at 37 C for 24 hours in microaerophilic conditions 
prior to any further analysis. For counting colony forming units (CFU), C. jejuni 
strains were spotted on Mueller-Hinton agar (MHA, Oxoid LTD) and the protocol 
described by Miles et al. 1938 was followed. For growth in liquid media, C. jejuni was 
grown on a CBA+ plate as a lawn for 24 hours in microaerophilic conditions at 37 C; 
bacterial cells were removed from this plate with a sterile swab to produce a starter 
bacterial suspension in phosphate buffered saline (PBS, pH 7.4, Sigma-Aldrich®) or 
Mueller-Hinton broth (MHB, Oxoid LTD); the starter suspension was used to 
inoculate a volume of MHB to a starting concentration of bacterial cells equal to 0.1 
optical density measured as turbidity at 600 nm with a spectrophotometer in a 
cuvette with 1 cm of path length, OD600.  
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E. coli strain TOP 10 was used for molecular cloning experiments. E. coli was 
stored in glycerol (30% v/v) or on CryobankTM ceramic beads (Copan Diagnostics 
Inc.) and maintained at -80 C. For growing E. coli, plates of lysogeny broth agar 
(LBA) or lysogeny broth (LB) were used, with incubation at 37 C and supplementary 
antibiotics as required. 
 
2.2 DNA amplification (PCR) 
All primers in this study were designed with Clone Manager Professional 9 
software (Scientific & Educational Software) and synthesised by Eurofins Scientific 
UK (HPSF quality, scale 0.01). Standard DNA amplification was achieved using the 
following protocol, unless otherwise stated: Buffer Q5 (1X, New England Biolabs); 
MgCl2 (2mM to 4 mM if needed); dNTP (0.2 µM, Thermo Fisher Scientific Inc.), 
primers (1 µM each); Q5® High-Fidelity DNA Polymerase (0.5 units/reaction, New 
England Biolabs); bacterial DNA (10-50 ng); MilliQ water to a final volume of 25 µl. 
For each reaction in this work Q5® High-Fidelity DNA Polymerase (New England 
Biolabs) was used, with the following thermal protocol, unless otherwise stated. 
1- 30 seconds at 95 C; 
2- 10 seconds at 95 C; 
3- 10 seconds at 45-55 C, according to the annealing temperature 
of each primer pair; 
4- 30 seconds per kbp at 72 C;  
5- Repeat steps 2 to 4 for 35 times; 
6- 2 minutes at 72 C; 
7- Hold 12 C.  
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Primers used in this work are listed in the appropriate result section. PCR 
products were run electrophoretically on agarose gels for analysis. Unless otherwise 
stated, 1% w/v agarose/Tris-EDTA acetate buffer (TAE) gels were made according 
to manufacturer’s directions (Hi-Res standard agarose, ATGC bioproducts). Agarose 
gels were stained with 5 µL/100 ml of Midori green advanced gel stain (Geneflow 
LTD.) according to manufacturer’s directions. 20 µL of PCR product was mixed with 
an appropriate volume of DNA Gel Loading Dye (6X, Thermo Fisher Scientific Inc.) 
and loaded on agarose gel for electrophoresis with a current of 120 V/cm for a 
variable time (between 30 and 90 minutes, according to the specific experiment 
requirements). Gel imaging was performed with a Gel Doc™ Gel Documentation 
System (BioRad Laboratories, inc.). 
 
2.3 DNA purification 
Whole genome bacterial DNA extractions were performed using Wizard® 
Genomic DNA Purification Kit (Promega corp.), according to the specific protocol for 
Gram negative bacteria. When DNA was extracted from C. jejuni, cells were lawn-
plated on a CBA+ plate and left to grow overnight at 37 C. Cells were then 
dislodged with a swab and suspended in 5 ml of PBS buffer. 1 ml of bacterial 
suspension was used for DNA extraction (OD600 between 0.8 and 1.5). 
For the PCR reactions described in Chapter 3.1, a thermal lysis extraction 
method was used. One colony of C. jejuni was picked from a plate with a sterile 
toothpick and suspended in 100 µL of MilliQ water. The bacterial suspension was 
incubated at 95 C for 15 minutes in a thermal block, then transferred immediately to 
ice for 5 minutes. The suspension was then spun for 5 minutes at 13000 x g. 2 µl of 
supernatant were used for template in a PCR reaction. 
50 
 
DNA was extracted from agarose gels following electrophoresis using the 
GeneJET® Gel Extraction Kit (Thermo Fisher Scientific Inc.), according to the 
manufacturer’s directions. 
Plasmid DNA was extracted from E. coli using GeneJET® Plasmid Miniprep Kit 
(Thermo Fisher Scientific Inc.), according to the manufacturer’s directions.  
Plasmid DNA was extracted from C. jejuni strains using either QIAprep® Spin 
Miniprep Kit (QIAGEN Ltd.) following the protocol modification advised for low copy-
number plasmids; QIAGEN Plasmid Midi Kit (QIAGEN Ltd.); or PureYield™ Plasmid 
Midiprep System (Promega corp.), according to the manufacturer’s directions. For 
QIAprep® Spin Miniprep Kit and PureYield™ Plasmid Midiprep System, C. jejuni 
was grown overnight in 25 ml of MHB at 37 C, and 10 ml or 25 ml of bacterial 
culture was used as starting material. For QIAGEN Plasmid Midi Kit 50 ml of 
bacterial culture was used. 
DNA was stored at 4 C up to 1 month or at -20 C for longer periods. DNA 
concentration was evaluated with Nanodrop® ND-1000 (Thermo Fisher Scientific 
Inc.), when needed, according to the manufacturer’s directions. 
 
2.4 Molecular cloning 
DNA digestions were performed using restriction enzymes from Thermo Fisher 
Scientific, following manufacturer’s directions. 
pGEM®-T Easy Vector System II (Promega corp.) was used to build the 
constructs used for Campylobacter mutagenesis, according to the TA cloning 
protocol described by the manufacturer. A-tailing of PCR products was used to 
achieve successful cloning according to pGEM®-T Easy Vector System II protocol, 
using Qiagen HotstarTaq® (QIAGEN Ltd.). 
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Ligation of digested DNA fragments in digested vectors was achieved using 
DNA ligase (Thermo Fisher Scientific Inc.), following manufacturer’s directions for 
sticky-ends. Insert to vector molar ratio was calculated to be between 3:1 and 5:1 
using the following formula: 
 
[(mass of vector (ng)* size of insert (bp))/size of vector (bp)] * insert/vector molar 
ratio = mass of insert (ng) 
 
Ligations were transformed in 100 µL of chemically competent E. coli strain 
TOP 10. 
 
2.5 Transformation of chemically competent E. coli 
Chemically competent E. coli strain TOP 10 was produced according to the 
following protocol: 5 ml of E. coli were grown overnight in LB medium at 37 C; 1 ml 
of overnight growth was used to inoculate 99 ml of LB medium; once the bacterial 
culture reached to 0.4-0.5 OD600 (1.5-3 hours), the culture was divided in two 50 ml 
falcon tubes and centrifuged at 4000 x g for 10 minutes at 4 C; the supernatant was 
removed and the pellet was resuspended in 10 ml of ice cold 0.1 M CaCl2; the 
bacterial suspension was incubated on ice for 1 hour, then centrifuged at 4000 x g 
for 10 minutes at 4 C; the supernatant was discarded and the bacterial cell pellet 
was carefully resuspended in 1.5 ml of ice-cold 0.085 M CaCl2 and 15% (v/v) 
glycerol. After 1 hour’s incubation in ice, the chemically competent cells were divided 
in 100 µL aliquots and used immediately for chemical transformation of DNA or 
snap-frozen in liquid nitrogen and stored at -80 C for up to 1 month. 
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100 µL of chemically competent E. coli strain TOP 10 were inoculated with 10 
µL of ligation mixture or 100 ng of purified plasmid DNA in an Eppendorf tube and 
incubated on ice for 1 hour. The mixture was incubated for 2 minutes at 42 C, and 
transferred immediately back to ice for at least 2 minutes. 1 ml of LB broth was 
added to the Eppendorf tube and incubated in orbital agitation (200 rpm) at 37 C for 
1 hour, in order to allow antibiotic resistance to be expressed. After 1 hour, 100 µL of 
bacterial suspension was spread-plated on an appropriate LBA plate supplemented 
with antibiotic/screening molecule. 
LB plates supplemented with ampicillin (100 µL/ml), IPTG (0.1 mM) and X-gal 
(40 µL/ml) (LB-Amp100-IPTG-Xgal) or kanamycin (50 µL/ml) (LB-Kan50) were used 
when required. 
 
2.6 Transformation of electro-competent C. jejuni 
The protocol for producing electro-competent C. jejuni and subsequent 
electroporation was described previously (Van Vliet et al., 1998). Briefly, C. jejuni 
was grown overnight as lawns on 4 CBA+ plates at 37 C; cells were collected with a 
sterile swab and resuspended in 2 ml of MH broth. Bacterial cells were then washed 
three times: the suspension was centrifuged for 5 minutes at 10000 x g at 4C, the 
supernatant was removed, and cells were carefully resuspended in 2 ml of ice-cold 
wash buffer (272 mM sucrose, 15% glycerol). Finally, the cells were resuspended in 
1 ml of ice-cold wash buffer, and 100 µL aliquots were used immediately for 
electroporation. 
For electroporation 1 to 5 µg of plasmid DNA in a maximum volume of 10 µL 
was added to 100 µL of electro-competent cells. The mixture was added to an ice-
cold electroporation cuvette (1mm chamber, BioRad Laboratories, Inc.) and 
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electroporated immediately at 2.5 kV, 200 Ω, 25 pF; 1 ml of MHB was used to wash 
the cuvette and transfer the bacteria to a fresh 1.5 ml Eppendorf tube; the bacterial 
suspension was spotted on an MHA plate (15 µL spots), and the plate was incubated 
at 37 C in microaerophilic conditions for 5 hours. Cells were then collected with a 
sterile swab and resuspended in 500 µl of MHB. The bacterial suspension was then 
centrifuged at 6000 x g for 2 minutes, the supernatant was removed and the cell 
pellet was resuspended in 100 µl of MHB, which was then spread on the appropriate 
MHA screening plate. 
MHA plates supplemented with kanamycin (50 µL/ml) (MHA-Kan50) or 
chloramphenicol (30 μg/ml) (MHA-Cat30) were used in this study. 
 
2.7 Mutagenesis of Campylobacter jejuni  
The allelic exchange protocol used in this work to produce mutant strains of 
Campylobacter jejuni is detailed in Chapter 5. Section 5.4 lists the primers and the 
plasmid vectors used for the mutant design. 
 
2.8 Complementation of the mutant strains of Campylobacter jejuni 
Mutant strains of Campylobacter jejuni that exhibited a phenotypic difference 
when compared to the wild-type have been complemented re-introducing the deleted 
gene in the genome of the mutant strain. 
The strategy used here to complement the mutant strains was described by 
Jervis et al. in 2015. The study describes the construction of a series of suicide 
expression vectors for the integration of heterologous genes in C. jejuni: these 
plasmids were named pCJC1, pCJC2, pCJC3, and pCJC4. Each one of them was 
characterised by a selection marker conferring resistance to chloramphenicol and 
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one of four different promoters followed by the cloning site for the gene of interest. 
These elements were included between the upstream and the downstream sections 
of the gene Cj0223, promoting the integration of the chloramphenicol resistance and 
the gene of interest in the chromosome of the target strain. To produce the 
complemented mutants in this study, the vector pCJC1 was used (kindly provided by 
Dr Dennis Linton), in which the expression of the integrated gene is controlled by the 
chloramphenicol (cat) cassette promoter. The section of the plasmid vector showing 
the orientation of the cat cassette, the Cj0023 genes and the position of the 
restriction sites is represented in Figure 2.1. 
The genes of interest for each complementation (namely hicA, unk9 and tetO) 
were amplified using the primers described in Table 6.3. Each primer pair introduced 
a restriction site for the enzymes NcoI and NheI in the 5’ and the 3’ end of the PCR 
product respectively, which were then used to clone the gene in the 
complementation vector, as described in paragraph 2.4. The vectors built for the 
complementation of the mutants are reported in Table 6.4.  
Each mutant was transformed with the corresponding complementation vector 
via electroporation (DhicA with pCJC1::hicA, Dunk9 with pCJC1::unk9, DtetO with 
pCJC1::tetO), as described in paragraph 2.5. Successful transformation was 
screened via chloramphenicol resistance, using MHA plates supplemented with 30 
μg/ml of chloramphenicol. 
The correct insertion of each wild-type gene was checked by PCR, using 
primers annealing outside the integration site. Sanger sequencing confirmed the 
correct integration in each of the complemented mutants. 
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Figure 2.1 – Representation of the integration cassette of pCJC1 expression vector. The vector 
is described in Jervis et al. in 2015. A fragment of Cj0223 was cloned into pUC18 and interrupted by a 
chloramphenicol resistance cassette (cat). NheI and NcoI restriction sites were used to insert the 
gene to be complemented in each mutant.  
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2.9 Phenotypic assays 
2.9.1 Growth curves 
A starter culture of C. jejuni was prepared suspending bacteria grown as a lawn 
on CBA+ plates overnight in MHB. The initial OD600 of 25 ml of MHB was adjusted to 
0.1. Bacterial cultures (in a volume of 25 ml) were incubated for up to 30 hours in 
microaerophilic conditions at 37 C. 
Bacterial growth was monitored removing 1 ml for OD600 measurement when 
needed. 
 
2.9.2 Identification of minimal inhibitory concentration (MIC) of antibiotics 
MIC of different antibiotics for the different C. jejuni strains used in this study 
was calculated in different ways, as described in different results sections (e.g. 
Chapter 3.1 or 6.5). 
MIC of tetracycline was calculated on plate, preparing MH plates supplemented 
with increasing quantity of tetracycline (1, 2, 5, 10, 20 and 50 mg/l). The tested strain 
of C. jejuni was streaked on the different plates and after 48 hours incubation in 
microaerophilic conditions at 37 C, the lowest concentration of antibiotic inhibiting 
the growth of the bacterium was identified as MIC. 
MIC for tetracycline was also calculated with etest® strips (bioMérieux UK Ltd.), 
following manufacturer specifications for C. jejuni (a bacterial suspension of 2 
McFarland standards in PBS was spread onto MHA plates supplemented with 5% of 
horse blood and incubated in microaerophilic conditions for 48 hours). 
MIC for phenotypic testing of mutants (Chapter 6.5) was calculated with the 
plate dilution method, unless otherwise stated. Each well of the first column of a 96-
wells plate was filled with 100 µl of MHB supplemented with twice the maximum 
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concentration of antibiotic to be tested. All remaining wells were filled with 50 µL of 
MHB. Each column was subsequently topped-up with 50 µL of MHB with antibiotic 
taken from the previous column (e.g.: column 2 was topped-up with 50 µL of 
MHB+antibiotic taken from column 1, then column 3 was topped-up with 50 µL of 
MHB+antibiotic taken from column 2 and so on). In the final layout, each well was 
filled with 50 µL of MHB and each column had half the concentration of the antibiotic 
present in the previous column. The last column was filled with MHB and no 
antibiotic (growth positive control). C. jejuni grown overnight as a lawn on CBA+ in 
microaerophilic conditions at 37 C were suspended in MHB, and the cell density 
was adjusted to 0.2 OD600. Each well was topped-up with 50 µL of bacterial 
suspension and the plate was finally incubated for 24 hours in microaerophilic 
conditions at 37 C. The last row was filled with fresh MHB instead of bacterial 
suspension as a sterility control. After incubation, the OD600 in each well was 
measured with a microplate reader (Infinite® 200 PRO, Tecan Trading AG, 
Switzerland): the lowest concentration of antibiotic inhibiting the growth of the 
bacterium was identified as MIC. 
 
2.9.3 Acid tolerance assay 
Strains of C. jejuni were harvested in MHB after growing overnight on CBA+ 
plates at 37 C in microaerophilic condition. 
MHB pH 3, pH 4 or pH 5 (Test conditions) were prepared by adding drops of 2 
M HCl to normal MHB (pH 7.2, Control condition). Bacteria were collected with a 
sterile swab from solid medium and resuspended in MH broth. Each suspension was 
diluted to an OD600 of 0.5, then bacteria were centrifuged @ 13000 x g for 5 minutes 
and resuspended in standard MHA or in modified MHA at pH 3. 
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Suspensions were incubated for 20 minutes at 37°C in microaerophilic 
conditions, centrifuged for 5 minutes at 13000 x g, resuspended in standard MH 
medium, and serially diluted to 10-7 of the control test. 
Finally, three 10 µl drops for each dilution point were spotted on separate MHA 
plate. After 48 hours of incubation in microaerophilic condition at 37 °C colonies in 
each spot showing a number of colonies between 30 and 300 were counted. 
Acid tolerance data are here expressed in % of survival following the equation 
% survival = (test cfu/ml ÷ control cfu/ml) x100. 
 
2.9.4 Survival in Synthetic Gastric Fluid (SGF) 
The SGF test medium was produced according to the “Simulated stomach 
environment” as reported by Beumer et al., 1992. The pH of the SGF was buffered to 
4.0, as shown by Reid et al, 2008. The SGF was composed of proteose-peptone (8.3 
g/liter), D-Glc (3.5 g/liter), NaCl (2.05 g/liter), KH2PO4 (0.6 g/liter), CaCl2 (0.11 
g/liter), KCl (0.37 g/liter), bile (bovine; 0.05 g/liter), lysozyme (0.1 g/liter), and pepsin 
(13.3 mg/liter) (15). All of the components except the enzymes were dissolved in 
distilled water, the pH of the solution was adjusted to 4.0 with 1 M HCl, and the 
solution was filter sterilized and stored at 4 °C. Prior to its use, lysozyme and pepsin 
were added from fresh stock solutions. 
Bacterial suspensions to a concentration of 1.0 OD600 in PBS were prepared by 
collecting bacteria grown overnight as a lawn on CBA+ in microaerophilic conditions 
at 37 C with a sterile swab. 
1 ml of bacterial suspension in PBS was spun down and resuspended in 200 µl 
of sterile MilliQ water, then quickly transferred to 4.8 ml of SGF or MHB (Control 
condition). After 20 minutes, 3 hours or 6 hours of incubation at 37 °C in 
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microaerophilic conditions, 100 µL of bacterial suspension in SGF or MBH were 
transferred to a microtiter plate (96 wells) and serially diluted for cell counting. 
Cell counting and % survival was estimated as reported in “acid tolerance 
assay”. 
 
2.9.5 Motility assays 
The ability of C. jejuni to move in soft agar was evaluated following a 
modification of the protocol described in Reuter et al., 2013. 
Cells grown overnight on CBA+ in microaerophilic conditions at 37 °C as a 
lawn, were suspended in PBS with a sterile swab and cell concentration was 
adjusted to OD600 1.0. 5 µL of bacterial suspension was spotted onto each plate for 
testing the motility: two or three strains were tested at the same time on each plate. 
MH motility plates were prepared starting from MHB powder (Oxoid LTD.) and 
adding agarose (Agar n. 2 bacteriological, Lab M, Ltd.) separately to a final 
concentration of 0.4 % w/v. The quantity of MHB powder was also adjusted to half 
the advised quantity when needed.  
The two tests conditions were: MH plates with full quantity of nutrients (21 g/l of 
MHB powder) and 0.4% w/v agarose; MH plates with half quantity of nutrients (10.5 
g/l of MHB powder) and 0.4% w/v agarose.  
Media were autoclaved at 121 °C, 2 atm for 20 minutes and allowed to cool 
down to 50 °C before pouring in the petri dishes. Plates were incubated at room 
temperature for, at the least, over night before being inoculated. After inoculation, 
spots were left to dry on the bench for 30 minutes and plates were incubated in 
microaerophilic conditions at 37 °C upside-down (lid up); pictures were taken every 
24 hours. Measurements of the diameter of the bacterial movement area were 
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performed analysing each picture with imageJ software (version 1.48, 
https://imagej.nih.gov/ij/). 
 
2.9.6 Biofilm production 
MH plates with half quantity of nutrients (10.5 g/l of MHB powder) were 
prepared as described in “Motility Assay” section (2.7.5) with two adjustments: the 
quantity of agarose used was 0.8% w/v and before autoclaving 40 µg/ml of Congo 
red (Certified biological stain, Thermo Fisher Scientific Inc.) and 20 µg/ml of 
Coomassie Brilliant Blue G-250 (Thermo Fisher Scientific Inc.) were added to the 
medium. 
5 µL of bacterial suspension prepared as described in motility assay section 
(2.9.5) were spotted on each plate: two or three strains were tested at the same time 
on each plate. 
After inoculation, spots were left to dry on the bench for 30 minutes and plates 
were incubated in microaerophilic conditions at 37 °C for 48 hours upside-down. 
Plates were then incubated in aerobic conditions for 48 hours upside-down (lid up) 
and before observing the results of the test and taking pictures. 
 
2.9.7 Persister cells formation 
Persister cells were induced incubating a bacterial culture in MHB 
supplemented with a quantity of antibiotic up to 100 times the MIC. 1 ml of bacterial 
culture supplemented with the appropriate quantity of antibiotic was incubated for 24 
hours in microaerophilic conditions at 37 °C in a 12 wells plate (Corning Inc.), 
together with the appropriate controls (bacterial culture without antibiotic, 
uninoculated broth). 100 µL of bacterial suspension were transferred to a microtiter 
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plate for serial dilutions and the number of CFU per ml was enumerated as 
described in 2.1 (Miles et al., 1938). 
 
2.9.8 Survival in water 
Tap water was collected from Geoffrey Pope building (Exeter, EX4 4QD, lab. 
401), and autoclaved for 20 minutes at 121 °C, 2 atm. C. jejuni grown overnight as a 
lawn on CBA+ in microaerophilic conditions at 37 C were suspended in autoclaved 
tap water and cells concentration was adjusted to 0.5 OD600. 5 mL of bacterial 
suspension in water was incubated at 4 °C for 8 days. 100 µL samples were 
collected at the start of the experiment and after 8 days of incubation. Cell counting 
and % survival was estimated as reported in “acid tolerance assay”. 
 
2.9.9 Galleria mellonella larvae injection 
Larvae of G. mellonella TruLarvTM were provided by Biosystems Technology 
(biosystemstechnology.com). Larvae were maintained in plastic pots for up to 2 
weeks at 15 °C and were weighted before each experiment: only larvae with a body 
weight between 0.2 and 0.3 grams were challenged with C. jejuni. 
The injection of G. mellonella larvae was performed as reported by Champion 
et al., 2010, with the following adjustments. 
C. jejuni grown overnight as a lawn on CBA+ in microaerophilic conditions at 37 
°C were suspended in PBS buffer with a sterile swab; cell concentration was 
adjusted to 2.0 OD600. 10 µL of bacterial suspension was injected with the aid of a 
microsyringe (Hamilton) in the first right foreleg of the larvae. 10 larvae per strain 
were injected. Each experiment included 10 larvae injected with sterile PBS buffer 
and 10 non-injected control larvae. Larvae were incubated in microaerophilic 
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conditions at 37 °C for up to 48 hours in empty petri dishes, lined at the bottom with 
a disc of filter paper. 
 
2.10 Bioinformatics techniques and Genome sequencing  
2.10.1 Genome Sequencing 
All the strains analysed in this study, were sequenced using the in-house 
Illumina MiSeq facility available at the University of Exeter. 
Paired End Library preparation for each genome was carried out following the 
procedure reported in the Illumina protocols (Preparing Samples for Paired-End 
Sequencing, Rev. A, June 2008) on 1 to 5 µg of DNA, shearing the DNA to obtain a 
final length of <800 bp per fragment. 
Illumina MiSeq V3 reagent kit was used, allowing a read length of 300 bp per 
fragment in each paired read. 
 
2.10.2 Bioinformatics tools and analysis 
In this work, for the scripting and programming activity, the following 
programming languages were used: Perl (version 5.10.1, www.perl.org) with BioPerl 
module, when necessary (ver 1.0069, www.bioperl.org); R (version 3.3.0, R Core 
Team (2016), https://www.R-project.org/) and GNU/Linux Bash (under Ubuntu server 
environment, version 14.04). Scripts used in this work are available in the online 
supplementary material. 
 
2.10.3 Quality check and trimming of sequence reads 
In this study FastQC (version 0.10.0, 
www.bioinformatics.bbsrc.ac.uk/projects/fastqc/) package was used for the quality 
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check step of all the raw data. The report that FastQC outputs highlights the 
following: (i) Basic statistics, a report of the number, length, overall GC% and the 
sequencing pipeline used; (ii) Per base sequence quality; (iii) Per base quality score; 
(iv) Per base sequence content; (v) Per base GC content; (vi) Per sequence GC 
content; (vii) Per base N content; (viii) Sequence length distribution; (ix) Duplicate 
sequences; (x) Overrepresented sequences; (xi) Overrepresented k-mers. 
Fastq-mcf (from package ea-utils, version 1.1.2-537. Aronesky, 2013) software 
was used for the adaptors-removal process. It was run with the following options: (i) 
an adapter file, listing the overrepresented sequences in the input file; (ii) an initial 
sub-sampling of 100000 of reads; (iii) an average quality of 20 and the presence of 
more than 1% of N to discard a read; (iv) a minimum sequence length of 45 bp 
remaining after the cleaning; (v) Illumina PF filtering was enabled. Fastx_trimmer 
(from FASTX-toolkit package, version 0.0.7, http://hannonlab.cshl.edu/fastx_toolkit/) 
software was used to trim the beginning and/or the end of each read when a drop 
under 28 points in quality or a GC% bias was identified. After this, Fastq-mcf was run 
again with the only purpose of eliminating all the reads shorter than 35 bp, in order to 
avoid issues in the assembly phase due to the presence of too short reads. 
 
2.10.4 Genome assembly and annotation 
Once raw reads were cleaned and trimmed a series of software was used to 
produce a draft assembly. SPAdes genome assembler software (version 3.9, Nurk, 
Bankevich et al., 2013, http://bioinf.spbau.ru/SPAdes) was used to assemble each 
genome. This software is composed of a series of algorithms designed to apply the 
de Brujin graph to a shotgun sequencing composed of very short reads. Briefly, the 
de Brujin graph is preferred to classical and “greedy” assembly methods with very 
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short reads: it is based on the identity between a series of k-mers in which each read 
is fragmented and the sequence of the assembly is represented by a "path" that 
connects k-mers that differs by just one base (Miller et al., 2010).  
The optimisation of the k-mer length was performed as advised by the software 
developers for assembly of reads obtained with Illumina MiSeq technology: after 
running the assembler with a k-mer value of 21, 33, 55, 77, 99 and 127, the output 
was processed via QUAST software (version 3.2, http://bioinf.spbau.ru/quast, 
Gurevich et al., 2013) which estimates all the typical statistics for the assembled 
genomes, such as N50, longest contig, total length of the assembly. 
Genome assemblies obtained this way have been annotated with RAST 
(“Rapid Annotation using Subsystem Technology”, Overbeek et al., 2014, 
http://rast.nmpdr.org/), an automated on-line pipeline for the annotation of bacterial 
genomes. 
Final genome assembly graphs were visualised with Bandage software (Wick, 
et al., 2015); the software displays the connections between contigs that are not 
present in the final assembly file, also highlighting circular contigs that can be 
identified as plasmids. 
 
2.10.5 Alignment and coverage analysis 
The approach used to evaluate the presence and absence of plasmid genes 
from each genome analysed in this study was composed of two main steps: (i) the 
alignment of the raw reads of each sample to a reference sample, and (ii) the 
evaluation of the coverage of each annotated feature in the reference in each 
alignment. 
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The plasmid pTet or the plasmid pan genome genes (described in section 
2.8.7) were used as a reference for the reads alignment. For the genomes retrieved 
as scaffolds or completed (e.g the genomes retrieved from the NCBI database 
http://www.ncbi.nlm.nih.gov/) a set of raw reads for each one was produced with an 
ad-hoc perl script (generate_reads.pl). These artificial read sets were composed of 
300000 reads 100 bp long in fasta format, randomly obtained from the whole 
genome. 
For the strains of C. jejuni that were sequenced in this study or for which the 
sequencing reads were available, a subset of 300000 reads was used for the 
alignment of reads obtained with Hi-seq technology (up to 100 bp long, for the 
sequencing reads used in this study), and a subset of 100000 reads was used for 
reads obtained with Miseq technology (up to 300 bp long, for the sequencing reads 
used in this study). Fastq reads subsets were randomly sub-sampled with an ad-hoc 
perl script (reads_subset.pl).  
The random sub sampling of sequencing reads provided the same theoretical 
coverage for each alignment, which was on average ~20X considering the length of 
C. jejuni strain 81-176 genome, according to the formula: 
 
Expected coverage = (Read Length * Number of Reads) / Genome length 
 
In order to ascertain whether the depth of coverage fell within 10% difference of 
the expected coverage, the alignments were inspected using and the “depth” module 
of Samtools (http://samtools.sourceforge.net/), which provides the depth of coverage 
per site for the sequence alignment and visually inspected using Integrated Genome 
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Viewer software (version 2.3.5, Thorvaldsdóttir et al., 2013, 
http://www.broadinstitute.org/igv/).  
For the sequencing read alignments, Bowtie 2 software was used (version 
2.10.0, Langmead and Salzmed 2012, http://bowtie-
bio.sourceforge.net/bowtie2/index.shtml). The software is specifically designed to 
align a set of short reads to a genome sequence or an assembly and outputs an 
alignment file in sam format (detailed information about the format can be found at 
http://samtools.sourceforge.net/SAMv1.pdf). In order to evaluate the coverage of 
each feature, the sam file was converted to bam format 
(http://samtools.sourceforge.net/SAMv1.pdf), ordered and indexed with three 
softwares belonging to the samtools suite (Samtools view, Samtools order and 
Samtools index respectively). CoverageBed was finally used (software included in 
Bedtools suite, version 2.17.0, Quinlan and Hall, 2010, 
https://code.google.com/p/bedtools) in order to assign a point scale from 0 to 1 to 
each annotated feature, where 0 is completely non-covered and 1 is fully covered. 
An ad-hoc perl script was used to produce a table containing the percentage of 
coverage of each feature in each strain (compare_coverages.pl). Alignments were 
visually inspected with the aid of Integrated Genome Viewer software. R software 
(version 3.0.1, R core team, 2013) was then used to produce a graphical analysis as 
well as a cluster analysis of the obtained data.  
In particular, the aheatmap function contained in the NMF package (version 
0.17.6, Gaujoux R and Seoighe C, 2010) was used to produce the heatmap showing 
the presence and absence of each plasmid feature, in order to graphically identify 
clusters of gene presence or absence in different strains. 
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Hierarchical clustering analysis was performed with the Rfunction “hclust” on a 
Jaccard distance matrix calculated using the with R functions “vegdist” contained in 
the “vegan” pagkage (version 2.4.3, https://cran.r-
project.org/web/packages/vegan/index.html). Hierarchical clustering trees were 
converted into Newick tree format when needed (e.g. for the annotation on Evolview 
software, as described in results chapter 3), with the R function “as.phylo” (“ape” 
package, version 3.5, http://ape-package.ird.fr/).  
 
2.10.6 Sequence retrieving, pairwise alignments and phylogenetic 
analysis 
To retrieve the sequences by similarity from genome assemblies (e.g in the 
MLST analysis in Chapter 3.2.3.2), a BLAST alignment approach was used. The 
sequence of each fragment in a reference strain (strain C. jejuni NTCC 11168 in the 
MLST analysis) was used as template for command line BLAST (blastall version 
2.2.21, Camacho et al., 2009, 
ftp://ftp.ncbi.nlm.nih.gov/blast/executables/blast+/2.2.21/). 
Each genome file in FASTA format (contigs or the completed genome 
sequence) was formatted as a database with the format-db command, then blastall 
command was run with the following input arguments and options: (i) the sequences 
in fasta format we wanted to find in each genome as input file, (ii) the database 
formatted sequence of the genome as database to perform the alignment, (iii) 
“blastn” as the BLAST algorithm used for the research, (iv) 1 x 10-6 as the e-value 
used for the reliability of the alignment. 
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The result of the BLAST alignment was parsed with an ad-hoc perl script using 
the bio-perl module to facilitate the input-output of the sequences, in order to obtain 
a fasta file showing the hits of the BLAST alignment. 
For pairwise alignment, MUSCLE (version 3.7, Edgar, 2004) algorithm was 
used. The alignment was then visually inspected and used as input for phyML 
(version 3.0, Guindon et al., 2010) in order to produce a maximum likelihood 
phylogenetic tree. Option used for PhyML were the following, unless otherwise 
stated: (i) GTR (General Time Reversible) as tree model, (ii) aLTR (SH-like) as 
branch support algorithm (Anisimova and Gascuel, 2006), (iii) Optimized across site 
variation rate, (iv) NNI (Nearest-Neighbor-Interchange) as tree searching model, and 
(v) BioNj with optimized tree topology as starting tree. 
Alignments and phylogenetic tree building was performed with of SEAVIEW 
software (version 4.2, Gouy et al., 2010, http://pbil.univ-
lyon1.fr/software/seaview.html) that provides a graphical user interface for MUSCLE 
and PhyML. Trees were explored and formatted for presentation using Mega 5 
(version 5.2, Tamura et al., 2011, http://www.megasoftware.net/) or CLC sequence 
viewer (version 7, QIAGEN Inc.), and annotated with Evolview online suite (version 
2, https://evolview.codeplex.com/, He et al, 2016). The branching layout of each tree 
as inferred by PhyML was not modified. 
 
2.10.7 Plasmid pan genome construction and analysis 
Plasmid pan-genomes (described in Chapter 3.3) were built pooling all the 
orthologous proteins in all the plasmids annotations then extracting a representative 
gene sequence for each orthologous protein.  
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The list of proteins and genes in fasta format annotated on each plasmid was 
retrieved from the output of the RAST annotation pipeline. The list of proteins of each 
plasmid was used as input for ProteinOrtho software (Version 5.15, Lechner et al., 
2011). The output of this software was parsed with an ad-hoc perl script 
(pangenome_parser.pl) in order to extract a representative gene sequence from the 
annotation of a representative plasmid. 
The final output of the plasmid-pan genome shows one representative gene 
sequence for each of the orthologous proteins identified by the ProteinOrtho 
software. The list of genes in FASTA format was used as a reference for the 
alignment of the sequencing reads of each C. jejuni strain analysed in this study 
using an approach similar to the one described previously (Section 2.10.5 - 
Alignment and coverage analysis). In contrast to Section 2.10.5, an ad-hoc perl 
script (presence_absence_bowtie2.pl) was used to align the sequencing reads to the 
reference and produce a pileup file using the “mpileup” module of SamTools 
(Handsaker et al., 2009). The pileup file indicates the coverage of each base in the 
reference—in this case the gene lists: the breadth of coverage for each gene was 
calculated as number of covered bases divided by length of the gene. 
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Chapter 3 - Conservation and distribution 
of plasmid pTet in Campylobacter jejuni 
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The plasmid pTet is reported to be present in a large number of strains of C. 
jejuni (Schmidt-Ott et al., 2005), but its importance has yet to be elucidated. 
The first section of this chapter will assess the presence of a plasmid pTet in 
the collection of C. jejuni strains hosted by the Molecular Pathogenesis Lab in 
Exeter. In each strain I will check for the presence of the plasmid using PCR markers 
on genes that have been described in pTet, and determine the tetracycline 
resistance phenotype (Batchelor et al., 2004). The strains exhibiting the presence of 
one of the molecular of phenotypic markers will be sequenced in order to assess the 
variability of the plasmid pTet-like family. 
Secondly, I will assess the presence of the plasmid pTet in all the available 
sequenced C. jejuni strains (corrected in May 2016). I will profile the frequencies of 
the genes found in the plasmid pTet in all the sequenced Campylobacter strains and 
assess where the greatest conservation and greatest variability resides. I will also 
assess the association of plasmid presence with the strain origin, year of isolation 
and phylogeny. 
Finally, I will describe the gene composition of the plasmid pan-genome of C. 
jejuni and the frequency of those genes amongst the sequenced strains of C. jejuni. I 
took a pan-genome approach in order to describe the full picture of the plasmid 
genes in the C. jejuni species instead of describing every plasmid singularly. 
The aims of this chapter are to assess the presence of the plasmid pTet and 
the plasmids pTet-like amongst all the sequenced C. jejuni strains, to describe the 
variablility of this plasmid family and the genes composing it and, ultimately, studying 
the frequencies of the different genes annotated in the plasmids pTet-like to 
ascertain whether this plasmid appears to be maintained solely for the purpose of 
antibiotics resistance, a thesis already challenged by Friis et al., 2006.  
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3.1 In vitro testing for the presence of the plasmid pTet 
To assess the distribution of the plasmid pTet in C. jejuni, the collection of 121 
C. jejuni strains hosted by the Molecular Pathogenesis Lab in Exeter (Table S1) was 
first tested with PCR markers specific for the plasmid pTet and for the tetracycline 
resistance phenotype. Moreover, all the strains positive for at least one marker were 
sequenced using MiSeq sequencing technology and a 300+300 bp paired end 
library. The first step was to identify markers for the plasmid pTet. Four primer pairs 
were designed, covering four different regions of the plasmid pTet in the strain 81-
176 (Table 3.1). These primers were designed to amplify a 300 to 400 bp section of 
the helicase gene, the virD4 gene of the T4SS cluster, the tet(O) gene, and the 
hicA/B cluster, described for the first time on the plasmid pTet in this thesis (and its 
presence is detailed in Chapter 4). Secondly, I measured the MIC of tetracycline on 
plate for the strain 81-176 (10 ug/ml, as described in Section 2.7.2), and I used the 
same concentration for all the other 121 strains of the collection.  
Each strain was grown on Columbia Blood agar plates with Skirrow supplement 
(CBA+) for 2 days at 42°C in microaerophilic conditions, then re-streaked and grown 
at 37 °C in microaerophilic conditions. Single colonies were then tested for growth on 
tetracyline (Muller-Hinton agar plates w 10 ug/ml of antibiotic), and for presence of 
virD4 PCR marker (DNA was obtained with the thermal lysis method described in 
Section 2.3). In case of growth or positive PCR, the strain was tested for the 
remaining PCR markers, tested with a PCR assay to identify the Campylobacter 
species (C. jejuni or C. coli, Wang et al., 2002), and grown for plasmid and genomic 
DNA extraction. 
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Table 3.1 - Sequences of PCR primers for the plasmid genes marker. Table columns (from right 
to left): Primer name, primer sequence, product length for the primer pair, description of the PCR 
product. 
 
  
Primer Name Sequence Product Length Description
hicAB_markF GATCAGGATGGATATTTTGCAC
hicAB_markR TTAGGGTGCAATATTTCTCC
tet_markF        TACGGGTCTGTGCCTGTATG
tet_markR    CTCACGTTGACGCAGGAAAG
virD4_markF TATCTACCGCCAGCACAAAG
virD4_markR TATCCGCCCACGCATTAATC
hel_markF TGGATTGCCTGTTGCTTCTG
hel_markR TGGGTGCTGGAACAAATGTG
Plasmid marker for the hicBA  operon342
Plasmid marker for the helicase gene329
Plasmid marker for the virD4  gene399
Plasmid marker for the tet(O)  gene303
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3.1.1 Molecular and phenotypic test overview 
A total of 23 strains out of 121 were found to be positives for at least one 
marker between virD2, helicase gene, or hicA/B. The PCR products were visualised 
on agarose gel, as reported in Material and Methods (section 2.2). Figure 3.1 shows 
the result PCR for each of the markers on selected strains. 20 strains out of 121 
were able to grow on MH plates supplemented 10 ug/ml of Tetracycline. All the 
strains positive for the tet(O) gene were also resistant to tetracycline. One of the MH 
plates is shown in Figure 3.2. Table 3.2 summarises the results of the PCR and the 
tetracycline screening for the strains that were identified as C. jejuni. The full results 
of this analysis are reported in Supplementary Materials Table S1. Four different 
makeups were identified according to the presence of the PCR markers and the 
phenotypic resistance to tetracycline: (i) three strains are positive for 3/5 markers, 
and negative for both tetracycline resistance on plate and the tetracycline PCR 
marker; (ii) three strains are positive for both tetracycline resistance on plate and the 
tetracycline PCR marker and negative for the virD4, the helicase and the hicA/B 
PCR marker; (iii) two strains are negative for the hicA/B marker and positive to the 
other four makers, (iv) fifteen strains are positive for all the PCR markers tested and 
for tetracycline resistance. 
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Figure 3.1 - PCR gels for the 23 strains positive to at least one marker. (A) Marker virD4, (B) 
Marker tet(O), (C) Marker hIcAB, (D) Marker Helicase. Each image is composed of 2 gels; the lanes 
are ordered as follows: 1kb Plus marker (Thermo scientific®, Lane 1), 100 bp Plus marker (Thermo 
scientific®, lane 14 for the first gel and lane 13 for the second gel), strain 93/372, strain MB3, strain 
MB12, strain Hi81006, strain Hi81214, strain MB8, strain Goose_222, strain K2, strain 11818, strain 
Hi40620300, strain PS623, strain PS762 (lanes 2-13 of the first gel), strain A1.CF.12, strain A6.T2.15, 
strain A8/35/15A, strain C1/C/2, strain C3/T/25col3, strain C5/T2/8, strain MB9, strain MB18, strain 
Cj1, strain Cj2, strain Cj3 (lanes 2-12 of the second gel), positive control (strain 81-176, lane 14 of the 
second gel), negative control (no template, lane 15 of the second gel). Agarose gel 1% in TAE, 30 
minutes run, 120 V. 
 
      
 
       
 
       
 
      
 
 
A 
B 
C 
D 
500 
1500 
1500 
500 
500 
1500 
500 
1500 
500 
1500 
1500 
500 
1500 
500 
1500 
500 
76 
 
Figure 3.2 - Example of one plate for tetracycline resistance screening. The plate is divided into 
three sectors for strains EX1286, MB9 and PS304. The strain present in each sector is recorded on 
the plate. Each strain is streaked in triplicate with an “X” shape. 
 
 
Table 3.2 - Summary of the PCR and tetracycline resistance screening for the 23 positive 
strains. Table columns (from right to left): strain name, origin of isolation of the strain, ability of 
growing on MH plates with tetracycline 10µg/ml, presence of virD4 marker, presence of tet(O) marker, 
presence of Helicase marker, presence of hicA/B marker, species (identified via pcr screening Wang 
et al, 2002), plasmid setup 1 to 4 according to the presence of the different markers. Y = present, N = 
absent. 
 
 
 
Strain Origin Growth Tet R virD4 mark tet(O) mark hel mark hicA/B mark Species Setup
93/372 Unknown (Pet) Y N Y N Y Y jejuni 1
MB3 Poultry Y N Y N Y Y jejuni 1
MB12 Poultry Y N Y N Y Y jejuni 1
Hi81006 Human Y Y N Y N N jejuni 2
Hi81214 Human Y Y N Y N N jejuni 2
MB8 Poultry Y Y N Y N N jejuni 2
222 Goose Y Y Y Y Y N jejuni 3
K2 Human Y Y Y Y Y N jejuni 3
11818 Human Y Y Y Y Y Y jejuni 4
Hi40620300 Human Y Y Y Y Y Y jejuni 4
PS623 Pig Y Y Y Y Y Y jejuni 4
PS762 Pig Y Y Y Y Y Y jejuni 4
A1.CF.12 Poultry Y Y Y Y Y Y jejuni 4
A6.T2.15 Poultry Y Y Y Y Y Y jejuni 4
A8/35/15A Poultry Y Y Y Y Y Y jejuni 4
C1/C/2 Poultry Y Y Y Y Y Y jejuni 4
C3/T/25col3 Poultry Y Y Y Y Y Y jejuni 4
C5/T2/8 Poultry Y Y Y Y Y Y jejuni 4
MB9 Poultry Y Y Y Y Y Y jejuni 4
MB18 Poultry Y Y Y Y Y Y jejuni 4
Cj1 Human Y Y Y Y Y Y jejuni 4
Cj2 Human Y Y Y Y Y Y jejuni 4
Cj3 Human Y Y Y Y Y Y jejuni 4
Strain Origin Growth Tet R virD4 mark tet(O) mark hel mark hicA/B mark Species S tup
93/372 Unknown (Pet) Y N Y N Y Y jejuni 1
MB3 Poultry Y N Y N Y Y jejuni 1
MB12 Poultry Y N Y N Y Y jejuni 1
Hi81006 Human Y N Y N N jejuni 2
Hi81214 Human Y N Y N N jejuni 2
MB8 Poultry Y N Y N N jejuni 2
222 Goose Y Y Y Y N jejuni 3
K2 Human Y Y Y Y N jejuni 3
11818 Human Y Y Y Y Y jejuni 4
Hi40620300 Human Y Y Y Y Y jejuni 4
PS623 Pig Y Y Y Y Y jejuni 4
PS762 Pig Y Y Y Y Y jejuni 4
A1.CF.12 Poultry Y Y Y Y Y jejuni 4
A6.T2.15 Poultry Y Y Y Y Y jejuni 4
A8/35/15A Poultry Y Y Y Y Y jejuni 4
C1/C/2 Poultry Y Y Y Y Y jejuni 4
C3/T/25col3 Poultry Y Y Y Y Y jejuni 4
C5/T2/8 Poultry Y Y Y Y Y jejuni 4
MB9 Poultry Y Y Y Y Y jejuni 4
MB18 Poultry Y Y Y Y Y jejuni 4
Cj1 Human Y Y Y Y Y jejuni 4
Cj2 Human Y Y Y Y Y jejuni 4
Cj3 Human Y Y Y Y Y jejuni 4
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The barplot in Figure 3.3 includes the number of strains that gave a positive 
result for at least one plasmid pTet marker and the origin of the strain. A higher 
number of strains were isolated from farm animal/environmental sources than from 
human patients. 8 out of 52 strains (15.4%) isolated from humans were positive for 
least one pTet marker, while out of 65 strains isolated from animal or environmental 
sources 14 were positive (21.5%). 
The percentages of strains showing the presence of at least 1 pTet marker are 
reported in Figure 3.4. Of positive strains 52% were isolated from poultry including 
goose, 35% from symptomatic humans (clinical strains), 9% from pigs, and 4% had 
unknown origins. 
The gel in Figure 3.5 shows an example of the plasmid extraction result for 
three strains found positive for at least one marker: strains Cj1, Cj2, and Cj3. The 
strain Cj1 did not show the presence of plasmid when subjected to extraction using 
the Promega PureYield™ Plasmid Midiprep System, the QIAprep Spin Miniprep Kit 
or the QIAprep HiSpeed® Plasmid Midi kit, designed to extract high molecular weight 
plasmid and equal the CsCl gradient results (HiSpeed® plasmid purification 
handbook, May 2012). The genomic set-up of Cj1 will be detailed in Chapter 5. 
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Figure 3.3 - Number of strains positive for at least one marker, divided by origin. The grey bar 
represents the total number of strain analysed; the blue part represents the number of strains 
identified as positive to at least one marker. 
 
 
Figure 3.4 - Percentage of analysed strains positive for at least one marker and their origin.  
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Figure 3.5 - Plasmid extraction from selected C. jejuni strains. Lane 1, 1Kb plus ladder (Thermo 
scientific); Lanes 2-5, strain Cj1, Cj2, Cj3 and 81-176. Extraction performed with QIAprep Hi-Speed 
plasmid midi kit (Qiagen). 0.8% agarose gel in TAE, 2.5 hours run, 60 V. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
20000 
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3.1.2 Plasmid sequence determination via whole genome sequencing 
The 23 strains positive for at least one molecular or phenotypic marker listed in 
Table 3.1.1.1 have been sequenced to identify the full sequence of the plasmid. Full 
assembly statistics for each sequenced genome are reported in Table 3.3; the 
sequences of each assembly can be retrieved as Electronic Supplementary Material 
(E1). After assembly, the sequence of the plasmid was identified with the help of 
Bandage (https://rrwick.github.io/Bandage/, Wick et al., 2015). This software shows a 
graphical representation of the de-novo assembly graph, showing connections that 
are not present in the draft genome contigs because the assembler was not able to 
resolve them. These connections derive from the physical distance between the 
paired end reads, whose sequence is determined by the sequencing process. This is 
a powerful tool for plasmid study, because it allows the identification of contigs 
deriving from a circular plasmid by a physical DNA connection between the ends. 
Another important feature of this software for this application is the possibility of 
using BLAST internally in order to identify the location of particular sequences in the 
assembly: I used this feature to identify the location of the PCR markers (tet(O), 
virD2, helicase gene, hicA/B) in the assembly, confirming that they were in the 
circular plasmid contig or locating them in the chromosomal contigs set. Figure 3.6 
shows an example output of Bandage, highlighting the presence of a small circular 
plasmid structure separated from the large chromosomic contigs set. For the rest of 
the work, for the strains isolated from animal hosts, the strain name and the host of 
isolation shown in Table 3.2 will be merged into a new strain name (e.g.: strain 222 
isolated from goose will be named strain Goose_222). 
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Table 3.3 - Assembly statistics for the sequenced strains. Table columns (from right to left): Strain 
name, number of contigs longer than 500 bp, largest contig in the assembly (bp), total length of the 
assembly (bp), percent of G+C, N50 (bp), L50 (bp), number of contigs of any length, number of 
contigs longer than 1000 bp. Unless otherwise specified, every statistic shown in this table is based 
on the number of contigs longer than 500 bp. The N50 is the weighted median statistic such that 50% 
of the entire assembly is contained in contigs or scaffolds equal to or larger than this value. The L50 is 
the number of contigs longer than or equal to the N50 value. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Strain name # contigs >=500 Largest contig Total length GC (%) N50 L50 # contigs >= 0 bp # contigs >= 1000 bp
11818 24 728271 1767836 30.45 191357 2 49 16
Poultry_C3_T_25 21 563591 1751552 30.24 331004 2 52 13
Cj1 22 543624 1763494 30.22 215989 3 24 20
Cj2 19 656205 1696696 30.43 297362 2 61 12
Cj3 22 547640 1746094 30.37 211082 3 46 20
Goose_222 24 559741 1674799 30.49 213026 3 78 16
Hi81006 19 688355 1722779 30.44 231706 2 32 14
Hi81214 28 553931 1636265 30.48 282176 2 69 12
Hi40620300 85 548118 1810698 30.36 272673 3 167 18
K2 33 301612 1786320 30.19 176277 4 50 30
Poultry_MB8 27 612691 1690067 30.31 190197 3 52 18
93/327 28 544865 1665129 30.48 189514 3 113 19
Pig_PS623 91 320151 1863679 30.23 170709 5 198 31
Pig_PS762 63 319777 1808539 30.2 175289 4 134 24
Poultry_A1_CF_12 31 563460 1757893 30.25 331004 2 82 15
Poultry_A6_T2_15 18 563464 1748612 30.25 331006 2 49 13
Poultry_A8_35_15A 33 563467 1758955 30.25 331006 2 101 13
Poultry_C1_C_2 19 563463 1749593 30.25 331002 2 50 13
Poultry_C5_T2_8 18 563589 1750271 30.25 331006 2 46 13
Poultry_MB12 21 776946 1676902 30.44 245358 2 48 14
Poultry_MB18 49 777734 1734473 30.39 189506 2 112 15
Poultry_MB3 29 658226 1695267 30.44 297333 2 58 14
Poultry_MB9 22 563964 1753260 30.27 331004 2 72 13
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Figure 3.6 - Graphical representation of the assembly of the strain Cj2 using Bandage 
software. Each segment of the figure represents a contig of the genome assembly (grey lines), linked 
to each other using the “graph” information provided by the software SPAdes. The red arrow indicates 
the plasmid pCj2 (zoomed in the image inset), which self-circularises in the assembly procedure 
thanks to the information deriving to the paired end. Colours on the contig indicated by the red arrow 
represent Blastn hits of the genes annotated in the plasmid pTet (NC008790.1), indicating the 
presence of the pTet genes on this contig, rather than on the rest of the assembly. 
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3.1.3 Overview of the plasmid sequences in the strains analysed 
Each of the sequenced plasmids from the previous analysis was graphically 
represented with the aid of BLAST Ring Image Manipulator (BRIG, Alikhan et al., 
2011) and is reported in Supplementary Material S2. Full plasmid DNA sequences 
and annotations are available as Electronic Supplementary Material E2. Table 3.4 
shows the general characteristics of each plasmid. 
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Table 3.4 - Summary of the characteristics of the sequenced plasmids. Table columns (from right 
to left): Strain name, name of the plasmid, Size in kilobases, G+C percentage, number of putative 
proteins, number of predicted genes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Organism Plasmid name Size (Kb) GC(%) Protein Gene
Campylobacter jejuni 11818 p11818 44.95 29.06 52 52
Campylobacter jejuni poultry C3_T_25 pPoultry_C3_T_25 47.66 28.04 56 56
Campylobacter jejuni Cj2 pCj2 43.67 27.57 48 48
Campylobacter jejuni Cj3 pCj3 42.01 27.84 46 46
Campylobacter jejuni goose 222 pGoose222 46.08 28.13 52 52
Campylobacter jejuni Hi40620300 pHi4062300 44.83 29.27 50 50
Campylobacter jejuni K2 pK2 47.59 28.77 54 54
Campylobacter jejuni Pet_93_327 pPet93_327 37.73 27.19 43 43
Campylobacter jejuni Pig_PS623 pPigPS623 45.38 28.72 50 50
Campylobacter jejuni Pig_PS762 pPigPS762 45.59 28.99 51 51
Campylobacter jejuni Poultry_A1_CF_12 pPoultry_A1_CF_12 47.64 28.05 54 54
Campylobacter jejuni Poultry_A6_T2_15 pPoultry_A6_T2_15 47.64 28.03 54 54
Campylobacter jejuni Poultry_A8_35_15A pPoultry_A8_35_15A 47.64 28.05 55 55
Campylobacter jejuni Poultry_C1_C_2 pPoultry_C1_C_2 47.64 28.05 54 54
Campylobacter jejuni Poultry_C5_T2_8 pPoultry_C5_T2_8 47.64 28.05 55 55
Campylobacter jejuni Poultry_MB12 pPoultry_MB12 37.53 27.23 45 45
Campylobacter jejuni Poultry_MB18 pPoultry_MB18 44.76 28.99 52 52
Campylobacter jejuni Poultry_MB3 pPoultry_MB3 38.15 27.17 43 43
Campylobacter jejuni Poultry_MB9 pPoultry_MB9 47.66 28.04 56 56
85 
 
3.1.3.1 Comparison of newly sequenced strains against plasmid pTet from 
strain 81-176 
The graphical representation of the BLASTn alignment between the genome 
assembly of the newly sequenced strains against the pTet reference sequence is 
shown in Figure 3.7. In this analysis, the sequence of pTet (NC008790.1) was re-
annotated with RAST automated annotation pipeline (Overbeek et al., 2014). This 
structural comparison was obtained using BRIG. Similar data are reported in Table 
3.5, where the raw reads of each sequenced strain were mapped to the reference 
plasmid with using Bowtie2 and assessing the breadth of coverage with the tool 
CoverageBed, as described in materials and methods 2.10.5. 
The columns in Table 3.5 are ordered from the lowest to the highest difference 
compared with the reference: the method used to quantify the difference was as 
follows. Given the value of 1 as 100% breadth of coverage and 0 as 0% coverage of 
each feature, considering 52 as the number of features in the plasmid pTet, the sum 
of the breadths of coverage in each strain would be a maximum of 52. The rows of 
Table 3.5 have been ordered from the start of the plasmid pTet as retrieved from the 
NCBI database, accession number NC008790.1. 
The presence of conserved domains and further hypothetical functions has 
been assessed with the CDS engine from the ncbi 
(http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi?). Each CDS result reported 
from here on is associated to an e-value lower than 10-3.  
The greatest variability occurred around specific regions of the reference 
plasmid; the gene encoding for “replication protein” was present in 9 of the strains. 
The plasmids from other strains are missing the gene encoding the replication 
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protein of the reference plasmid pTet. Interestingly, this CDS is missing from nearly 
all the strains isolated from poultry, except from the strain Poultry_MB18. 
The BRIG plot in figure 3.7 highlights several conserved gaps when the 
sequences of the newly isolated plasmids are compared to the pTet plasmid 
NC008790.1: in particular, in the regions around the replication protein and the 
surrounding hypothetical proteins, and the hypothetical proteins FIG00469861 and 
FIG00471987. 
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Figure 3.7 - Graphical representation of the BLASTn alignment of each genome sequence of 
the 23 strains in Table 1.2.1 and the plasmid pTet (NC008790.1). Coloured line shows >70% 
identity. Each ring represents (starting from the inner ring): strain HI81214, strain HI81106, strain 
MB8, strain MB12, strain 93/327, strain MB3, strain goose222, strain K2, strain pig726, strain 
Hi40620300, strain 11818, strain Pig623, strain A6/T2/15, strain A1/CF/12, strain C1/C/2, strain 
A8/35/15A, strain T3/C/25, strain MB9, strain Cj3, strain Cj1, strain Cj2, gene annotation of pTet 
(NC008790.1) produced with RAST automated annotation pipeline (Overbeek et al., 2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG00471987: hypothetical protein Virulence-associated protein 2 
FIG00470952: hypothetical protein (hicB) 
FIG00471111: hypothetical protein (hicA) 
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Table 3.5 - Breadth of overage of each ORF of pTet in strain 81-176 (NC008790.1) in the newly 
sequenced strains of C. jejuni (Table 3.4). Columns are (from left to right): gene name, position in 
NC008790.1, and each of the newly sequenced strain. Each cell shows the value of coverage 
percentage in each strain, and is coloured in dark grey if it is higher than 90%, in light grey if it is lower 
than 10%, and in shades of grey for intermediate values.  
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A series of genes encoding for hypothetical proteins annotated close to the 
replication protein were missing or showed up to 50% coverage in plasmids that 
lacked the pTet replication protein (Table 3.6). These proteins carry a partial 
CRISPR/Cas domain (FIG00471069_hypothetical_protein), a partial Ras/GTPase 
enhancer domain (FIG00471024_hypothetical_protein), and a partial TolA domain 
involved in several cellular processes, from the uptake of colicins and filamentous 
DNA to pathogenesis (TolA_protein).  
Two other hypothetical proteins from the reference plasmid pTet were absent in 
the pTet-like plasmids from a large number of the strains analysed (Table 3.7): 
FIG00469644 hypothetical protein, present in 11 of the plasmids and which encodes 
for a partial acetyl transferase or sialyl tranferase largely found in C. jejuni (Gilbert et 
al., 2000) and FIG00469861 hypothetical protein, which carries a conserved domain 
shared with bacteriophage resistance proteins and is present in 11 analysed strains. 
The pTet plasmid from 3 strains, Pet 93 327, Poultry MB3 and Poultry MB12 
lacked the tetracycline resistance gene. Moreover, all these plasmids were missing 
genes flanking the tet(O) gene. In particular: the replication protein and the proteins 
associated with it (described above in this section), the DNA topoisomerase III 
encoded by a gene upstream tet(O), and two hypothetical proteins—FIG00470802 
encoding for a conserved domain of unknown function and a hypothetical protein 
encoding for no putative conserved domains.  
The strains Poultry MB8, Hi81214 and Hi81006 possessed the tet(O) gene and 
a gene encoding a single hypothetical protein flanking the tet(O) gene but lacked any 
other genes from the reference pTet plasmid. The tet(O) in these strains is integrated 
in the chromosome. 
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Table 3.6- Conserved domains identified in the hypothetical protein sequences of 
FIG00471069_hypothetical_protein FIG00471024_hypothetical_protein and TolA_protein in the 
strain 81-176. For each hypothetical protein, a screenshot of the results retrieved from NCBI’s CD-
Search search engine, the name of each conserved domains, the accession number of the conserved 
domain, the region showing the predicted domain, and the e-value is reported.  
FIG00471069_hypothetical_protein 
 
 
 
CRISPR/Cac system associated domain Csx1 
cl21516 130-321 6.28e-6 
FIG00471024_hypothetical_protein 
 
 
 
Ras GTPase Activating domain, enhancer of the hydrolysis of GTP bound to Ras-GTPases 
cl02569 19-375 7.29e-5 
TolA_protein 
 
 
 
TolA protein, part of the Tol/Pal complex involved in maintaining outer membrane integrity. Also 
implicated in transport of colicins, filamentous dna and pathogenesis 
Relaxase/mobilisation nuclease domain 
TIGR02794 
cl21589 
55-417 
301-603 
2.62e-6 
6.65e-7 
 
 
 
Table 3.7 - Conserved domains identified in the hypothetical protein sequences of 
FIG00469644_hypothetical_protein, FIG00469861_hypothetical_protein. For each hypothetical 
protein a screenshot of the results retrieved from NCBI’s CD-Search search engine, the name of each 
conserved domain, the accession number of the conserved domain, the region showing the predicted 
domain, and the e-value is reported.  
FIG00469644_hypothetical_protein 
 
 
 
N-Acetyl transferase superfamily NAT_SF 
Alpha-2,3-Sialyltransferase CST-I 
cl17187 
cl05511 
244-429 
1-312 
1.98e-3 
8.06e-3 
FIG00469861_hypothetical_protein 
 
 
 
Abi-2 superfamily, Abi-like protein found in various bacterial species involved in phage resistance 
cl01988 145-528 7.35e-5 
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The integration point of the tet(O) gene from strains Poultry MB8 and Hi81214 
showed a repeated sequence, highlighted in the following sequence: 
5’_ATTTAGGGTATAACAAAATAACCCACCCGAATATC<tet(O)___Hypothetica
lProtein>CTATGAGCCTTTCAAAGCGTTCCTGTGCCTGTCTGTTG_3’ 
A BLASTn alignment of this sequence against the bacterial genomes database 
highlights how the same sequence is present in several strains of C. jejuni and in 
different bacterial species, such as Streptococcus spp. (Figure 3.8), when the gene 
tet(O) is present chromosomically.  
The plasmid of about 37 kbp that can be identified in the Poultry MB8 appears 
to belong to a different plasmid family compared to the other families described in 
this chapter: it shows >90% similarity to the plasmid pVir (Bacon et al., 2000), and for 
this reason it will not be discussed further (data not shown). 
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Figure 3.8 Localisation of tet(O) gene in the genome of Streptococcus species. Graphic 
representation of a BLASTn alignment of the 73 bp surrounding the tet(O) gene in the strain MB8 
against the complete genome of Streptococcus suis NSUI060. The red arrow indicates the query 
sequence; the green arrow indicates the gene tet(O) in S. suis genome.  
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3.1.3.2 Global plasmid comparison 
To understand the differences and the similarities amongst all the plasmids, a 
global comparison of all the plasmids sequenced from C. jejuni strains (19 plasmids) 
and the original pTet (NC008790.1) was next carried out. 
In order to do so, the plasmids were linearised starting from the gene annotated 
as virB2. This was chosen because it was present in each of the plasmids. The 
plasmids were aligned using the internal aligner of CLC sequence viewer (standard 
parameters) and visualised with the same software (ClustalW2 algorithm, Thompson 
et al., 1994). This software was chosen because it was relatively simple to retain the 
annotation in the alignment and this allowed a better visualisation. The output is 
shown in Figure 3.9, and Table S3 (Supplementary material) shows the annotated 
genes identified in each plasmid. 
This alignment revealed that the most conserved parts of the alignment 
correspond to the type four secretion system cluster, a helicase gene (involved in the 
ATP-dependent unwinding of DNA), a virD2 homologous gene involved in the DNA 
transfer, a DNA primase gene 40000 bp from the beginning of the alignment, and a 
hypothetical protein (FIG00470960) possessing a domain associated with DNA 
repair (Table 3.8). 
This analysis also highlights several differences amongst the plasmids, 
unnoticeable according to the analysis performed in the previous section. This is 
because the approach previously adopted did not take into account features absent 
from the original plasmid pTet. 
Several hypothetical proteins were completely absent from the plasmid pTet of 
strain 81-176 and are highlighted for the first time in this analysis. 
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Figure 3.9 - Representation of the global alignment between 19 pTet like plasmids and the 
plasmid pTet (NC008790.1). pTet_original = sequence of pTet accession NC008790.1. Each black 
line represents the sequence of a plasmid linearised at the start of the annotated gene virB2. 
Numbers are related to the length of each plasmid. Red squares highlight sections of the alignment 
described in paragraph 3.1.3.2; red numbers on top of the alignment are referred in the text when the 
relevant part of the alignment id described.  
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Starting from the beginning of the alignment, (1) the CDS encoding the DNA 
topoisomerase in pCj3 was absent despite the fact that it appears to be present in 
Table 3.5. It is possible to notice an insertion of 127 bp that seems to disrupt the 
CDS is present in this strain. (2) where 17 plasmids show the presence of the tet(O) 
gene, the three plasmids (pPet_93_327, pPoultry_MB3 and pPoultry_MB12) lacking 
the tetracycline resistance gene show a protein annotated as hypothetical protein 
pVir0015, conserved in the C. jejuni pVir plasmid. 
(3) CDS encoding for several different hypothetical proteins are present in the 
region of the alignment around the “replication protein” gene of pTet. This region was 
already described as highly variable in Figure 3.7. It is possible to identify a gene 
encoding for a small hypothetical protein in the three strains lacking the tetracycline 
resistance gene, a gene encoding for a hypothetical protein FIG00471065 in the 
strain Cj3, and a gene encoding for a hypothetical protein FIG00471069 in most of 
the strains isolated from poultry. None of these hypothetical proteins shows any 
putative conserved domain. 
(4) Strains Poultry C3_T_25 and Cj2 lack the complete helicase (snf2 family) 
gene because of a 127 bp insertion at the 3’ end of it. Downstream of the Helicase 
(snf2 family) gene, plasmid pTet NC008790.1 has a CDS encoding a hypothetical 
protein (FIG00469644) carrying a conserved acetyl transferase domain (Table 
3.1.3.2.3). (5) Upstream the gene encoding for the hypothetical protein 
FIG00469644, seven plasmids (p11818, pPoultryMB18, pHi40620300, pPigPS762, 
pCj2, pK2 and pCj3) show the presence of a gene encoding for a putative protein 
FIG00472625 carrying a LabA-like conserved domain, involved with the regulation of 
several cellular process (from circadian rhythm in cyanobacteria to degradation of 
toxic substance, Taniguchi et al., 2007; Tang et al., 2008). In the same region of the 
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plasmid, most of strains isolated from poultry (Poultry_A6_T2_15, Poultry_C5_T2_8, 
Poultry_C1_C_2, Poultry_MB9, Poultry_A1_CF_12, Poultry_A8_35_15_A and 
Poultry_C3_T_25), show a different gene cluster. It is formed by 5 CDSs, all 
encoding for hypothetical proteins, with conserved domains associated with acetyl 
transferase, a porin, type 2 secretion system associated proteins, and with a 
peptidase for bacteriocin processing (Table 3.9).  
(6) Moreover, between 40000 and 50000 bp from the beginning of the 
alignment, a CDS encoding for a hypothetical protein FIG00469861 (described in 
section 3.1.3.1) present in pTet was missing from 10 plasmids (p11919, 
pPoultry_MB18, pHi40620300, pPoultry_A6_T2_15, pPoultry_C5_T2_8, 
pPoultry_C1_C_2, pPoultry_MB9, pPoultry_A1_CF_12, pPoultry_A8_35_15_A and 
pPoultry_C3_T_25). In the same area of the alignment, a CDS encoding for a 
serine/threonine kinase signal transductor was only found in 2 plasmids (pK2 and 
pGoose222). 
(7) Towards the 3’ end of the alignment, a gene cluster is present that is 
associated with strains isolated from poultry. It contains four CDSs, with domains 
associated with signal transduction and regulation (TIR_2 bacterial toll like receptor), 
virulence (VapD), and protein metabolism (metallo-beta-lactamase) (Table 
3.1.3.2.3). Plasmid pCj2 and pGoose222 possessed a single gene encoding for a 
hypothetical protein with no CD identifiable in the same region, while a membrane 
aromatic cluster protein (lipoprotein associated with Mycoplasma) is identifiable in 
the plasmid pK2. 
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Table 3.8 - Conserved domains identified in the hypothetical protein sequence of 
FIG00470960_hypothetical_protein. A screenshot of the results retrieved from NCBI’s CD-Search 
search engine: the name of each conserved domain, the accession number of the conserved domain, 
the region showing the predicted domain, and the e-value is reported. 
FIG00470960_hypothetical_protein 
 
 
 
AAA_25, AAA domain, N-loop NTPase presumably involved in DNA repair 
pfam13841 88-528 1.72e-15 
 
Table 3.9 - Conserved domains identified in the hypothetical protein sequences of 
FIG00472625_hypothetical_protein, FIG00469644_hypothetical_protein, 
FIG00470281_hypothetical_protein, Hypothetical protein (FIG|354242.88.peg.1849 on the 
annotation of strain A6/T2/15), FIG00628667_hypothetical_protein, Serine threonine protein 
kinase PrkC, Hypothetical protein (FIG|354242.88.peg.1854 on the annotation of strain 
A6/T2/15), Virulence associated protein D (VapD), Hypothetical protein 
(FIG|354242.88.peg.1851 on the annotation of strain A6/T2/15). For each hypothetical protein, a 
screenshot of the results retrieved from NCBI’s CD-Search search engine, the name of each 
conserved domain, the accession number of the conserved domain, the region showing the predicted 
domain, and the e-value is reported. 
FIG00472625 hypothetical protein 
 
 
 
LabA_like; conserved domain involved in several cellular processes, no defined function. 
cd06167 52-684 6.40e-20 
FIG00469644 hypothetical protein 
 
 
 
Acetyltransferase (GNAT) family 
pfam00583 244-426 2.21e-03 
FIG00470281 hypothetical protein 
 
 
 
Porin superfamily, form non-specific channels for small hydrophillic molecules 
cl21487 7-354 2.96e-03 
Hypothetical protein (FIG|354242.88.peg.1849) 
 
 
 
FliE super family 
Parallel beta-helix repeat, found in many carbohydrate-binding proteins and sugar hydrolases. 
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cl09139 
TIGR03804 
1-183 
187-282 
3.76e-03 
2.11e-03 
FIG00628667 hypothetical protein 
 
 
 
Predicted double-glycine peptidase 
COG3271 1-537 4.53e-40 
Serine threonine protein kinase PrkC 
 
 
 
PKc_superfamily, Catalytic domain of protein kinase 
cd00180 64-702 1.99e-44 
Hypothetical protein (FIG|354242.88.peg.1854) 
 
 
 
Borrellia_orfA, Plasmid-associated dna-repeats in Borrellia spp. 
TIR_2 superfamily domain, bacterial toll-like receptor 
cl20231 
cl22869 
43-567 
805-1083 
2.83e-6 
2.67e-7 
Virulence associated protein D (VapD) 
 
 
 
VapD, Virulence associated protein (unknown function) 
COG3309 1-285 7.63e-42 
Hypothetical protein (FIG|354242.88.peg.1851) 
 
 
 
Metallo beta lactamase superfamily 
cl00446 1-48 3.45e-3 
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The alignment shown in Figure 3.9 was used to infer the phylogeny of the 
plasmids. A tree was produced using the software CLC Sequence Viewer (Neighbor-
joining algorithm, Jukes-Cantor distance measuring method, 100 bootstrap 
replicates). The result of this analysis is shown in Figure 3.10. 
The tree has several characteristics worth highlighting: the plasmids isolated 
from the same source do not always cluster together (e.g.: the two plasmids isolated 
from pig, the plasmids isolated from a human host, or the plasmids isolated form 
poultry do not cluster with each other). Moreover, there is not a clear clustering 
related to the length of the plasmid. Plasmids in cluster A exhibit a higher average 
length than the plasmids in cluster B. When compared to the plasmid pTet 
NC008790.1 (isolated from 81-176), the strains identified in cluster A appear to have 
acquired several gene—for instance, the gene cluster towards the 3’ end of the 
alignment described in above (area highlighted with number 7 in Figure 3.9). The 
strains identified in the cluster B on the other hand appear to have lost several 
genes, in particular the gene cluster around the tetracycline resistance gene. None 
of the other strains in this analysis follows any pattern associating phylogeny and 
length of the plasmid. 
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Figure 3.10 - Phylogenetic tree obtained with the alignment of the linearised plasmid 
sequences (shown in Figure 3.9). Neighbor-joining algorithm, Jukes-Cantor distance measuring 
method, 100 bootstrap replicates. (pC3_T_25 = pPoultry_C3_T_25). Plasmids highlighted by A show 
a higher average length than plasmids highlighted by B. 
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3.2 - Survey of all available Campylobacter jejuni genome sequences for 
the presence of pTet 
To understand the distribution of the plasmid pTet amongst C. jejuni, I built a 
database of all available C. jejuni genome sequences (updated in May 2016). This 
included 3211 strains from a study conducted by the Sanger Institute between 2008 
and 2012, monitoring an Oxford Hospital’s patients 
(http://www.ebi.ac.uk/ena/data/view/ERP000129, “The genomic speciation of 
Campylobacter”, unpublished, study accession number PRJEB2075). It also 
included 78 strains from a Genome-Wide Association Study (GWAS) reported by 
Sheppard et al., 2013 (http://datadryad.org/resource/doi:10.5061/dryad.28n35) and 
679 strains sequenced in the last 15 years and retrieved from the NCBI database 
(completed and draft stage, retrieved in May 2016 - 
http://www.ncbi.nlm.nih.gov/genome/). Finally, I included 37 strains sequenced at 
Exeter University, before or during this work. 
The final database included a total number of 4005 strains and is summarised 
in Table 3.10. The complete table with the meta-data associated for each strain is 
available in electronic format (Electronic Supplementary Material E3). 
In this analysis, the presence of each gene of the plasmid pTet in the database 
of 4005 C. jejuni has been assessed. Briefly, raw reads were aligned to the pTet 
sequence, using Bowtie2 as described at 2.10.5. If the raw reads were not available, 
the draft genome or the complete genome was treated with an ad-hoc perl script to 
obtain a set of artificial raw reads (generate_reads.pl). All of the alignments were 
then analysed using CoverageBed. Each file reporting the “breadth of coverage” for 
each alignment was parsed with a perl script (compare_coverages.pl) to obtain a 
single table showing the breadth of coverage of each single gene in each strain. 
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Table 3.11 shows a subset of the full analysis, reporting the breadth of 
coverage of the 50 strains showing the highest number of genes covered and the 50 
strains showing the lowest number of genes covered. The full result of this analysis 
is available in electronic format (Electronic Supplementary Material E3). 
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Table 3.10 - Number of strains of C. jejuni genome sequences used for surveying the presence 
of the plasmid pTet. Columns are (from left to right): number used for each group of strains (i to iv), 
number of strain in each group, study from which the group was retrieved, status of the genome 
sequences in each group. 
 
 
 
 
Table 3.11 - Breadth of coverage of each ORF of pTet in strain 81-176 (NC008790.1) in the 50 
strains showing the highest number of genes covered and the 50 strains showng the lowest 
number of gene covered. One different strain per row. Columns are (from left to right): strain name, 
study name (according to Table 3.10: SANGER = i, GWAS = ii, NCBI = iii, IN-HOUSE = iv), origin of 
isolation (where unavailable = N/A), year of isolation (where unavailable = N/A), breadth of coverage 
of each gene annotated in pTet (NC008790.1). Last column is the sum of the breadths of coverage. 
Each cell shows the value of coverage percentage in each strain, and the dot present in each cell is a 
graphical representation of each number (completely black = 80-100%, three quarters black = 60-
80%, half black = 40-60%, one quarter black = 20-40%, blank = 0-20%). The full table is available in 
xlsx format (Electronic Supplementary Material E3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
# of strains Study Sequencing status
(i) 3211 "The genomic speciation of campylobacter" (Unpublished) Raw reads
(ii) 78 Sheppard et al. 2013 Contigs (draft)
(iii) 679 Various - retrieved from http://www.ncbi.nlm.nih.gov/genome/ Complete - Contigs (draft)
(iv) 37 Seqeunced in-house Contigs (draft)
Total 4005
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3.2.1 Overview of the pTet presence survey 
A general analysis of the number of strains possessing pTet-like plasmids is 
reported in this paragraph.  As shown in Figure 3.11, a total of 1344 (33.6%) strains 
show the presence of at least 1 gene annotated in the 81-176 pTet plasmid. To 
establish the presence of a gene, I defined a cut-off of 80% in breadth of coverage in 
the coverage table described in Section 3.2. Of this set of strains, 617 had more than 
50% (n>26) of the total 81-176 pTet genes. This indicates that 15.4% of the total 
database analysed has more than half of the annotated genes for the plasmid pTet 
(NC008790.1) identified in this study with RAST (Overbeek et al., 2014), and 45.9% 
of the strains showed evidence of possessing a pTet-like plasmid.  Of the 1344 
strains with at least 1 pTet gene in their genome, 941 strains show the presence of 
the tetracycline resistance gene tet(O), while 403 lacked this gene sequence. From 
the analysis of the group showing the presence of at least 50% of the plasmid pTet 
81-176, it emerges that a total of 461 strains out of 617 (74.7%) showed the 
presence of the tet(O) gene, while 156 (25.3%) strains show a complete lack of 
tet(O) sequence. One of the main reasons why pTet is believed to be conserved is 
because it encodes resistance to the tetracycline (Batchelor et al., 2004). This 
analysis highlights a possible absence of this association, as the 25.3% of C. jejuni 
sequenced strains showing the presence of the majority of the pTet plasmid from 81-
176 do not appear to possess the tet(O) gene. 
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Figure 3.11 - Overview of presence of pTet genes in the 4005 genome sequences of C. jejuni 
analysed. A gene is defined as present in a genome if it is covered for at least 80%, when the 
breadth of coverage is assessed as described in Section 2.1. tet(O) + or - = Tetracycline resistance 
gene is present or absent, plasmid + or - = at least 26 genes of the plasmid pTet are present, plasmid 
“traces” = at least one gene of the plasmid pTet is present. 
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The heatmap in Figure 3.12 A (also reported in full electronically in Electronic 
Supplementary Material E4) is obtained using the data matrix of breadth of coverage 
of the 52 pTet NC008790.1 genes (columns) in the 617 strains showing more than 
26 genes present (rows). The clustering tree of the column dimension is also 
reported in Figure 3.12 B. Cluster one, corresponding to the rightmost side of the 
heatmap, shows genes conserved in the majority of the strains having the pTet-like 
plasmid. A second cluster shows less conserved genes characterised by a higher 
variability (including some of the vir genes of the type four secretion system), and 
four clusters alternatively present in different groups of strains, including the tet(O) 
gene and the replication protein. 
If the same type of analysis is expanded to the strains exhibiting the presence 
of at least one plasmid gene, the result obtained is shown in Figure 3.13 A and B 
(heatmap in Figure 3.13 A is available as Electronic Supplementary Material E5). In 
this case, the data matrix used as input for the heatmap clustering shows the 
breadth of coverage of the 52 pTet NC008790.1 genes (columns) in the 1344 strains 
showing at least 1 of the genes present (rows). The plasmid genes are clustered in 
three main clusters in this case: this is because the small frequency differences 
between the 617 strains showing the presence of the majority of the plasmid genes 
are masked by the high number of C. jejuni strains showing the lack of the genes in 
the cluster II, and the presence of the tetracycline resistance gene chromosomally 
(cluster III). 
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Figure 3.12 - Cluster analysis of the plasmid pTet genes (1). (A) Heatmap built with the breadth of 
coverage table of each gene annotated in the plasmid pTet (NC008790.1) in each of the 617 strain 
showing at least the presence of 26 genes of the plasmid pTet. Clustering distance for columns and 
rows = euclidean, clustering method = complete. The 52 genes annotated on the plasmid pTet are in 
the column, the 617 strains are in the rows. Each cell is coloured from white (0% coverage) to dark 
green (80-100%) as reported in the legend. (B) Clustering tree for the genes (columns). The rightmost 
element is on top (rotated 90 degrees left). The clusters identified on the tree (numbered from I to IV) 
are also highlighted on the heatmap. The full heatmap is available in pdf format (Electronic 
Supplementary Material E4). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
110 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
A 
B 
Genes 
S
tr
a
in
s
  
111 
 
Figure 3.13 - Cluster analysis of the plasmid pTet genes (2). (A) Heatmap built with the breadth of 
coverage table of each gene annotated in the plasmid pTet (NC008790.1) in each of the 1344 strains 
showing at least the presence of 1 gene of the plasmid pTet. Clustering distance for columns and 
rows = euclidean, clustering method = complete. The 52 genes annotated on the plasmid pTet are in 
the column, the 617 strains are in the rows. Each cell is coloured from white (0% coverage) to dark 
green (80-100%) as reported in the legend. (B) Clustering tree for the genes (columns). The rightmost 
element is on top (rotated 90 degrees left). The clusters identified on the tree (numbered from I to IV) 
are also highlighted on the heatmap. The full heatmap is available in pdf format (Electronic 
Supplementary Material E5). 
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3.2.3 Association with the presence of the plasmid pTet and the time of 
isolation, the origin of the strain and phylogeny 
The previous analysis was performed on a set of 4005 C. jejuni isolates, 
composed of strains isolated at different times, by different labs, following different 
standards for recording the metadata of each strain. For this reason, each of the 
following Sections describes just a subset of the entire dataset. For instance, strains 
with unknown year of isolation are not included in Section 3.2.3.1. 
 
3.2.3.1 Year of isolation 
For this analysis, a subset of strains from the Sanger Institute collection and 
from the NCBI database was used. Most of the strains from the Sanger Institute 
collection were isolated from symptomatic patients between 2009 and 2012, and the 
genome sequencing deposited on the NCBI database were obtained from strains 
isolated between 1980 and 2014: the metadata were retrieved from the project page 
at the MLST database of Campylobacter jejuni/coli (http://pubmlst.org/perl/bigsdb/, 
Jolley and Maiden, 2010) and from the BioSample database entry associated with 
each genome assembly (http://www.ncbi.nlm.nih.gov/biosample). Unfortunately, the 
number of strains isolated each year is not consistent and not all the strains included 
in the collection have a timestamp. The numbers of strains isolated in each year is 
reported in Table 3.12. 
The number of strains possessing a pTet-like plasmid is reported in the barplot 
in Figure 3.13 for strains showing the presence of at least 1 gene annotated in pTet 
and in Figure 3.14 for strains showing the presence of at least half of the genes 
annotated in the pTet. 
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From this analysis, I identified strains retaining the pTet-like plasmid every year 
between 2006 and 2013—particularly, between year 2009 and 2012, when the 
sample size is larger, the number of strains positives for the plasmid presence was 
34.5% (2009), 13.1% (2010), 20.1% (2011), 13.6% (2012). 
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Table 3.12 - Number of strains isolated per year included in the analysis described in 3.2.3.1.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Year Number of CJ strains
1980 1
1985 1
1993 1
1994 2
1995 2
1996 12
1997 1
1998 2
1999 4
2000 10
2001 8
2002 14
2003 13
2004 13
2005 9
2006 8
2007 14
2008 5
2009 52
2010 130
2011 844
2012 545
2013 8
2014 1
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Figure 3.14 - Number of strains per year showing the presence of at least 1 gene annotated on 
the plasmid pTet. The inset shows a zoom for the years 2009 to 2012. 
 
 
 
 
Figure 3.15 - Number of strains per year showing the presence of at least 26 genes annotated 
on the plasmid pTet. The inset shows a zoom for the years 2009 to 2012. 
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3.2.3.2 Phylogeny 
In order to understand whether the possession of the pTet-like plasmids is 
associated with the phylogeny of C. jejuni, the presence of each gene was 
associated to the phylogenetic analysis of the Multi-Locus Sequence Tag of C. jejuni. 
A 400 to 600 bp fragment of 7 core genes have been extracted from the genome 
sequence of a subset of 168 strains. This included the strains in the GWAS study 
(Sheppard et al., 2013), the completed genomes retrieved from the NCBI database 
(NCBI bacteria), and 20 strains sequenced in-house up to 2013. The MLST of C. 
jejuni is described in “Multilocus Sequence Typing System for C. jejuni” (Dingle, 
2001), curated by http://pubmlst.org/Campylobacter/, which includes the sequence of 
internal fragments of 7 housekeeping genes: aspA (aspatase), glnA (glutamine 
synthetase), gltA (citrate synthase), glyA (serine hydroxy methyl transferase), pgm 
(phospho glucomutase), tkt (transketolase), uncA (ATP synthase alpha subunit). The 
sequence of these fragments in the reference strain 11168 were retrieved from the 
NCBI database (NC_002163.1), aligned against the entire draft or complete genome 
of each strain included in the analysis using BLASTn, and the matching sequence 
extracted. 
The sequences of the 7 fragments were concatenated, pairwise-aligned with 
MUSCLE (http://www.ebi.ac.uk/Tools/msa/muscle/) and the phylogenetic tree was 
built as described in 2.8.6. The phylogenetic tree was then annotated with EvolView 
(version 2, https://evolview.codeplex.com/, He et al., 2016): the presence or absence 
of each gene is reported as breadth of coverage in the alignment of raw reads or 
artificial reads (as described in Section 2.8.5 of materials and methods). 
Figure 3.16 shows the result of the analysis. It is clear that none of the clusters 
are associated with the presence of one or more plasmid genes. 
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Figure 3.16 - MLST analysis tree for a subset of 168 strains and presence of pTet genes. The 
table shows the presence of each gene annotated on the plasmid pTet in each strain as percent of 
coverage as reported in the legend (white = 0% coverage, black = 100% coverage). Strains are listed 
on the rows of the table, corresponding to the leaves of the phylogenetic tree, genes are listed on the 
columns. 
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3.2.3.3 Origin 
For this analysis a subset of strains of known origin of isolation was used. This 
included the NCBI sequence assembly whose origin could be retrieved from the 
“Biosample” database (http://www.ncbi.nlm.nih.gov/biosample), 36 of the strains 
sequenced in-house, the strains from the GWAS analysis and part of the strains 
retrieved from the Sanger Institute Database. The total number of strains with 
recorded origin used in this section was 821, and they were divided in 7 groups as 
reported in Table 3.13. The poultry group includes every strain isolated from chicken, 
goose, duck, and turkey; the clinical group includes the strains isolated from humans 
in a clinical environment; the environmental group includes strains that were not 
isolated from animals or stool (e.g. from soil or water). 
The results are reported in Figures 3.17 and 3.18 and are associated with 
strains showing at least one gene or half of the genes of pTet plasmid. 
The analysis reveals that 206 strains of known origin of isolation show at least 
half the 52 genes of the 81-176 pTet covered. Of these, 64 are found in the 234 
strains isolated from poultry (27.3% of poultry strains), 131 in the 503 clinical isolates 
(26.0%), 9 in the 61 strains isolated from cattle (14.7%), and 2 out of 3 strains 
isolated from pig. None of the environmental strains or the strains isolated from 
sheep and rabbit exhibit the presence of the majority of the plasmid pTet genes. 
Almost the same percentage of clinical isolates and strains isolated from poultry 
shows more than 26 genes associated with the plasmid pTet (more than 25% of the 
isolates in both groups), while 14.7% of isolates from cattle possessed a pTet-like 
plasmid. 
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Table 3.13 - Number of strains per different origin included in the analysis described in Section 
3.2.3.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Origin Number of CJ strains
cattle 70
clinical 503
environment 7
pig 3
poultry 234
rabbit 1
sheep 3
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Figure 3.17 - Number of strains per different origin of isolation showing the presence of at 
least 1 gene annotated on the plasmid pTet. The inset shows a zoom for the strains isolated from 
cattle, poultry and clinical environment (symptomatic humans). 
 
 
Figure 3.18 - Number of strains per different origin of isolation showing the presence of at 
least 26 genes annotated on the plasmid pTet. The inset shows a zoom for the the strains isolated 
from cattle, poultry and clinical environment (symptomatic humans). 
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The heat-map reported in Figure 3.19 shows clustering according to gene 
presence and the rows are annotated with the origin of each strain (for the 377 
strains showing the presence of at least 1 gene annotated on the plasmid pTet), 
showing that the presence of different pTet genes is not linked to a particular origin 
of the strain. 
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Figure 3.19 - Cluster analysis of the plasmid pTet genes and the strains of known origin. 
Heatmap built with the breadth of coverage table of each gene annotated in the plasmid pTet 
(NC008790.1) in each of the 377 strains of known origin showing at least the presence of 1 gene of 
the plasmid pTet. Clustering distance for columns and rows = euclidean, clustering method = 
complete. The 52 genes annotated on the plasmid pTet are on the column, the 617 strains are on the 
rows. Each cell is coloured from white (0% coverage) to dark green (80-100%) as reported in the 
legend. The leftmost row shows the annotation related to the origin of the strain (as shown in legend). 
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3.3 Plasmid pan-genome analysis 
Pan-genome studies are described in the literature (Rouli et al., 2015) and are 
used to define the set of core and accessory genes of a bacterial species. A pan-
genome study aims to identify the core and the accessory genome of a species or a 
set of strain belonging to a species: every gene annotated in every genome 
sequence that is part of the study is compared, in order to identify every orthologous 
sequence present in at least one genome. The list these unique orthologous genes 
is the pan-genome of the species. Usually, if the genes are present in every strain, 
they are defined as “core genes”, essential for the bacterium survival or lifestyle; 
otherwise, they are defined as “accessory genes” (Ozer et al., 2014). Several pan-
genome studies have been published in recent years, including studies on C. jejuni 
(Meric et al., 2014; Lefeubre et al., 2010). I treated the plasmids as genomes to try to 
define groups of core and accessory plasmid genes, focusing particularly on the 
pTet-like plasmids. With the exception of two works in Acinetobacter that used a 
completely different approach to the one used here (Fondi et al., 2010, where the 
focus was the plasmids rearrangement and the exchange of information between 
plasmids and chromosomes), this is the first time that plasmids isolated from 
different strains of a bacterial species have been treated as a plasmid pan-genome 
to assess the presence and infer the importance of each gene for the make up of a 
plasmid family. 
The study of 20 plasmids isolated and sequenced highlighted a variety of 
different plasmid organisations. The analysis of the entire database of C. jejuni 
strains described in Section 3.2 shows a remarkably high number of strains with 
traces of plasmid sequences. In order to separate the comparison of these plasmids 
from the single reference pTet, I decided to pool all the sequenced plasmids in C. 
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jejuni in a pan-genome-like study in order to assess the variability in gene presence. 
At the end of this section, I will narrow down the plasmid pan-genome analysis only 
to the pTet-like plasmids, and define a core and an accessory set of genes for this 
plasmid family. 
 
3.3.1 Overview of the genes distribution of C. jejuni plasmid pan-genome 
To assess the full list of plasmid genes, the full list of sequenced C. jejuni 
plasmids was retrieved (corrected in February 2016, Table 3.14). The first analysis 
included pTet and pTet-like plasmids, along with other sequenced plasmids including 
pVir plasmids, small “cryptic plasmids” (Jesse et al., 2006; Hiett et al., 2013; 
pCJ1170-pCJ01-pTIW94- pCJ419) and large plasmids longer than 100 kbp. This 
allowed the relationships of these plasmids to be explored. 
The plasmid pan-genome was built according to the protocol detailed in 
Materials and Methods, Section 2.10.7. Briefly, in this analysis I assessed the 
orthologous proteins between the plasmids and extracted one gene sequence for 
these orthologous proteins. This resulted in a list of 178 genes (the plasmid pan-
genome of C. jejuni).  
In order to assess the presence of each of these 178 genes in the 4005 strains 
that were described in Section 3.2, sequencing reads were aligned to their DNA 
sequence as described in Section 2.10.5.  
The breadth of coverage of each gene, for each strain, compared to the 
reference, was used to produce the heatmap in Figure 3.20 (an electronic version is 
available as Electronic Supplementary Material E6) and the representation of the 
hierarchical clustering of the genes according to the presence in the database 
analysed in Figure 3.21. For these analyses, the breath of coverage value was 
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turned into presence or absence, selecting a cut-off of 0.8 (80% of sequence 
covered) for a gene to be present. In other words, if the breadth of coverage were 
greater than 80% the gene was considered present and the coverage value was 
converted into a 1; if the breadth of coverage were lower than 80% the gene was 
considered absent and the coverage value was converted into a 0. The heatmap 
shows how different genes clusters are associated with different strains, which is not 
surprising considering that this analysis is obtained using several different plasmid 
families of C. jejuni: the different genes clusters are associated to these different 
plasmids.  
The hierarchical clustering is reported in Figure 3.21 in the same order as the 
heat-map columns, and it is annotated with the frequency of each gene. The 
dendrogram was produced on the basis of a Jaccard distance matrix built on the 
presence and absence of each gene in each strain as described in Material and 
Methods section 2.10.6. The clusters are highlighted by different colours. They are 
associated with different genes frequencies, and contain genes deriving from 
different plasmids. In particular we can observe: cluster V in green, containing genes 
present in pTet-like plasmids (present also in pcjDM T1-T2, as it contains ~40000 bp 
homologous to pTet); cluster II in red, associated with plasmid pCJDM202, 
containing, amongst others, genes for the type 6 secretion system; cluster III in light 
blue, associated with the genes of the plasmid pVir; clusters I and IV in yellow, 
containing genes deriving from several different pTet-like plasmids, showing an 
intermediate frequency between pTet-like cluster (V) and pVir cluster (III). 
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Table 3.14 - Summary of the characteristics of the plasmids included in the C. jejuni plasmid 
pan-genome analysis. Table columns (from right to left): Strain name, name of the plasmid, 
Accession number (where available), Size in kilobases, G+C percentage, number of putative proteins, 
number of predicted genes, number of predicted pseudogenes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Organism Plasmid name RefSeq INSDC Size (Kb) GC(%) Protein Gene Pseudogene
Campylobacter jejuni 11818 p11818 This study This study 44.95 29.06 52 52 -
Campylobacter jejuni poultry C3_T_25 pPoultry_C3_T_25 This study This study 47.66 28.04 56 56 -
Campylobacter jejuni Cj2 pCj2 This study This study 43.67 27.57 48 48 -
Campylobacter jejuni Cj3 pCj3 This study This study 42.01 27.84 46 46 -
Campylobacter jejuni goose 222 pGoose222 This study This study 46.08 28.13 52 52 -
Campylobacter jejuni Hi40620300 pHi4062300 This study This study 44.83 29.27 50 50 -
Campylobacter jejuni K2 pK2 This study This study 47.59 28.77 54 54 -
Campylobacter jejuni Pet_93_327 pPet93_327 This study This study 37.73 27.19 43 43 -
Campylobacter jejuni Pig_PS623 pPigPS623 This study This study 45.38 28.72 50 50 -
Campylobacter jejuni Pig_PS762 pPigPS762 This study This study 45.59 28.99 51 51 -
Campylobacter jejuni Poultry_A1_CF_12 pPoultry_A1_CF_12 This study This study 47.64 28.05 54 54 -
Campylobacter jejuni Poultry_A6_T2_15 pPoultry_A6_T2_15 This study This study 47.64 28.03 54 54 -
Campylobacter jejuni Poultry_A8_35_15A pPoultry_A8_35_15A This study This study 47.64 28.05 55 55 -
Campylobacter jejuni Poultry_C1_C_2 pPoultry_C1_C_2 This study This study 47.64 28.05 54 54 -
Campylobacter jejuni Poultry_C5_T2_8 pPoultry_C5_T2_8 This study This study 47.64 28.05 55 55 -
Campylobacter jejuni Poultry_MB12 pPoultry_MB12 This study This study 37.53 27.23 45 45 -
Campylobacter jejuni Poultry_MB18 pPoultry_MB18 This study This study 44.76 28.99 52 52 -
Campylobacter jejuni Poultry_MB3 pPoultry_MB3 This study This study 38.15 27.17 43 43 -
Campylobacter jejuni Poultry_MB9 pPoultry_MB9 This study This study 47.66 28.04 56 56 -
Campylobacter jejuni pCJ419 NC_004997.1 AY256846 4.01 30.15 4 4 -
Campylobacter jejuni pVir NC_005012.1 AF226280 37.47 25.88 52 54 2
Campylobacter jejuni pTet NC_006135.1 AY394561 45.21 29.14 49 49 -
Campylobacter jejuni pTet NC_007141.1 AY714214 45.21 29.14 44 44 -
Campylobacter jejuni pCJ1170 NC_008052.1 DQ518173 4.38 30.79 3 3 -
Campylobacter jejuni pCJ01 NC_008438.1 AF301164 3.21 33.50 4 4 -
Campylobacter jejuni pTIW94 NC_021493.1 KF192842 3.86 31.11 5 5 -
Campylobacter jejuni unnamed NZ_CP013117.1 CP013117 82.73 29.82 103 106 3
Campylobacter jejuni unnamed NZ_CP014345.1 CP014345 81.08 25.99 70 80 10
Campylobacter jejuni pCJDM67 L NZ_CP014745.1 CP014745 116.88 26.91 97 108 11
Campylobacter jejuni pCJDM67 S NZ_CP014746.1 CP014746 36.60 26.07 45 46 1
Campylobacter jejuni pCJDM202 NZ_CP014743.1 CP014743 119.54 27.24 104 116 12
Campylobacter jejuni subsp. jejuni 01-1512 pCj1 NZ_CP010073.1 CP010073 48.87 29.01 51 54 3
Campylobacter jejuni subsp. Jejuni 01-1512 pCj2 NZ_CP010074.1 CP010074 36.60 25.95 46 47 1
Campylobacter jejuni subsp. Jejuni 00-0949 pTet NZ_CP010302.1 CP010302 48.87 29.01 52 55 3
Campylobacter jejuni subsp. Jejuni 00-0949 pVir NZ_CP010303.1 CP010303 36.60 25.95 46 47 1
Campylobacter jejuni subsp. jejuni 00-2544 unnamed NC_022354.1 CP006710 46.90 29.41 51 52 1
Campylobacter jejuni subsp. jejuni 81-176 pVir NC_008770.1 CP000550 37.47 25.89 46 47 1
Campylobacter jejuni subsp. jejuni 81-176 pTet NC_008790.1 CP000549 45.03 29.09 50 50 -
Campylobacter jejuni subsp. jejuni 81-176-UMCW7 pVir NZ_AZNS01000034.1 AZNS01000034 37.57 25.85 46 47 1
Campylobacter jejuni subsp. jejuni IA3902 pVir NC_017284.1 CP001877 37.17 25.91 48 48 -
Campylobacter jejuni subsp. jejuni ICDCCJ07001 pTet - CP002030.1 44.08 28.69 37 37 -
Campylobacter jejuni subsp. jejuni S3 pTet NC_017282.1 CP001961 43.22 28.99 42 45 3
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Figure 3.20 - Cluster analysis of the C. jejuni plasmid pan genome. Heatmap built with the 
breadth of coverage table of each gene identified in the plasmid pan-genome of C. jejuni  in each of 
the strains showing at least the presence of 9 genes (5%) of genes identified in the plasmid pan-
genome of C. jejuni. Clustering distance was calculated with Jaccard distance matrix. The 178 genes 
are in the column; the strains are in the rows. Each cell is coloured in light green if the percentage of 
coverage is smaller than 80% or dark green if it is greater than or equal to 80%. The full heatmap is 
available in pdf format (Electronic Supplementary Material E6). 
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Figure 3.21 - Hierarchical clustering tree of the genes identified in the C. jejuni plasmid pan 
genome. The clustering tree was built according to the presence/absence data used for the heatmap 
in Figure 3.2.3. Clustering distance was calculated using Jaccard distance matrix. The colours 
(yellow, red, green and light blue) highlight different clusters. The tree annotation (roman numbers I to 
V) follows the description in the text, the blue bar next to each leaf of the tree represent the frequency 
of each gene in the subset of strains used for the heatmap in Figure 3.3.1.3. 
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The analysis was then narrowed down to just the pTet-like plasmids. In order to 
identify which plasmids to include in this final analysis, I aligned every plasmid 
isolated from C. jejuni using the software Mauve 
(http://darlinglab.org/mauve/mauve.html, Darling et al., 2004) and obtained the result 
in Figure 3.22 (available as electronic supplementary material E7). For clarity, in the 
image I masked the pVir-like plasmids and the small plasmids pCJ1170-pCJ01-
pTIW94- pCJ419, and I did not include the plasmids pTet NC006135.1 and 
NC007141.1. The plasmids included in the following analysis are the ones indicated 
by the arrows: they require a clear similarity with pTet, in length and gene content. 
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Figure 3.22 - Mauve alignment of the plasmids used in the C. jejuni plasmid pan genome 
analysis. The name of each plasmid is indicated in the figure, if the coloured bars above the plasmid 
name (representing the plasmid sequence) are missing, that plasmid sequence has been masked for 
clarity.  Red arrows indicate the plasmids picked for the pTet-like plasmid pan-genome analysis. The 
image is available in jpeg format (Electronic Supplementary Material E7). 
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Table 3.15 - Summary of the characteristics of the plasmids included in the pTet-like plasmid 
pan-genome analysis. Table columns (from right to left): Strain name, name of the plasmid, 
Accession number (where available), Size in kilobases, G+C percentage, number of putative proteins, 
number of predicted genes, number of predicted pseudogenes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Organism Plasmid name RefSeq INSDC Size (Kb) GC(%) Protein Gene Pseudogene
Campylobacter jejuni 11818 p11818 This study This study 44.95 29.06 52 52 -
Campylobacter jejuni poultry C3_T_25 pPoultry_C3_T_25 This study This study 47.66 28.04 56 56 -
Campylobacter jejuni Cj2 pCj2 This study This study 43.67 27.57 48 48 -
Campylobacter jejuni Cj3 pCj3 This study This study 42.01 27.84 46 46 -
Campylobacter jejuni goose 222 pGoose222 This study This study 46.08 28.13 52 52 -
Campylobacter jejuni Hi40620300 pHi4062300 This study This study 44.83 29.27 50 50 -
Campylobacter jejuni K2 pK2 This study This study 47.59 28.77 54 54 -
Campylobacter jejuni Pet_93_327 pPet93_327 This study This study 37.73 27.19 43 43 -
Campylobacter jejuni Pig_PS623 pPigPS623 This study This study 45.38 28.72 50 50 -
Campylobacter jejuni Pig_PS762 pPigPS762 This study This study 45.59 28.99 51 51 -
Campylobacter jejuni Poultry_A1_CF_12 pPoultry_A1_CF_12 This study This study 47.64 28.05 54 54 -
Campylobacter jejuni Poultry_A6_T2_15 pPoultry_A6_T2_15 This study This study 47.64 28.03 54 54 -
Campylobacter jejuni Poultry_A8_35_15A pPoultry_A8_35_15A This study This study 47.64 28.05 55 55 -
Campylobacter jejuni Poultry_C1_C_2 pPoultry_C1_C_2 This study This study 47.64 28.05 54 54 -
Campylobacter jejuni Poultry_C5_T2_8 pPoultry_C5_T2_8 This study This study 47.64 28.05 55 55 -
Campylobacter jejuni Poultry_MB12 pPoultry_MB12 This study This study 37.53 27.23 45 45 -
Campylobacter jejuni Poultry_MB18 pPoultry_MB18 This study This study 44.76 28.99 52 52 -
Campylobacter jejuni Poultry_MB3 pPoultry_MB3 This study This study 38.15 27.17 43 43 -
Campylobacter jejuni Poultry_MB9 pPoultry_MB9 This study This study 47.66 28.04 56 56 -
Campylobacter jejuni pTet NC_006135.1 AY394561 45.21 29.14 49 49 -
Campylobacter jejuni pTet NC_007141.1 AY714214 45.21 29.14 44 44 -
Campylobacter jejuni subsp. jejuni 01-1512 pCj1 NZ_CP010073.1 CP010073 48.87 29.01 51 54 3
Campylobacter jejuni subsp. jejuni 00-0949 pTet NZ_CP010302.1 CP010302 48.87 29.01 52 55 3
Campylobacter jejuni subsp. jejuni 00-2544 unnamed NC_022354.1 CP006710 46.90 29.41 51 52 1
Campylobacter jejuni subsp. jejuni 81-176 pTet NC_008790.1 CP000549 45.03 29.09 50 50 -
Campylobacter jejuni subsp. jejuni ICDCCJ07001 pTet - CP002030.1 44.08 28.69 37 37 -
Campylobacter jejuni subsp. jejuni S3 pTet NC_017282.1 CP001961 43.22 28.99 42 45 3
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This second analysis the 27 pTet-like plasmids reported in Table 3.15 were 
analysed with the same technique described above and in section 2.10.7. The 
plasmid pan-genome narrowed down to just the pTet-like plasmids (the pTet-like 
plasmid pan-genome) was composed of 79 genes. The sequencing reads deriving 
from the 4005 C. jejuni strains analysed here were aligned to the DNA sequence of 
these 79 genes, as described above in this section. 
The same clustering performed with the C. jejuni plasmid pan-genome was 
performed with the pTet-like plasmid pan-genome (Figures 3.23 A and B, Available 
as Electronic Supplementary Material E8 and E9). The heatmap shown in Figure 
3.23 A was produced with the frequency of the 79 genes of pTet-like plasmid pan-
genome in the strains exhibiting at least the presence of 5% of the genes (n=4). This 
heatmap highlights the presence of a high number of strains showing just a few 
genes, for instance, the tetracycline resistance gene. The second heatmap, Figure 
3.23 B, was produced with the strains showing at least 26 genes (half of the genes 
present in the original plasmid pTet). The second heatmap is essentially a close-up 
of the bottom section of Figure 3.23 A, which highlights the presence of a cluster 
present in most of the strains and several genes clusters present in just some groups 
of strains. 
The gene names shown in the heatmaps (Electronic Supplementary Material 
E8 and E9) and in the hierarchical clustering described in section 3.3.2 have been 
simplified for clarity. The sequence of an orthologous gene with the accession 
number and the putative function of each gene will be discussed in Chapter 4. 
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Figure 3.23 - Cluster analysis of the pTet-like plasmid pan-genome. (A) Heatmap built with the 
breadth of coverage table of each gene identified in pTet-like the plasmid pan-genome in each of the 
strains showing at least the presence of 4 genes (5%) of genes identified in the plasmid pan-genome 
of C. jejuni. (B) Heatmap built with the breadth of coverage table of each gene identified in pTet-like 
the plasmid pan-genome in each of the strains showing at least the presence of 26 genes (half of the 
plasmid pTet NC008790.1) of genes identified in the plasmid pan-genome of C. jejuni. Clustering 
distance was calculated using Jaccard distance matrix. The 178 are on the column; the strains are on 
the rows. Each cell is coloured in light green if the percent of coverage is smaller than 80% or dark 
green if it is greater than or equal to 80%. The full heatmaps are available in pdf format (Electronic 
Supplementary Material E8 and E9). 
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3.3.2 Core genes and accessory genes of the plasmid pan-genome 
associated with pTet-like plasmids 
Figure 3.24 shows the clustering dendrogram associated with the column of the 
heat-map in Figure 3.23 A (at least 5% of pTet-like plasmid pan genome). The 
hierarchical clustering tree is annotated with two bar-plots: the green plot shows the 
total frequency of the genes in all 4005 strains, the blue barplot shows the frequency 
of the genes in the strains showing at least the presence of 26 genes associated with 
the pTet-like plasmid pan-genome. It is important to notice the CDs encoding for X43 
hypothetical protein, Tet(O), and X57 FIG00469861 hypothetical protein showing a 
remarkable difference between the two barplots. This highlights the presence of 
these genes on the chromosomes of several strains regardless of the presence of 
the plasmid pTet or on plasmids different from pTet. 
 
 
 
 
 
 
 
 
 
 
 
 
 
140 
 
 
Figure 3.24 - Hierarchical clustering tree of the genes identified in the pTet-like plasmid pan 
genome. The clustering tree was built according to the presence/absence data used for the heatmap 
in Figure 3.3.1.8 (A). Clustering distance was calculated using Jaccard distance matrix. The colours 
(yellow, red, green, and light blue) highlight different clusters. The tree annotation (I to IV) follows the 
description in the text; the bars next to each leaf of the tree represent the frequency of each gene in 
the subsets of strains used to produce the heatmaps in Figure 3.3.1.8 A (green bar) and B (blue bar), 
respectively. 
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Moreover, the clusters that are identifiable in the heatmaps and in this 
hierarchical clustering analysis are associated with different frequencies of the genes 
included in the cluster. In the clustering tree, four main clusters can be identified. The 
average frequency relative to each cluster is reported in Figure 3.25. 
Clusters I and II are present in most of the strains exhibiting at least 26 genes 
associated with the plasmid pTet. The genes that are easily identifiable from the 
annotation encode for all the type four secretion system proteins, for proteins 
associated with conjugations and DNA repair, and for proteins associated with 
virulence and pathogenicity. Clusters III and IV are associated with a lower 
frequency, with the exception of the cluster IIIB, which includes the tet(O) gene and 
other genes that have been frequently identified in chromosomes. These clusters 
include, for instance, genes for antibiotic resistance and genes encoding a virulence 
associated protein, a Tol protein (associated with translocation of colicins in E. coli, 
Lazzaroni et al., 2002), and other hypothetical proteins. 
The core and the accessory pTet-like plasmid pan genome were defined 
combining the gene frequencies of clusters I and II and the frequencies of clusters III 
and IV. Genes present in cluster I and II combined form the “core” part of the pTet-
like plasmid pan genome; genes present in the clusters III and IV form the 
“accessory” part pTet-like plasmid pan genome. The average gene frequency of the 
core and the accessory pTet-like plasmid pan genome is shown in Figure 3.26. 
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Figure 3.25 - Average gene frequency per cluster identified in Figure 3.24. Error bars indicate 
standard deviation.  
 
 
 
 
 
Figure 3.26 Average gene frequency per core and accessory gene set of the pTet-like plasmid 
pan genome. Error bars indicate standard deviation. 
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3.4 Discussion 
In this chapter, I analysed the distribution of pTet-like plasmids in genome 
sequenced strains of C. jejuni. I assessed the sequence diversity of the plasmid pTet 
and sequenced 19 strains carrying the plasmid. I described the plasmid pan-genome 
of C. jejuni, focusing on the pTet-like plasmid pan genome and defining a core and 
an accessory set of genes. 
The method used in this chapter to assess the presence, absence, and 
variability of the genes annotated on the plasmid pTet or identified on the pTet-like 
plasmid pan-genome involved the alignment of raw sequencing reads to the plasmid 
or pan-genome reference. This method was chosen because for the majority of the 
4005 strains analysed the sequencing reads were available, and to avoid the bias 
which may be introduced by the genome assembly step. For 679 strains for which 
the sequencing reads were not available, it was necessary to transform the draft or 
the completed genome in a set of simulated reads. Although this method may also 
introduce bias in the analysis, this extra step was necessary to apply the same 
pipeline to every sample analysed. The ability of correctly identifying gene presence 
and absence in the set of strains in which raw sequencing reads was not available, 
was confirmed manually in a subset of those strains (via BLAST alignment of the 
annotated genes of the plasmid pTet against the draft or the completed genome 
assembly, data not shown). If this analysis was to be repeaded in the future with a 
larger subset of genomes for which sequencing reads is not available, those strains 
could be treated separately. 
A further source of bias in this anaylsis may originate from the alignment 
technique. The default parameters used with Bowtie2 in this study are stringent 
(corresponding to the “sensitive” paramenters set described in the Bowtie2 manual, 
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http://bowtie-bio.sourceforge.net/bowtie2/manual.shtml), and were chosen to allow a 
balance between computational cost and precision of the alignment. With these 
paramenters, the alignment of a sequencing read needs a score of at least -0.6 + 
(0.6 * Length of the read) to be valid. Considering the length of the read to be 150, 
the score threshold for an alignment to be valid is -90. The scoring system for the 
default “sensitive” parameters set in Bowtie2 is: mismatch penality of -6, a gap 
penality of -5 for gap opening, and -3 for gap extension. This means that 16 bases 
mismatch, or 10 bases mismatch and 10 bases gap, are enough to consider the 
alignment of the read non-valid. Both these examples show how the cut-off for the 
read alignment is below 20% mismatch. Although this value could be improved in 
future analyses, having used sequencing reads that have been cleaned as described 
in section 2.10.3 (quality check and trimming of sequence reads), and having used 
the scoring system described here, artefacts such as those with very short 
alignments, which may skew the analysis, were ruled out.  
The findings described in this chapter regarding the distribution and the 
diversity of pTet are in accordance with previous literature. For instance, in the study 
from Smidt-Ott et al., 2007, 29% of strains analysed are reported to have a plasmid 
up to 66 kbp long of which 2% was pVir plasmid. Here, I show that a plasmid pTet-
like is likely to be present in 15.4 to 33.6 % of the 4005 C. jejuni strains analysed 
(where 15.4 % of strains show half of the genes annotated in pTet and 33.6 % of 
strains show the presence at least one feature annotated in pTet). It has been 
reported previously that the tetracycline resistance is not always associated with the 
presence of pTet and in some strains the gene is located chromosomally (Pratt et al., 
2005). It is interesting to note a group of strains that has the majority of the genes for 
the plasmid pTet but lacks the tetracycline resistance gene. This characteristic has 
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never been suggested at a sequence level before and reinforces the hypothesis that 
the function of the plasmid pTet is not limited to a tetracycline resistance phenotype. 
A study of the presence of the pTet plasmid in association with the phylogeny 
of the different strains, the year of isolation, and the ecological niche of isolation did 
not show any clear association. This plasmid has been shown to be transmitted via 
conjugation (Avrain et al., 2004; Smitt-Ott et al., 2007), and the broad distribution of 
the plasmid is in accordance with this observation.  
A molecular and phenotypic survey was carried on 120 C. jejuni strains. This 
showed 100% association between the presence of tetracycline resistance gene 
tet(O) and the tetracycline resistance phenotype confirming what recently shown in 
Zhao et al., 2016. It also showed the presence of 4 different plasmid makeups. The 
20 strains positive for at least one molecular marker have been sequenced, in order 
to obtain the full sequence of 19 completely new pTet-like plasmids.  
Three of these plasmids lack the tetracycline resistance gene: this is the first 
complete sequence of a plasmid showing homology with part of the plasmid pTet but 
lacking the tetracycline resistance gene. These plasmids have also lost genes 
flanking the tetracycline resistance gene. The loss of the replication protein gene 
repA may influence the compatibility group of the plasmid and the possible 
distribution of the plasmid. Also, the loss of a Topoisomerase III encoding gene 
suggests the involvement of this protein in a recombination event (Roja, 1995). 
Plasmids pPoultry_MB3, pPet93_372 and pPoultyry_MB12 may have lost the 
tetracycline resistance or they may have yet to acquire it. What is possible is that 
these plasmids belong to a lineage that either did not ancestrally acquire the gene, 
or they belong to a lineage that lost the gene. In either of these cases, the plasmids 
would be closely related, as they are. If they have yet to acquire the gene for the 
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tetracycline resistance, it would be reasonable to expect to find the gene cluster that 
they are missing (tet(O), with genes for a DNA topoisomerase II, replication protein 
RepA, a protein TolA and a further 3 hypothetical proteins, as reported in table 
3.1.3.1.1) in any of the strains analysed that show the chromosomal presence of the 
tet(O) gene. Such a gene cluster is missing from the strains sequenced in this study: 
in fact, in the three sequenced strains that encode for Tet(O) chromosomally 
(PoultryMB8, Hi81214, and Hi81006), tet(O) is associated with just one single 
hypothetical protein. Furthermore, when the plasmid pTet genes distribution is 
analysed in the 4005 sequenced strains database (Figure 1.6.2.1), we can identify a 
single hypothetical protein clustering together with tet(O), suggesting that the gene 
cluster missing from the plasmids pMB3, pPet93, and pMB12 is not present in any of 
the strains exhibiting a chromosomal integration of tet(O). It is reasonable to expect 
that the plasmids pPoultry_MB3, pPet93_327, and pPoultry_MB12 have lost the 
gene cluster containing tet(O); however, the possibility that these plasmids belong to 
a lineage that has not yet acquired the tetracycline resistance cannot be dismissed. 
The reason why the plasmids lack the tetracycline resistance can only be 
conjectured. The reduction in use of tetracycline in the farming industry might have 
played a role in the loss of selective advantage in carrying the resistance gene. The 
fact that the plasmid is still conserved in the largest part suggests further selective 
advantage of the remaining genes. 
The plasmids lacking the tet(O) gene show the presence of a gene originally 
annotated in pVir but with no predicted function. This could indicate the exchange of 
material between the plasmids pTet and pVir (Bacon et al., 2004). 
Two of the three strains that possess the tet(O) gene chromosomally also have 
a repeated sequence at each end of the gene cluster that includes tet(O). This 
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repeated sequence might represent a previously undescribed integration point, or 
part of it. It has been reported that tetracycline resistance is acquired via HGT in the 
intestine of chicken (Avrain et al., 2004), and this event may also happen in other 
ecological niches. I described the existence of the same tet(O) chromosomal cluster 
in the three strains MB8, Hi81006, and Hi81214 and in Streptococcus spp., which 
include the gene tet(O) and the a small CDS upstream. This observation, together 
with a marginally different G+C content of the tet(O) cluster compared to the rest of 
the plasmid, reinforces the theory that the gene cluster was acquired horizontally 
(Batchelor et al., 2004; Luangdonkum et al., 2009). 
A global comparison of the pTet-like plasmid sequenced in this study highlights 
the presence of areas that are more conserved than others. The type four secretion 
system (T4SS) gene cluster appears is present in all the plasmids sequenced and is 
highly conserved. The T4SS is involved in the conjugal transfer of the genetic 
material (Wallden et al., 2010). Also highly conserved between the plasmids are 2 
hypothetical proteins involved with DNA repair (FIG00470960) and a DNA primase. 
Other small differences are identifiable within the sequenced plasmids; the most 
striking one is the presence of a cluster of 5 different genes in seven strains isolated 
from poultry. This cluster encodes proteins whose functions signal transduction and 
regulation, virulence, and protein metabolism, which have not previously been 
described in plasmids of the pTet-like family. The literature focuses on the presence 
of different antibiotic-resistance genes on the C. jejuni plasmids: recently, papers 
showing the association of tet(O) with several different antibiotics resistances have 
been published, including very recently the sequence of a plasmid encoding for 
tetracycline and kanamycin resistance, in which the maintenance of the structure of 
the plasmid pTet was described (Crespo et al., 2016).  The study of the plasmid pan-
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genome of C. jejuni in section 3 also highlighted that the genes tet(O) and aph3 
(aminoglycoside resistance) appear at remarkably different frequencies, and they 
appear in two different clusters when their presence in the sequenced C. jejuni 
genomes is assessed. Several papers reported an association between these 2 
resistances (Gibreel et al., 2004; Zhao et al., 2016), but the data reported in this 
chapter are in contrast with this observation. They are present together in a fraction 
of sequenced plasmid as reported by Zhao et al., 2016, but this association is not 
universally present in C. jejuni. 
Focusing on the plasmid pan-genome of C. jejuni showed in Section 3.3.1, 
strong differences are noticeable in frequencies between the genes present in the 
different clusters highlighted by the analysis. For instance, the cluster III of the Figure 
3.21 shows the frequency of several genes associated with the plasmid pVir. When 
the frequency of the genes belonging to this cluster is compared to the genes 
belonging to cluster V, which is composed of genes associated with plasmids pTet-
like, it appears clear that the plasmid pVir appears less frequently in C. jejuni (as 
reported by Friis et al., 2006), and this may be an indication of the lack of phenotypic 
advantage brought by the plasmid pVir (Friis et al., 2007; Schmitd-Ott et al., 2005). 
Another gene cluster present in several strains reported in the global plasmid 
pan-genome is cluster II, which includes the genes encoding for the type six 
secretion system (T6SS). The T6SS have been reported to be present 
chromosomally in several Campylobacter strains (Harrison et al., 2014; 
Lertpiriyapong et al., 2012), and it is known to be resent on a plasmid (pCJDM202). 
It is associated with virulence (Lertpiriyapong et al., 2012), but it lacks association 
with the plasmid pTet.  
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When the plasmid pan-genome analysis is narrowed down to the plasmids 
pTet-like only, it appears that there are different genes clusters associated with 
different plasmids set-ups. The plasmid pTet-like, have been identified via a global 
alignment with the software Mauve, and 79 genes are picked up when these 
plasmids are parsed into a plasmid pan-genome pipeline. 
As shown in the Figure 3.3.1.8 and highlighted in the clustering analysis 
3.3.2.1, two clusters are present in most of the strains exhibiting a plasmid pTet, and 
two clusters are present to a much lower extent. As highlighted in the heatmap, 
these gene clusters can be associated to a CORE and an ACCESSORY plasmid 
pan genome. 
This distribution suggests that the plasmid pTet has a mosaic structure, built on 
a foundation that is generally conserved, and different genes originated from 
different bacterial sources (which may be strains of C. jejuni or other commensal 
bacteria) are added on to it. One might speculate, in this regard, that the accessory 
genome might add a phenotypic advantage in particular ecological niches and that 
different strains might conserve the genes useful in the particular environment that 
they are colonising. 
Simply, one remark can be addressed to the antibiotics resistance carried by 
the pTet-like plasmids. According to the gene distribution of tet(O) and aph3, it 
appears clear that there are other functions associated with the plasmids. Two 
scenarios can be imagined if the function of this plasmid family were only linked to 
the presence of antibiotic resistance: either they were much more frequent or the 
plasmid would have been lost by Campylobacter, leaving the resistance at a 
chromosomal level. None of these scenarios appear to have occurred: plasmids 
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pTet-like are very common and hundreds of strains exhibit the presence of the 
plasmid and no antibiotic resistance, three of which are fully sequenced in this study 
In the next chapter, the putative function of each of these hypothetical proteins 
will be inferred, searching for conserved domains in the putative protein sequence. 
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Chapter 4 - Function prediction of the 
genes in the p-Tet like plasmid pan-
genome 
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Approximately 60 percent of genes in the pTet-like plasmid pan genome are 
predicted to encode for “hypothetical proteins”, accorded to the RAST automatic 
annotation pipeline. In order to try to understand the putative function of the encoded 
proteins, I searched for conserved domains using the NCBI Conserved Domains 
Search tool (CD-Search, Marchler-Bauer et al., 2015).  
NCBI’s CD-search tool allows searching in the Conserved Domain Database 
using a protein or a nucleotide query (which is translated in 6 possible reading 
frames). The search algorithm used by this tool is RPS-BLAST (Reverse Position-
Specific Blast), which uses the query sequence to scan quickly a database of pre-
calculated Position-Specific Score Matrices, corresponding to conserved domain 
models retrieved from several different databases sources: NCBI-curated domains, 
SMART database (Simple Modular Architecture Research Tool - Letunic et al., 
2015), Pfam (Protein families - Finn et al., 2016), COGs database (Clusters of 
Orthologous Groups of proteins - Tatusov et al., 1997), TIGRFAM (The Institute for 
Genomic Research's database of protein families) and PRK (NCBI’s collection of 
Protein Clusters). 
The CD-Search result includes hits at various confidence levels, such as 
specific hits (top ranked RPS-BLAST hits) or non-specific hits (RPS-BLAST hits that 
exceed the confidence threshold for statistical significance), Multi-domains hits, and 
the Superfamily to which the domains hits belong. 
Each ORF identified in the pTet-like plasmid pan genome was used as input in 
the CD Search interface. The sequence was searched against the CDDs database 
v3.15 (Marchler-Bauer et al., 2015), with an e-value threshold of 10e-3, and the 
output reported shows only domain models identified in the reading frame +1. 
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This chapter opens with a section summarising the conserved domains 
identified. The full results are reported in Section 4.3. 
 
4.1 Summary of CD-search results 
Table 4.1 was produced in order to summarise the results of the domains 
identified in the hypothetical proteins of pTet. 
In Supplementary material section S4, the details of each conserved domains 
identified in each gene are described: this includes the results retrieved from NCBI’s 
CD-Search search engine for each hypothetical protein, together with the name, the 
accession number and the e-value of each conserved domain, and a description of 
the putative function of each conserved domain identified. 
Table 4.1 shows the gene names used in Chapter 3.3.1 for the genes identified 
in the pTet-like plasmid pan-genome. 
Several key functions emerge from the identified conserved domains. VirB/D4 
genes have been identified, together with a group of proteins involved in DNA 
transfer (e.g. TrbM). Horizontal transfer of DNA is one of the main functions 
described for this plasmid family (Batchelor et al., 2004), and the identification of the 
expected conserved domains in the plasmid pan-genome seems to confirm this 
function. 
A second function associated with this plasmid family was antibiotic resistance: 
the sequenced pTet-like plasmids are primarily associated with tetracycline 
resistance (tet(O)) and aminoglycoside resistance (aph3) (Smitt-Ott et al., 2007, 
Zhao et al., 2016). In this analysis, conserved domains for resistance to tetracycline, 
aminoglycoside, and glycopeptide antibiotics have been identified, together with a 
154 
 
series of peptidase involved in bacteriocins resistance and multidrugs toxin extrusion 
(MATE-like) proteins.  
A group of hypothetical proteins are associated with CRISPR/Cas domain (e.g. 
18_FIG00470991_hypothetical_protein, 58_FIG00471069_hypothetical_protein, 
76_hypothetical_protein). This function was not identified in any of the pTet-like 
plasmids before and is associated with bacterial immunity from bacteriophages. 
Other key functions that emerge from this analysis include an HicA/B toxin-
antitoxin system for plasmid stabilisation (19_FIG00471111_hypothetical_protein, 
23_FIG00470952_hypothetical_protein); several proteins that are associated with 
regulation or signal transduction, such as the ATPase domain in 
12_FIG00471537_hypothetical_protein 32_FIG00469957_hypothetical_protein and 
45_Ribbon-helix-helix_protein_copG_family_domain_protein, the acetyl transferase 
domain in 6_FIG00469644_hypothetical_protein, the regulatory domain in 
77_FIG00472625_hypothetical_protein; and several hypothetical proteins carrying 
conserved domains for membrane transporters and receptors, like the ABC 
transporter domains in 54_FIG00470281_hypothetical_protein or 
20_FIG00471065_hypothetical_protein, the carbohydrate transporter in 
70_FIG00469626_hypothetical_protein, the colicin uptake domain in 
68_TolA_protein, the C4 carbohydrate transporter in 
7_FIG00471069_hypothetical_protein. 
 
  
155 
 
Table 4.1 - Results summary of the conserved domains search in the hypothetical proteins 
encoded by the pTet-like plasmid pan genome. Columns are (from left to right): hypothetical 
protein name (as reported in the pTet-like plasmid pan genome analysis in chapter 1), predicted 
function according to the conserved domains found, gene length, +/- = conserved domains found or 
not found, accession numbers for the conserved domains hits 
(56_FIG00470802_hypothetical_protein shows 12 conserved domains whose accession number is 
not reported in the table for lack of space). 
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4.2 Association between cluster analysis and predicted functions 
Table 4.2 shows the genes displayed in Table 4.1 ordered and coloured 
according to the clustering analysis shown in Section 3.3.2. 
The table shows how the functions predicted for the genes appearing in the 
pTet-like plasmid pan genome can be clustered according to how frequently they are 
present in a bacterial strain. 
In particular, the analysis highlights how the majority of the core genes of the 
plasmid pan genome (yellow cluster and red cluster) are associated with DNA 
transfer, with a few exceptions, such as the ABC Transporter 
20_FIG00471065_hypothetical_protein or the 33_cag_pathogenicity_island_protein. 
These genes encode for the virB/D2 cluster, topoisomerases, and conjugative 
proteins. Moreover, the hicAB system for plasmid stabilisation is present in the 
yellow cluster, which is associated with a higher frequency in the C. jejuni database 
analysed. The proteins of the plasmid pan genome associated with lower 
frequencies (green and light blue clusters) seem to be associated with functions 
presumably associated with adaptation, like membrane transporters and nutrients 
uptake, antibiotic resistances, regulation, and signal transduction. 
 
 
 
 
 
 
 
 
158 
 
Table 4.2 - Results summary of the conserved domains search in the hypothetical proteins 
encoded by the pTet-like plasmid pan genome. Columns are analogous to Table 4.1. The second 
column is coloured according to the different clusters identified in the pTet-like plasmid pan genome 
analysis (Chapter 3, Section 3.3.2).  
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4.3 Discussion 
In this chapter, a conserved domain search was used to identify the putative 
functions in the genes identified in the pTet-like plasmid pan genome. 
 For the majority of the proteins annotated as “hypothetical” by the automated 
pipeline RAST (Overbeek et al., 2014), several conserved domains have been 
identified with a high degree of confidence (e-value lower than 10e-3). 
The genes predicted to be involved in the conjugational DNA transfer and with 
the Type Four Secretion System, have all been confirmed to be present by the 
presence of the expected conserved protein domains in the translated sequence. 
DNA replication-associated proteins (RepA, ParA/B) have also been identified, 
even if the CDS identified as “67_repA_replication_protein” does not show the 
presence of any conserved domains associated with the function. The sequence of 
the gene “67_repA_replication_protein” is homologous to the repA gene of the 
plasmid pTet, but no conserved domain is identified in the translated sequence. This 
might be a mis-annotation in the original pTet NC008790.1 plasmid (locus tag 
CJJ81176_pTet0001) annotated for the first time in 2004 (Batchelor et al, 2004).  
Several CRISPR/Cas system associated hypothetical proteins have been 
identified in this study: in particular, two CRISPR/Cas2 domains associated with the 
virulence-associated proteins VapD and VapD2 and domains associated with Cas9, 
Cas8, Cas6, Csx1 in other hypothetical proteins. 
CRISPR/Cas systems have been described extensively in literature recently 
and they are associated with bacterial resistance to phages (Boyaval et al., 2007; 
reviewed by Marrafini in 2015). They are described as bacterial adaptive immunity: 
CRISPR loci are formed by arrays of short repeated sequences with intervening 
short sequences of viral or plasmid origins. The small RNAs produced by the 
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transcription of the spacers target the complementary viral sequence, and they are 
used as a guide by the Cas endonucleases as guide for the direct cleavage of the 
viral genome. The function of CRISPR/Cas Systems have also been associated to 
virulence in pathogenic bacteria (reviewed by Louwen et al., 2014): in particular, it 
was observed that the deletion of cas9 in C. jejuni affected the ability of the 
bacterium to translocate across intestinal epithelial cells (Louwen et al., 2013). 
A HicA/HicB system is part of the pTet-like plasmid pan genome. This system is 
a toxin/antitoxin system used for plasmid stabilisation in bacterial cells by Post 
Segregational Killing (PSK). The function of this system is reviewed by Van 
Melderen and De Bast in 2009. The system is organised into an operon: the toxin is 
expressed constitutively and is more stable than the antitoxin, which degrades the 
mRNA encoding for the toxin. If the bacterial cell does not inherit the plasmid after 
duplication, it loses the antitoxin and is killed the stable toxin protein still present in it. 
The HicAB system has been shown to be involved with other functions in other 
bacterial species, such as chemotaxis and biofilm formation in E. coli, to promote 
virulence in Salmonella and to have a role in persister formation in Burkholderia 
pseudomallei (De la Cruz et al., 2013, Butt et al., 2014, Kim et al., 2009). The TA-
system described here in particular was found to share between 70% and 80% 
protein sequence identity with TA-systems described in the chromosome of several 
strains of H. pylori. Recently the expression of one TA-system of H. pylori (hp0968–
hp0967, a TA-system of the same family of the HicAB system described here in C. 
jejuni) was described to be regulated by environmental signals relevant in the 
context of human infection and to be induced in biofilm formation (Cárdenas-
Mondragón et al., 2016). 
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The presence of this TA-system may explain why it was not possible to cure a 
pTet-like plasmid when it is found without other plasmids in a C. jejuni strain (Smitd-
Ott et al., 2004), but its involvement in environmental adaptation or virulence cannot 
be excluded. 
Several conserved domains associated with antibiotic resistance and 
membrane transport were identified in the pTet-like plasmid pan-genome. These 
include an ABC transporter in 54_FIG00470281_hypothetical_protein, an ABC 
transporter/glycopeptide antibiotic resistance in 
20_FIG00471065_hypothetical_protein, a MATE-like protein involved in multidrug 
and toxin extrusion in 11_FIG00469626_hypothetical_protein, the tetracycline 
resistance gene tet(O), a resistance to aminoglycoside antibiotics (aph3) a C39G 
peptidase involved in resistance to bacteriocins in 
42_FIG00638667_hypothetical_protein. ABC (ATP-binding cassette) transporters 
rely on the hydrolysis of an ATP molecule for the uptake or the extrusion of 
molecules (reviewed by Wilkens in 2015) and are used by bacteria for uptake of 
nutrients or extrusion of toxic molecules. In C. jejuni, a class of amino acid ABC-
transporters have been recently linked to abiotic stress resistance (peroxide, heat, 
and osmotic shock) and virulence in mouse and macrophage cell infection models 
(Lin et al., 2009). As far as the antibiotic resistance genes are concerned, 
Campylobacter species are known to exhibit resistance to a wide variety of 
antibiotics (Luangtongkum et al, 2010), and it is not surprising to find several 
antibiotic-resistance genes and MATE-like transporters in this analysis.  
A number of proteins carry conserved domains identified in other bacterial 
species, and some of them seem involved with pathogenicity. Examples are the 
conserved domains highlighted in the hypothetical proteins 
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26_FIG00470038_hypothetical_protein (a factor promoting the initiation of blood 
coagulation in S. aureus, Friedrich et al., 2003), 
33_cag_pathogenicity_island_protein (a membrane protein expressed by the Cag12 
pathogenicity island of H. pylori, Kim et al., 2006), and 4_hypothetical_protein (a cell-
surface protein promoting the lysis of blood cells and associated with pathogenicity 
of the insect pathogen Xenorhabdus nematophila, Cowles et al., 2005). The 
presence of genes derived from other bacterial species has been already observed 
in this plasmid family, as described in the previous chapter for the gene tet(O) and in 
the mosaic structure of a multiple-drug resistance plasmid (Nirdnoy et al, 2005). 
Several studies highlighted the genome plasticity of C. jejuni: Gibreel et al. in 2004 
were able to transfer a plasmid from C. jejuni to E. coli, and C. jejuni is naturally 
competent and can efficiently uptake DNA from the environment (De Boer 2002, 
Wang 1990, Vegge 2012). These mechanisms can be used by the bacterium in the 
process of adaptation. 
The regulative function often appears in the conserved domains identified in the 
hypothetical proteins encoded by the pTet-like plasmid pan-genome. A large number 
of conserved domains are associated with ATPases, Protein Kinases, 
Acetyltransferases, and Membrane receptors for signal transduction. It is not clear in 
which regulative process these proteins are involved, but their presence highlights 
the possibility of the association of the plasmid family pTet-like in a large number of 
regulative functions. 
A number of membrane transporter-associated conserved domains are also 
identified. For instance, a carbohydrate transporter domain is present in 
70_FIG00469626_hypothetical_protein and 7_FIG00471069_hypothetical_protein; 
ABC transporter domains are present in the hypothetical proteins 
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20_FIG00471065_hypothetical_protein and 54_FIG00470281_hypothetical_protein. 
The C4-carbohydrate transporter domain identified in the hypothetical protein 
7_FIG00471069_hypothetical_protein may be of particular interest in the 
Campylobacter species: it is reported that most Campylobacter strains cannot utilise 
sugars and several works have shown how they rely on the use of amino acids and 
C4 carbohydrates for survival and successful colonisation (Guccione et al., 2008; 
Stahl et al., 2011). 
Because of the presence of these transporter proteins, one of the functions of 
the plasmid could be the uptake of molecules that are present just in particular 
environments, giving the bacterium a higher fitness in different ecological niches. 
Finally, the comparison of the cluster analysis performed in the previous 
chapter (3.3.1) with the putative functions of the hypothetical proteins highlights 
different hypothetical functions associated with different gene frequencies in the set 
of C. jejuni strains analysed. 
In Campylobacter, several studies showed genes for particular functions 
associated with different ecological niches, such as a cluster of six genes within the 
O-linked flagellin glycosylation locus associated with strains isolated from livestock 
and a series of strains isolated from a sandy beach environment lacking a putative 
serine protease (Champion et al., 2005), or a gene cluster implicated in the 
production of B5 vitamin in strains isolated from cattle (Sheppard et al., 2013). In 
these cases, the association was found with chromosomal genes. 
The distribution of gene functions associated with frequencies at which those 
genes are found in a Campylobacter strain explains the composition of the plasmid 
pan-genome of the pTet-like plasmids. The “core” genes, found at a higher 
frequency, are associated with plasmid maintenance and transfer; the “accessory”, 
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found at a lower frequency, genes are associated with metabolism, regulation and 
resistance: it is possible that they give a higher fitness to the organism in 
determinate conditions and are added to the plasmid or maintained just in particular 
niches.  
In the next chapters, I explain the functions of some of the genes identified in 
the pTet-like plasmids via a mutagenesis analysis and phenotype evaluation. 
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Chapter 5 - Mutagenesis of pTet-like 
plasmid pan-genome accessory and core 
genes 
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After assessing a possible function for the 79 genes in the pTet plasmid pan-
genome, I next carried out a functional study of a set of these genes via targeted 
mutagenesis. 
In the last 30 years, several protocols for targeted mutagenesis in this C. jejuni 
have been described and successfully applied. These protocols are based on the 
introduction of a plasmid vector carrying an antibiotic resistance marker in C. jejuni 
via electroporation or conjugation. These plasmid vectors were constructed to be 
unable to replicate in Campylobacter (suicide-vector) and to include an antimicrobial 
resitance cassette, surrounded by two regions homologous to Campylobacter 
genome—specifically upstream and downstream of the gene targeted for deletion. 
Once the plasmid is transformed in Camptlobacter, and under selective pressure, the 
homologous regions would facilitate the recombination event that will result in the 
stable integration of the antimicrobial resistance cassette in the genome of the 
bacterium, substituting the gene targeted for deletion with the resistance cassette. 
The use of these protocols was successfully described in several recent publications 
(Reuter et al., 2013; Vegge et al., 2009). 
The main aims of this chapter are to develop a reliable method for the 
application of one these mutagenesis protocols and to mutate a subset of genes 
from the pTet-like plasmid pan-genome. 
Moreover, I will describe the genomic set up of the only C. jejuni strain in which 
I was able to stably introduce foreign DNA. 
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5.1 Assess the possibility to introduce mutations in C. jejuni strains 
I performed two studies in order to assess the possibility of producing mutants 
in different C. jejuni strains. 
First, the copy number of the pTet-like plasmid in different strains was 
measured. This is important: if the plasmid is present at a copy number higher than 1 
per cell, only one copy would be mutated. In this analysis, I evaluated the copy 
numbers of pCj2 and pCj3 and some of the plasmid genes present in the strain Cj1. 
Sequencing reads of Cj1, Cj2, and Cj3 were aligned back to the corresponding draft 
genome assemblies using Bowtie2 software. The “Mpileup” module of SamTools 
was then used to calculate the coverage per site of the alignment (Li et al., 2009). An 
ad hoc perl script extracted the average coverage value for each contig, and the 
coverage of plasmid genes (tetO, virD4, traQ and traR) was compared to the 
coverage of chromosomal genes (extract_pileup_coverage_gene.pl). The results are 
reported in Figure 5.1 and Table 5.1. The average coverage value of the plasmid 
genes—compared to the rest of the genome—suggests a copy number of 1. 
Once the low copy number of the plasmid pTet-like genes was established in 
the strains Cj1, Cj2, and Cj3, assuming the low copy number is conserved in the 
other strains analysed, the possibility of transforming C. jejuni strains with 
exogenous DNA was assessed. In order to do so, 19 strains of C. jejuni were 
transformed with pGEM::cj1411 via electroporation. Plasmid pGEM::cj1411 was 
designed in the University of Exeter’s Molecular Pathogenesis Laboratory (Olivia 
Champion, personal communication), to integrate fully into gene cj1411 of C. jejuni 
strain 11168 (AL111168.1). This gene is broadly conserved in C. jejuni and encodes 
a cytochrome P450 protein (Alvarez et al., 2013). Transformant strains could be 
identified thanks to the kanamycin cassette marker, in case of a successful 
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transformation and chromosomic integration of the resistance marker. The strains 
used in this analysis are reported in Table 5.2, together with the percentage of 
similarity of the gene cj1411, which was always higher than 98%. Only strain Cj1 
gave positive results, showing 102 transformant cells/ml able to grow on kanamycin 
when transformed with 1g of vector DNA (Materials and methods, Section 2.6). I 
decided to use the strain Cj1 to produce mutants of plasmid genes. 
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Figure 5.1 - Depths of genomic sequencing coverage for strains Cj1, Cj2, and Cj3. Genomic 
shotgun sequence reads were aligned against the respective genome assembly using BWA-mem and 
the depth of coverage was calculated for each site. Blue bars are the average depths across the 
entire genome sequence; red bars are the average depths for four plasmid genes (tetO, virD4, traQ 
and traR). The differences between whole genome and plasmid genes are not significant in any of the 
3 strains (Single tailed, t-test, p<0.01) 
 
 
 
 
Table 5.1 - Data associated to Figure 5.1 Average coverage per site of the alignment of Cj1, Cj2, 
and Cj3 sequencing reads versus their own assemblies. 
 
Genome average SD Plasmid genes SD 
Cj1 299.70 249.28 359.39 131.47 
Cj2 180.57 110.08 276.99 63.2 
Cj3 421.15 246.87 429.44 79.03 
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Table 5.2 - Strains used to assess for transformability with exogenous DNA. Columns show 
(from left to right): strain name (accession number in bracket, where available), nucleotide sequence 
identities versus the cj1411 gene, % of identity with the cj1411 gene, +/- = positive or negative result 
of the transformation. 
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5.2 Description of the strain Cj1 genome 
C. jejuni Cj1 is a strain originally isolated in Thailand from a hospitalised patient 
with bloody diarrhoea in 2009. That strain was positive when tested using the PCRs 
for plasmid marker genes and the tetracycline resistance gene reported in Chapter 3. 
However, I was unable to isolate a plasmid from strain Cj1 (see Figure 3.5). This 
strain exhibits the majority of the genes annotated in the plasmid pTet NC00079.1 
(Table 3.5), as well as the majority of the genes (48) annotated in the pTet-like 
plasmid-pan genome. When compared to the global plasmid pan-genome of C. 
jejuni, it shows the presence of 99 genes out of 168. It possible that the plasmid is 
integrated into the chromosome or that the plasmid is larger than 100 kbp and 
impossible to extract with any of the techniques I used in Chapter 3. 
Strain Cj1 was sequenced using Illumina HiSeq (100bp paired-end reads, short 
insert) and Illumina MiSeq (300bp paired-end reads, short insert). An assembly was 
performed from this sequencing data using SPAdes (Bankevich et al., 2012; 
Materials and Methods, Section 2.10.4). The final assembly statistics are reported in 
Table 3.3. The analysis of the graph file performed with Bandage (Wick et al., 2015) 
shows two distinct contig sets (Figure 5.2 A), whose contiguity can be inferred via 
the paired end information. The longer contig set is 1.6 Mb and represents the 
chromosome of strain Cj1. The shorter contig set is 115 kbp total and includes the 99 
genes from the plasmid pan genome (Figure 5.2 B). This is consistent with reports 
that some strains of C. jejuni possess megaplasmids (pCJDM202 and pCJDM67 L, 
Table 3.14). Analysing the coverage of the contigs included in the shorter set, it is 
possible that 2 of them (contig 18 and 19) are repeated in the mega plasmid of Cj1, 
assuming it is present, as they show a read coverage almost double when compared 
to the rest of the contigs included in this set (Figure 5.2 C).  
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A Blastn search against the bacterial sequence database of contigs 8, 15, 16, 
18, 19 and 20 against the NCBI database showed similarity between 95 and 100% 
with plasmids pCJDM202, pCJDM67 L, the plasmid from strain RM3194 and plasmid 
pcjDM (accession numbers CP014743.1, CP014745.1, CP014345.1, CP013117.1). 
The same contigs from the Cj1 genome assembly show a high percent of similarity 
(between 95% and 100%) with the genome of strains 00-1597 and RM1221, which 
are not reported to possess plasmids. 
Table 5.3 shows the results of the Blastn search against the bacterial sequence 
database for the contigs 8, 9, 15, 16, 18, 19, and 20. 
Contig 9 of strain Cj1 shows the presence of 45 genes listed in the pTet-like 
plasmid pan genome (Figure 5.2 D), and its sequence was used to design the 
mutants. An image representing the contig 9 is reported in Figure 5.3. The genes 
present in contig 9 of the genome sequence of Cj1 are described in Table 5.3. 
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Figure 5.2 - Genome assembly of the strain Cj1 (A) Graphical representation of the assembly of 
the strain Cj1 using Bandage software. Each grey segment of the figure represents a contig of the 
genome assembly (grey lines), linked to each other using the “graph” information provided by the 
software SPAdes. Numbers shown on the grey segments are referred to the number of the contig in 
the genome assembly. Two contig sets are identifiable; each contig in the different sets is linked 
thanks to the paired end information. (B) Zoom on the shorter contig set (total length 115 kbp). 
Colours are referred to the BLASTn hits of the C. jejuni plasmid pan-genome genes versus the strain 
Cj1. (C) Zoom on the shorter contig set. Average coverage of each contig, as reported by the 
automated assembler SPAdes, is shown on each contig. (D) Zoom on the shorter contig set. Colours 
are referred to the BLASTn hits of the pTet-like plasmid pan-genome genes versus the strain Cj1. 
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Table 5.3 – Results of the first four BLASTn hits of contigs 8, 9, 15, 16, 18, 19 and 20 of C. 
jejuni strain Cj1 genome assembly versus the bacterial genome database. For each of the seven 
contigs each column shows (from left to right): the description of the the sequence hit, the maximum 
BLASTn score, the total score, the % of coverage of the query, the e-value, the % of identity, the 
accession number of the hit sequence. Contigs 8, 15, 16, 18, 19, and 20 show hits both on the 
chromosome and on plasmids of C. jejuni strains. 
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Figure 5.3 - Graphical representation of the genes annotated on the Contig 9 
(NODE_9+_length_43551_cov_27.7867) of the Cj1 draft genome sequence. Yellow arrows 
represent the genes; the gene names (as reported in Chapter 3.3) are linked to each arrow. 
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Table 5.4 - Genes annotated on the Contig 9 (NODE_9+_length_43551_cov_27.7867) of the 
draft genome sequence of strain Cj1. Columns show (from left to right): gene name assigned by 
RAST automated annotation, gene name as assigned in the pTet-like plasmid pan genome analysis 
(chapter 3, section 3), relative position of the first gene nucleotide, relative position of the end 
nucleotide, transcription direction, names of the mutant strains (for genes selected for mutagenesis, 
described in Chapter 5.3), cluster number of the genes selected for mutagenesis (according to the 
pTet-like plasmid pan genome analysis described in Chapter 3.3.2). 
 
 
 
 
 
 
 
 
 
 
Gene name (RAST assembly) Gene name (Homologous to pTet-like plasmsd pan-genome) Start End Direction Mutant name Cluster (Figure 3.24)
fig|354242.102.peg.1781 31_FIG00471711_hypothetical_protein_NTPase 57 668 -
fig|354242.102.peg.1782 18_FIG00470991_hypothetical_protein 697 978 - Dcri 1
fig|354242.102.peg.1783 45_Ribbon-helix-helix_protein_copG_family_domain_protein 1172 1723 +
fig|354242.102.peg.1784 44_IncQ_plasmid_conjugative_transfer_TraR_(VirD2) 1723 3111 +
fig|354242.102.peg.1785 6_FIG00469644_hypothetical_protein 3134 3874 + Datr 3
fig|354242.102.peg.1786 77_FIG00472625_hypothetical_protein 3849 4577 - DlabA 3
fig|354242.102.peg.1787 56_FIG00470802_hypothetical_protein 4714 10524 -
fig|354242.102.peg.1788 25_FIG00469707_hypothetical_protein 10527 10793 - Dhyp25 2
fig|354242.102.peg.1789 21_hypothetical_protein 10796 11356 - DparA 2
fig|354242.102.peg.1790 13_FIG00469557_hypothetical_protein 11415 11681 -
fig|354242.102.peg.1791 12_FIG00471537_hypothetical_protein 11686 12243 - DepsG 3
fig|354242.102.peg.1792 11_FIG00469626_hypothetical_protein 12240 12752 - Dmate 3
fig|354242.102.peg.1793 20_FIG00471065_hypothetical_protein 12749 13102 - Dabc 1
fig|354242.102.peg.1794 58_FIG00471069_hypothetical_protein 13062 13295 -
fig|354242.102.peg.1795 67_repA_replication_protein 13647 14300 -
fig|354242.102.peg.1796 17_hypothetical_protein 14479 14661 -
fig|354242.102.peg.1797 16_Tetracycline_resistance_protein_TetO 15056 16975 - DtetO 3
fig|354242.102.peg.1798 15_DNA_topoisomerase_II 17334 17513 -
fig|354242.102.peg.1799 55_FIG00470802_hypothetical_protein 17532 18953 -
fig|354242.102.peg.1800 53_DNA_topoisomerase_III_28828-31020_00-0949_pTet 19059 21251 -
fig|354242.102.peg.1801 27_FIG00470273_hypothetical_protein 21514 22134 - Dhyp27 1
fig|354242.102.peg.1802 32_FIG00469957_hypothetical_protein 22205 23002 - DparB 1
fig|354242.102.peg.1803 28_IncQ_plasmid_conjugative_transfer_protein_TraQ 23005 23769 -
fig|354242.102.peg.1804 33_cag_pathogenicity_island_protein 23781 24218 - Dcag 2
fig|354242.102.peg.1805 29_Coupling_protein_VirD4_ATPase 24199 26010 -
fig|354242.102.peg.1806 34_VirB11 26011 27003 -
fig|354242.102.peg.1807 39_VirB10 26984 28159 -
fig|354242.102.peg.1808 36_VirB9 28186 29073 -
fig|354242.102.peg.1809 30_VirB8 29070 29732 -
fig|354242.102.peg.1810 38_VirB7 29722 29889 -
fig|354242.102.peg.1811 52_VirB6 29879 30877 -
fig|354242.102.peg.1812 51_Minor_pilin_of_type_IV_secretion_complex_VirB5 30874 31845 -
fig|354242.102.peg.1813 37_FIG00470457_hypothetical_protein 31849 32124 -
fig|354242.102.peg.1814 41_Single-stranded_DNA-binding_protein 32140 32562 -
fig|354242.102.peg.1815 9_FIG00469571_hypothetical_protein 32596 33162 - Dunk9 3
fig|354242.102.peg.1816 50_Phage_Rha_protein 33159 33710 -
fig|354242.102.peg.1817 49_VirB4 33721 36489 -
fig|354242.102.peg.1818 35_VirB2 36502 36765 - DvirB2 1
fig|354242.102.peg.1819 26_FIG00470038_hypothetical_protein 36935 37258 + Dcoag 1
fig|354242.102.peg.1820 22_Virulence-associated_protein_2_(vapD) 37249 37626 + DvapD 1
fig|354242.102.peg.1821 24_Site-specific_recombinase_resolvase 37623 38237 +
fig|354242.102.peg.1822 hypotetical protein 38246 38365 -
fig|354242.102.peg.1823 48_FIG00470960_hypothetical_protein 38447 40240 -
fig|354242.102.peg.1824 19_FIG00471111_hypothetical_protein 40243 40446 - DhicA 2
fig|354242.102.peg.1825 23_FIG00470952_hypothetical_protein 40439 40657 -
fig|354242.102.peg.1826 hypotetical protein 41391 41531 +
fig|354242.102.peg.1827 hypotetical protein 41918 42541 -
fig|354242.102.peg.1828 47_IncQ_plasmid_conjugative_transfer_protein_TraG 42992 43255 -
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5.3 Genes selected for mutagenesis 
A set of 17 genes were selected from the pTet-plasmid pan genome for 
mutagenesis. These genes were part of either the “core” or the “accessory” pTet 
plasmid pan-genome. They were selected on the basis of the automated annotation 
of the genome fo Cj1 and of the conserved domains identified, described in Chapter 
4. I decided to design mutants on genes present in the genome of the strain Cj1, 
whose function was not fully described or on genes whose function could be linked 
to phenotypes previously undescribed in C. jejuni. The following targets were 
selected for mutagenesis. The names given to the mutants reflect the conserved 
domains identified in the hypothetical protein if a conserved domain was found. 
Datr - 6_FIG00469644_hypothetical_protein (see S4.4) - A partial acetyl 
transferase domain is present in the hypothetical protein encoded by this gene 
(Neuwald et al., 1997, Cort et al., 2008). 
DlabA - 77_FIG00472625_hypothetical_protein (see S4.64) - This hypothetical 
protein shows a LabA-like conserved domain, associated with a variety of diverse 
regulatory and metabolic functions (Taniguchi et al., 2007; Taniguchi et al., 2010; 
Tang et al., 2008; Parsons et al., 2002). 
DepsG - 12_FIG00471537_hypothetical_protein (see S4.9) - Several 
conserved domains are here identified: a domain for an ATPase associated with 
diverse cellular activity (Iyer et al., 2004), a CsbA domain involved in stress response 
in B. subtilis (Petersohn et al., 2001), and an EpsG domain involved in production 
and maintenance of biofilm structure (Branda et al., 2004). 
Dabc - 20_FIG00471065_hypothetical_protein (see S4.15) - A conserved 
domain for an ABC (ATP-binding cassette) membrane transporter is described in this 
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hypothetical protein (Reizer et al., 1992), together with a VanZ domain for 
glycopetide antibiotics resistance (Arthur et al., 1995). 
DparB - 32_FIG00469957_hypothetical_protein (see S4.26) - Conserved 
domains involved with nuclease activity are identified in this hypothetical protein 
(ParB, AAA-domain, Easter and Gober, 2002). A domain for the cellular sensing of 
L-fucose is also described (Felder et al., 1999). Together with the ParA domain 
identified in the protein 21_hypothetical_protein, a putative function of this protein is 
the control and regulation of DNA replication.  
Dcag - 33_cag_pathogenicity_island_protein (see S4.27) - A conserved domain 
(Cag12) belonging to the cag pathogenicity island of Helicobacter pylori is described 
in this hypothetical protein. The function of Cag12 is unknown (Kim et al., 2006). 
Dunk9 - 9_FIG00469571_hypothetical_protein (see S4.6) - The only conserved 
feature identified in this hypothetical protein is associated with chromosomal 
structure in meiotic phase in eukaryotic cells (Meuwissen et al., 1992). Its function is 
not yet fully described but its structure shows motifs present in DNA-binding proteins 
and several potential targets for protein kinases. There is no function that can be 
associated with bacterial cells in this hypothetical protein. 
Dcoag - 26_FIG00470038_hypothetical_protein (see S4.20) - A conserved 
domain from a blood coagulase of S. aureus is described in this hypothetical protein 
(Friedrich et al., 2003). 
DvapD - 22_Virulence-associated_protein_2_(vapD) (see S4.17) - The VapD 
domain identified here is part of the CRISPR/Cas superfamily, involved in the 
protection of the bacterium against foreign DNA (Boyaval et al., 2007; Nam et al., 
2012). 
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DhicA - 19_FIG00471111_hypothetical_protein (see S4.14) - The HicA_toxin 
domain identifies this hypothetical protein as the cognate toxin of the HicA/B toxin-
antitoxin system (see 4.3.18, 23_FIG00470952_hypothetical_protein; Yamaguchi 
and Inouye, 2011; Makarova et al., 2006). 
Dcri - 18_FIG00470991_hypothetical_protein (see S4.13) - This hypothetical 
protein shows several conserved domains, including a a Cas8a1 domain associated 
to CRISPR/Cas proteins (Boyaval et al., 2007) and a PRK14149 domain, part of the 
GrpE superfamily which includes heat shock and bacterial chaperones proteins 
(Harrison, 2003). 
Dhyp25 - 25_FIG00469707_hypothetical_protein - the conserved domains 
search did not highlight the presence an any conserved domain in thys hypothetical 
protein. 
DparA - 21_hypothetical_protein (see S4.16) - This hypothetical protein shows 
the presence of a ParA domain, which is part of the ParA-ParB system and promotes 
the regulation of DNA replication (Easter and Gober, 2002). FlgG, a member of the 
ParA-ATPase superfamily, has been shown to be regulate the production of polar 
flagella in C. jejuni (Balaban and Hendrixson, 2011). 
Dmate - 11_FIG00469626_hypothetical_protein (see S4.8) - The conserved 
domain identified in this protein is associared with the MATE protein family 
(“Multidrug And Toxic compound Extrusion”; Putman et al., 2000; Hvorup et al., 
2003). The function of this protein family is exporting metabolites across the cell 
membrane and conferring multi drug resistance to bacteria. 
Dhyp27 - 27_FIG00470273_hypothetical_protein (see S4.22) - With the 
exception of a single domain of unknown function conserved in Mycoplasma species 
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(Sasaki et al., 2002), this protein does not show the presence of any conserved 
domain. 
DvirB2 – 35_VirB2 (see S4.29) - According to the automated annotation and 
the conserved domains search, this protein encodes for the main component of the 
type four secretion system pilus (VirB2; Kalkum et al., 2002; Schulein and Dehio, 
2002). 
A further mutant has been designed in the tet(O) gene in order to have a 
positive control for a mutation with a known phenotype.  
The targets selected for mutagenesis are also highlighted in Table 5.4, 
indicating the associated mutant name. The characteristics of the genes selected for 
deletion are summarised in Table 5.5. 
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Table 5.5 – Summary of the characteristics of the genes selected for deletion. Columns show 
(from left to right): mutant name, gene name (accordin to the pTet-like plasmid pan-genome described 
in Chapter 3.3), predicted gen function, gene length, and protein length. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Name (Chapter 3.3) Predicted function from associated domains Gene (bp)
Datr 6_FIG00469644_hypothetical_protein Acetyltransferase 705
Dunk9 9_FIG00469571_hypothetical_protein Unknown - Chromosome structure [Eukariotic] 552
DepsG 12_FIG00471537_hypothetical_protein AAA_23 ATPase - EpsG domain [Biofilm/EPS] 558
Dabc 20_FIG00471065_hypothetical_protein ABC transporter - Glycopeptide antibiotics resistance 399
Dcoag 26_FIG00470038_hypothetical_protein Blood coagulase (S. aureus) 324
Dcag 33_cag_pathogenicity_island_protein Membrane protein (Helicobacter pylori) 438
DparB 32_FIG00469957_hypothetical_protein ParB-like domain - Ligand-binding of fucose receptor - AAA15 ATPase 798
DlabA 77_FIG00472625_hypothetical_protein LabA regulatory domain family 729
DhicA 19_FIG00471111_hypothetical_protein HicA toxin 204
DvapD 22_Virulence-associated_protein_2_(vapD) CRISPR/Cas2 408
DtetO 16_Tetracycline_resistance_protein_TetO Tetracycline resistance 1920
Dcri 18_FIG00470991_hypothetical_protein CRISPR/Cas8 - Viral protein domain - Varous cellular functions 282
Dhyp25 25_FIG00469707_hypothetical_protein --- 267
DparA 21_hypothetical_protein ParA ATPase - replication protein 561
Dmate 11_FIG00469626_hypothetical_protein MATE-like protein [Multidrug toxin extrusion] 513
Dhyp27 27_FIG00470273_hypothetical_protein Alpha helices rich domain 621
DvirB2 35_VirB2 TrbC/VirB2 264
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5.4 Mutagenesis of Campylobacter jejuni 
The protocol for the mutagenesis of C. jejuni was a variation of the allelic 
exchange protocol used previously for Campylobacter and other bacteria (Van Vliet 
et al., 1998, Karlyshev and Wren 2005, Tunio et al., 2010). 
The protocol is summarised in Figure 5.4.1. PCR was used to amplify 500 to 
700 base pair regions upstream and downstream the target gene. The PCR primers 
were designed so that amplification would introduce a 20 to 25 bp complementary 
overhang at the 3’ end of the upstream region and the 5’ end of the downstream 
region. This overhang included a bamHI restriction site (Figure 5.4 A). 
An overlapping extension PCR was performed using the upstream forward 
primer (USF) and the downstream reverse primer (DSR) and the two purified PCR 
products from the previous step as template DNA (Figure 5.4 A). The construct, 
composed of 500 to 700 bp flanking the 5’ and the 3’ extremity of the gene of 
interest, intervaled by a bamHI site, was cloned in pGEM-T easy (Promega), via TA 
cloning (Figure 5.4.1 A, Materials and Methods, Section 2.4). The pGEM::construct 
vector was cloned into chemically competent E. coli TOP10 and positive clones were 
selected (Materials and Methods, Section 2.5). The pGem::construct vector was then 
digested with bamHI enzyme. A plasmid vector pJMK30 containing a kanamycin 
resistance cassette (kanR_cas, van Vliet et al., 1998, kindly provided by Dr Mark 
Reuters) was digested with bamHI, resulting in the digestion of the cassette from the 
plasmid (Karlyshev and Wren, 2005). The kanR_cas was subsequently cloned into 
the digested pGem::construct vector, resulting in pGem::construct::kanR_cas vector 
(Figure 5.4 B). This vector was then introduced in Campylobacter via electroporation 
(Van Vliet et al., 1998). 
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pGEM-T Easy is not able to replicate in Campylobacter: the homologous 
regions on the vector promotes the double recombination event on the 
Campylobacter genome. The result is a substitution of the gene of interest with the 
kanamycin cassette (Figure 5.4 C). C. jejuni transformants were screened on MH 
kan50 plates and patched replicated on CBA with Skirrow supplement (Materials and 
methods 2.6). 
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Figure 5.4 - C. jejuni mutagenesis protocol. (A) Primer pairs USF-USR and DSF-DRS are used to 
amplify 500-700 base pairs upstream and downstream of the gene of interest and to include a BamHI 
in the PCR product. Overlapping extension is used to join the upstream and the downstream 
segment, which is then cloned in a pGEM-Teasy vector (pGEM::construct). (B) A kanamycin 
resistance cassette is cloned in the pGEM::construct vector using the BamHI restriction site 
(pGEM::construct:: kanR_cas). (C) The pGEM::construct:: kanR_cas is transformed in C. jejuni. The 
homology regions promote the double recombination event, and the substitution of the target gene 
with the kanR cassette. 
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5.5 Constructs design and mutagenesis 
Primer pairs were used to amplify the upstream and the downstream section of 
each target gene according to Table 5.6. A gradient of temperatures was tested to 
find the optimal annealing temperature for each primer pair. Figure 5.5 A and B show 
the result of a temperature gradient of annealing temperature for the primer pairs 
Gac_USF/Gac_USR and Gac_DSF/Gac_DSR. The amplicons were then used in an 
overlapping extension PCR (Ho et al., 1988), inserting a BamHI restriction site 
between the two fragments. Figure 5.5 C shows the result of such reaction for the 
construct necessary for the mutant Dcag. 
The construct was cloned into pGEM-T Easy plasmid (Promega) obtaining the 
plasmids listed in Table 5.7 and transformed into chemically competent E. coli 
TOP10 cells. The presence of the construct in the pGEM-T Easy plasmid was 
assessed via amplification with SP6 and T7 primers (annealing outside the 
integration point of pGEM-T Easy) and sequencing. The recombinant plasmids 
pGEM carrying the construct of interest and plasmid pJMK30 carrying the kanamycin 
(kanR) resistance cassette were digested with the BamHI restriction enzyme, 
obtaining a linearised pGEM::construct plasmid and a 1440 bp kan cassette. The 
result of the BamHI digestion for the plasmid vector pJMK30 is shown in Figure 5.6.  
The kan cassette and the linearised pGEM::construct plasmid were purified 
from the agarose gel and ligated to obtain a pGEM::construct::kan_cassette plasmid; 
Table 5.7 lists the plasmids obtained. To check that the orientation of the kanR 
cassette was the same of the gene to be deleted, the plasmid pGEM::construct:: 
kanR _cassette was used as PCR template with the primer pairs kan_out_F/T7 and 
kan_out_R/SP6 (Figure 5.7, Table 5.8). The PCR with primers kan_out_F/T7 and 
kan_out_R/SP6 would only yield a product if the kanR cassette were integrated with 
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the same orientation to the fragments of the gene to be deleted. The result of the 
PCR reaction with the primers kan_out_R/SP6 for the vector pGEM::cag::kan_R is 
shown in Figure 5.8.  Each plasmid pGEM::construct::kan_cassette was also sanger-
sequenced using the SP6 and T7 primers and maintained in E. coli TOP10 cells. 
Finally, each plasmid was transformed into electro-competent C. jejuni strain 
Cj1 cells, promoting the double recombination and the substitution of the target gene 
with the kanamycin resistance cassette and therefore meaning recombinants should 
grow on MH plates supplemented with 50 µg/ml of kanamycin.  
Six transformant strains did not grow on the screening plate. These were the 
mutant strains Dcri, Dhyp25, DparA, Dmate, Dhyp27, and DvirB2. This can be due to 
the lack of recombination between the construct and the plasmid vector (the 
substitution of the target gene with the kanamycin cassette did not happen), to fact 
that the mutation disrupted an essential gene, or due to the fact that the pTet-like 
plasmid carried that may by the strain Cj1 was lost after the mutation of a gene that 
stopped it from replicating or transmitting to the daughter cells. 
The mutants that were able to grow on kanamycin were screened for 
successful mutation: five to ten colonies of transformant C. jejuni were tested for the 
substitution of the gene of interest with the kanamycin resistance cassette via PCR 
with the primers XXX_screenEXT_F and XXX_screenEXT_R (Table 5.9). The 
annealing site of these primers was 50-100 bp upstream of the USF primer and 50-
100 bp downstream of the DSR primer, respectively. The resulting PCR products are 
shown in Figures 5.9 to 5.16, the predicted length of each product and the primer 
sequences are shown in Table 5.9.  
The sequence of each PCR product was assessed via Sanger-sequencing in 
order to confirm the successful construction of the mutant. 
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Table 5.6 - Primers designed for the production of each mutant. Columns show (from left to right): 
mutant name as reported in Section 5.3, name of each primer, sequence of each primer, length of the 
amplified product, length of the overlapping PCR product. 
 
 
 
 
 
 
 
Mutant Name Primer Name Primer Sequence PCR product Length Overlapping PCR product Length
DtetO Dtet_USF GCAAAATATAATGAATTTGCA
Dtet_USR TATATGACTTTTGCAAGCTGggatccGTGATTTTCCTCCTATCAAC
Dtet_DSF GTTGATAGGAGGAAAATCACggatccCAGCTTGCAAAAGTCATATA
Dtet_DSR TTCATCAGCCGGATAAAGGT
Datr Datr_USF GGCTAAAGAATTGGCTAAG
Datr_USR AAATTATATAGGAGTAAGAAATAggatccTAAAAACAGACGAAAGGATG
Datr_DSF CATCCTTTCGTCTGTTTTTAggatccTATTTCTTACTCCTATATAATTT
Datr_DSR TAGAAAGGGTTGTAAGAG
DlabA Dlab_USF ATAAGCGGAGAAAGAACAG
Dlab_USR GTTTAATAAAAATAAAAGCAAAAAggatccTGTTGCGTAGTCCTAATTTATTA
Dlab_DSF TAATAAATTAGGACTACGCAACAggatccTTTTTGCTTTTATTTTTATTAAAC
Dlab_DSR GAAATAAGAGCGTTTGTG
DepsG Deps_USF TAATGCCTATATTTGTCGCG
Deps_USR TATCCATCTCTAGCATTTTAggatccTTATCCTCCTTTAATATTTC
Deps_DSF GAAATATTAAAGGAGGATAAggatccTAAAATGCTAGAGATGGATA
Deps_DSR ATGTTCTAAGTAAAGAATTG
Dabc Dabc_USF ATGTGAAAGACGGTATAAAG
Dabc_USR TGCTACTATTGTAATTTTTTggatccTAATCAATCTTTTTTCTTTTTC
Dabc_DSF GAAAAAGAAAAAAGATTGATTAggatccAAAAAATTACAATAGTAGCA
Dabc_DSR ATTTACTACTCTCATTTATC
DparB Dpar_USF AGTTAAACCACCTGAATG
Dpar_USR TTTGTATATAATTGTTCTGTggatccTGTTATTTCTCGTTTATCC
Dpar_DSF GGATAAACGAGAAATAACAggatccACAGAACAATTATATACAAA
Dpar_DSR TTGAAATTACAGCTATAAAC
Dcag Dcag_USF TCATAACCTCTTTCCCAATC
Dcag_USR AATTCAAATTATAGGAGAAAACAggatccAGGAGAGAAAAATGAAAAAAATAT
Dcag_DSF ATATTTTTTTCATTTTTCTCTCCTggatccTGTTTTCTCCTATAATTTGAATT
Dcag_DSR TTTATGGCTGGTTATTGG
Dunk9 Dunk_USF CAAGAAGTGCAATTTGGCAC
Dunk_USR CTTTTTGTTGGTGTAATATTTTTTggatccTGCAACTTCTTTGGATCTTT
Dunk_DSF AAAGATCCAAAGAAGTTGCAggatccAAAAAATATTACACCAACAAAAAG
Dunk_DSR ATTTGATCTGAATTAAGATC
Dcoag Dcoa_USF AAATTACTAAGTTCCATTTG
Dcoa_USR GATTTTTGATGAAAGGATAAAAAggatccATCGCAAAGCAATTAATTTT
Dcoa_DSF AAAATTAATTGCTTTGCGATggatccTTTTTATCCTTTCATCAAAAATC
Dcoa_DSR TCTTAGACGCAGGATTAG
DvapD Dvap_USF CCATCATCTTTGTATAATAAC
Dvap_USR AAGCTGAAGGAGAAGGAATggatccATATAGCATACATAAGAGTATC
Dvap_DSF GATACTCTTATGTATGCTATATggatccATTCCTTCTCCTTCAGCTT
Dvap_DSR ACATAAATGCAATTGTGAGTAG
DhicA Dhic_USF TAACTTATGGGTGATTGTATGC
Dhic_USR AATAGTATTGCGTTTAGGCATTTggatccTCAGGCATTTGCTAAAACCATTG
Dhic_DSF CAATGGTTTTAGCAAATGCCTGAggatccAAATGCCTAAACGCAATACTATT
Dhic_DSR TACAGAGCTACCCATAAGAC
Dcri Dcri_USF TTTCCACTTCTAAGAATC
Dcri_USR CTCCTATGATAAATTTTTGTTggatccAACATCTCCTTTATAATATT
Dcri_DSF AATATTATAAAGGAGATGTTggatccAACAAAAATTTATCATAGGAG
Dcri_DSR GTTGCTAATTTCTCTATCTG
Dhyp25 Dhyp25_USF TAACCATAAAGAAGATAGAG
Dhyp25_USR GCAAGGATATTGTAACATTTggatccTATTATTTATCCTTTCTAATAAAA
Dhyp25_DSF TTTTATTAGAAAGGATAAATAATAggatccAAATGTTACAATATCCTTGC
Dhyp25_DSR GCTTAGTTCGCTAACATC
DparA Dpaa_USF AGCTTCAGGAATACTATG
Dpaa_USR AAATGGTTTTTTTTCCATTAggatccAAAAAAACCTTTTTTATATTTTTG
Dpaa_DSF CAAAAATATAAAAAAGGTTTTTTTggatccTAATGGAAAAAAAACCATTT
Dpaa_DSR TTTAAAGCTTCTGCTATTG
Dmate Dmate_USF GTTGAGTTTCAGCCGAATG
Dmate_USR TTTGACAAATTTACTACTCTggatccCTTTGATTTACACTCCATGA
Dmate_DSF TCATGGAGTGTAAATCAAAGggatccAGAGTAGTAAATTTGTCAAA
Dmate_DSR TATCGCAAATGCCATAAC
Dhyp27 Dhyp27_USF AATCCTCCTAATGATGAAG
Dhyp27_USR CCTTTATGAGGTGCATATTTggatccTTTTTCTCCTTTTTAAATTTTTTA
Dhyp27_DSF TAAAAAATTTAAAAAGGAGAAAAAggatccAAATATGCACCTCATAAAGG
Dhyp27_DSR GTAATCTTGTCGCTATGG
DvirB2 Dvir_USF ATATTGTCTATGCTCGAAAC
Dvir_USR CTCCATAGCTAGTCCTATTggatccCCATATCCTTTCGTTAAAAAATTG
Dvir_DSF CAATTTTTTAACGAAAGGATATGGggatccAATAGGACTAGCTATGGAG
Dvir_DSR AGGTTAGTTTATCTTCGATAG
1240
1238
1194
635
550
505
551
626
659
624
623
557
704
629
551
541
610
651
548
625
718
1118
610
1107
544
1217
1132
594
667
595
632
1025
1130
1373
1130
1082
582
1154
622
594
1086
587
643
1218
621
558
1100
592
662
1227
614
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Figure 5.5 - Production of the construct for the mutant Dcag (A) Result of the amplification with 
the primers Dcag_USF/Dcag_USR. Lane 1: 1kb plus ladder; lane 2-9: amplification result on Cj1 
strain using a gradient of annealing temperature between 65 ̊C (lane 2), and 50   ̊C (lane 9); lane 10, 
NTC. (B) Result of the amplification with the primers Dcag_DSF/Dcag_DSR. Lane 1: 1kb plus ladder; 
lane 2-9: amplification result on Cj1 strain using a gradient of annealing temperature between 65 ̊C 
(lane 2), and 50   ̊C (lane 9); lane 10, NTC. Annealing temperature of 60   ̊C is shown in lane 4. (C) 
result of overlapping extension PCR used for the Dcag mutant. Lane 1-3, overlapping extension PCR 
(Dcag_USF/ Dcag_DSR primers, using the purified product from 3.5.1 A and 3.5.1 B as template); 
lane 4, 1kb plus ladder; lane 5, positive control (using the DNA extraction from strain Cj1 as templete); 
lane 6, NTC. Each gel was 1% agarose in TAE. Run 30-45 minutes at 120 V. 
A  
B  
C  
 
 
500 
1500 
500 
1500 
500 
1500 
5000 
A 
B 
C 
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Table 5.7 - Plasmid vectors used for the production of the mutant strains. Columns show (from 
left to right): plasmid name, length of the plasmid, brief description of the plasmid vector, markers 
present on each plasmid, reference (where available). 
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Figure 5.6 - Plasmid pJMK30 digested with BamHI. Lane 1 and 15, 1kb plus ladder (Thermo 
scientific); lane 2-14, digestion of pJMK30 with BamHI restriction enzyme. 1% agarose in TAE. Run 
for 1 hour at 120 V. 
 
 
 
Figure 5.7 - Graphical representation of a pGEM::construct::kanR Campylobacter suicide 
vector. Positions of primers SP6, T7, Kan_out_F and Kan_out_R are shown. 
 
 
 
Table 5.8 - PCR primers used to check the integration and the orientation of the kanamycin 
cassette in the plasmid vectors described in Table 5.7. 
 
 
 
 
 
 
 
 
 
 
 
Primer name Primer sequence
kan_out_F CATCCTCTTCGTCTTGGTAGC
kan_out_R TTGCCTTCTGCGTCCGGTCG
SP6 ATTTAGGTGACACTATAG
T7 TAATACGACTCACTATAGGG
500 
1500 
5000 
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Figure 5.8 - Result of the screening of six E. coli clones transformed with the ligation between 
pGEM::cag::kan_R and the kanamycin resistance cassette (both digested with BamHI). Lane 1, 
1kb plus ladder (Thermo scientific); lane 2-7, screening with kan_out_R/SP6 primers of 6 different E. 
coli clones; lane 8, NTC. 1% agarose in TAE. Run for 1 hour at 100 V. 
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Figure 5.9 - PCR testing the successful production of DhicA mutant. Amplification performed with 
primers annealing outside of the DNA fragments used for the construct production. Lane 1, 1kb ladder 
(Thermo scientific); Lane 2, DhicA mutant confirmation PCR; Lane 3, positive control (Cj1 WT); lane 
4, NTC.  1% agarose in TAE. Run for 1 hour at 100 V. 
 
 
 
Figure 5.10 - PCR testing the successful production of DlabA and Datr mutant. Amplification 
performed with primers annealing outside of the DNA fragments used for the construct production. 
Lane 1, 1kb plus ladder (Thermo scientific); lane 2, positive control (Cj1 WT) with DlabA mutant 
confirmation primers; lane 3, DlabA mutant confirmation PCR; lane 5, positive control (Cj1 WT) with 
Datr mutant confirmation primers; lane 6, Datr mutant confirmation PCR; lane 4 and 7, NTC. 1% 
agarose in TAE. Run for 45 minutes at 100 V. 
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Figure 5.11- PCR testing the successful production of DvapD mutant. Amplification performed 
with primers annealing outside of the DNA fragments used for the construct production. Lane 1, 1kb 
plus ladder (Thermo scientific); Lane 2, positive control (Cj1 WT); Lane 3, DvapD mutant confirmation 
PCR; lane 4, NTC.  1% agarose in TAE. Run for 45 minutes at 100 V. 
 
 
 
Figure 5.12 - PCR testing the successful production of Dcoag mutant. Amplification performed 
with primers annealing outside of the DNA fragments used for the construct production. Lane 1, 1kb 
plus ladder (Thermo scientific); Lane 2, positive control (Cj1 WT); Lane 3, Dcoag mutant confirmation 
PCR; lane 4, NTC.  1% agarose in TAE. Run for 45 minutes at 100 V. 
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Figure 5.13 - PCR testing the successful production of DparB mutant. Amplification performed 
with primers annealing outside of the DNA fragments used for the construct production. Lane 1, 1kb 
plus ladder (Thermo scientific); Lane 2, positive control (Cj1 WT); Lane 3, DparB mutant confirmation 
PCR; lane 4, NTC.  1% agarose in TAE. Run for 45 minutes at 100 V. 
 
 
 
Figure 5.14 - PCR testing the successful production of Dabc mutant. Amplification performed 
with primers annealing outside of the DNA fragments used for the construct production. Lane 1, 1kb 
plus ladder (Thermo scientific); lane 2, NTC; Lane 3, Dabc mutant confirmation PCR; Lane 4, positive 
control (Cj1 WT).  1% agarose in TAE. Run for 1 hour at 100 V. 
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Figure 5.15 - PCR testing the successful production of DepsG and Dunk9 mutant. (A) 
Confirmation of DepsG and Dunk9 mutant production. Amplification performed with primers annealing 
outside of the DNA fragments used for the construct production. Lane 1, 1kb plus ladder (Thermo 
scientific); lane 2, DepsG mutant confirmation PCR; lane 3, positive control (Cj1 WT) with DepsG 
mutant confirmation primers; lane 5, Dunk9 mutant confirmation PCR; lane 6, positive control (Cj1 
WT) with Dunk9 mutant confirmation primers; lane 4 and 7, NTC. 1% agarose in TAE. Run for 45 
minutes at 100 V. (B) Confirmation of DepsG mutant production, repeated at 55 ̊C. Amplification 
performed with primers annealing outside of the DNA fragments used for the construct production. 
Lane 1, 1kb ladder (Thermo scientific); Lane 2, DepsG mutant confirmation PCR; Lane 3, positive 
control (Cj1 WT); lane 4, NTC.  1% agarose in TAE. Run for 1 hour at 100 V. 
             
 
 
Figure 5.16 - PCR testing the successful production of DtetO and Dcag mutant. Amplification 
performed with primers annealing outside of the DNA fragments used for the construct production. 
Lane 1, 1kb plus ladder (Thermo scientific); lane 3, positive control (Cj1 WT) with DtetO mutant 
confirmation primers; lane 4, DtetO mutant confirmation PCR; lane 6, positive control (Cj1 WT) with 
Dcag mutant confirmation primers; lane 7, Dcag mutant confirmation PCR; lane 2 and 5, NTC. 1% 
agarose in TAE. Run for 45 minutes at 100 V. 
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Table 5.9 - Expected lengths and primers sequences for the mutant confirmation PCRs. 
Columns show (from left to right): name of the mutant strain, length of the target gene, expected 
length of the PCR product in the Cj1 WT strain, expected length of the PCR in the mutant strain. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mutant Name Primer Name Primer sequence Gene Length WT - screen PCR Length Mutant - screen PCR Length
DtetO Dtet_screen_F AATTGCGTTTATACAAGAAG
Dtet_screen_R   CTTCTTCCCGGTTTCGATAC
Datr Datr_screen_F TTCAAGCAATCCAAATATGG
Datr_screen_R            GTTATTATGTGAGTTATAAAACC
DlabA DlabA_screen_F AGCGATTTAAACAAAAGCAG
DlabA_screen_R TGAATTTTGAAATAGAGATAAG
DepsG DepsG_screen_F TAGCTATTTGTGCTGTTTGG
DepsG_screen_R AAGAAGCTCCACTACTCATAG
Dabc Dabc_screen_F TCTTATGGCTTGAAGTGTGG
Dabc_screen_R AACACGATTTATTCTCAAAAAC
DparB DparB_screen_F CCCATTTTGTGTTTTTGGTG
DparB_screen_R GTTTTTGTGCTTTCATTTCAGC
Dcag Dcag_screen_F CTTGTTCTCTTTGCGATAC
Dcag_screen_R TTTATGGCTGGTTATTGG
Dunk9 Dunk9_screen_F TGATGAAAAAGTATTAGAGC
Dunk9_screen_R TTCTTGTTTTTTGCAAAGCTC
Dcoag Dcoag_screen_F CTAGCTCTAGCATTTTCTAG
Dcoag_screen_R TTTGTCTATAAGAATTTGTGCT    
DvapD DvapD_screen_F GGAGCGTTTTATTTTATTAC
DvapD_screen_R AAATAGGTGCAACTTCTCTAAG
DhicA DhicA_screen_F ATAGAATTTACAAGCTATAAG
DhicA_screen_R TAAGTGGCTTTATTGATCTTG
28662165798
28321900567
438 1573 2634
378
324
1562
1847
2674
3022
303234541920
27911646354
29752034558
2853
31021925204
27852027741
2083729
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5.6 Discussion 
In this chapter, I described how 11 deletion mutants have been obtained in C. 
jejuni strain Cj1. 
I targeted plasmid genes, and consequently the first step was to assess the 
copy number of the plasmid in the selected strains. It is reported that large plasmids 
are present at low copy number in several strain of C. jejuni (Marasini, et al., 2014). 
In strains Cj1, Cj2, and Cj3 I showed that the copy number was close to one, so 
compatible with the production of a series of mutants. 
Even if the bacterium is reported to be naturally transformable (Vegge et al., 
2012), conferring a high level of genome plasticity, it is reported that the ability of 
producing mutants in C. jejuni is highly strain-specific, and it is linked to the ability of 
each strain to accept foreign DNA (Van Vliet et al., 1998). The technique described 
in this chapter to produce deletion mutants is a variation of the protocol described by 
Van Vliet et al., 1998, and Karlyshev and Wren, 2005. We used pGEM-T Easy as the 
backbone vector for cloning of the construct produced via overlapping PCR and 
subsequent cloning of the kanamycin cassette (derived from pJMK30) in substitution 
of the gene to be removed in the genome of C. jejuni. The vector is then transformed 
in C. jejuni via electroporation. I was not able to induce the allelic exchange of a 
target gene with a kanamycin resistance cassette in strains such 11168 or 81-176, in 
which such protocol has been already used for the production of deletion mutants. 
The reason for this might be the vector used (pGEM-T Easy) or in the E. coli strain 
used for maintaining and replicate the vector (TOP-10). 
I applied the targeted mutagenesis protocol to the several strains of C. jejuni 
available: the only strain that was able to accept the introduction of exogenous DNA 
was the strain Cj1. This strain has a particular genomic set-up; it shows the presence 
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of all the PCR markers tested in Chapter 3, together with the tetracycline resistance 
and a total of 48 genes of the pTet-like plasmid pan genome, but it is the only strain 
in which a full circular plasmid sequence of a pTet-like plasmid could not be 
determined by analysing the assembly graph with Bandage (Wick et al., 2015), nor 
could the plasmid be visualised on an agarose gel following a plasmid extraction (as 
shown in Chapter 3). 
The presence of a chromosomally-encoded tetracycline resistance has been 
observed in this work and previously (Albert et al, 2009; Pratt and Korolik, 2005), and 
although it has not been observed before, we cannot discard the possible integration 
of a full plasmid pTet-like in the chromosome of the strain Cj1. This strain could also 
carry a plasmid that cannot be extracted or properly assembled, similar to the 
megaplasmids isolated from strain RM3194 (NZ_CP014345.1) or pCJDM202 
(NZ_CP014743.1).  
Strain Cj1 showed the presence of a number of the genes of the pTet-like 
plasmid pan genome comparable to those strains showing a pTet-like plasmid, such 
as Cj2 or Cj3. It is unclear whether the strain possesses a larger plasmid or the 
plasmid pTet-like is integrated in the chromosome. According to the results shown in 
Section 5.2, the set of a small contigs set of the strain Cj1 shows a high percent of 
similarity (>90%) with the plasmids pCJDM202, pCJDM67 L, pcjDM, and the plasmid 
of strain RM3194 (accession NZ_CP014345.1) that are between 80 kbp and 120 kbp 
long, and the genome of the strain RM1221 that shows plasmid sequences 
integrated in the chromosome. The graph analysis of the genome assembly 
produced with the libraries derived by two different sequencing technologies show a 
structure that cannot be resolved but whose total length resembles the one of the 
plasmids pCJDM202 and pCJDM67 L. However, when trying to isolate the plasmid 
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from Cj1, I was never able to visualise it on an agarose gel. The kit used to isolate 
the plasmid from Cj1 is indicated for plasmid up to 50 kbp, so we cannot discount the 
possibility that the plasmid size might be greater.  
The 17 genes selected for deletion were chosen amongst the genes present in 
the strain Cj1 and in the pTet-like plasmid pan genome. For the majority of the 
mutants, I did select genes whose functions were unknown and focussed on 
hypothetical proteins whose function in C. jejuni was not described previously. 
Several mutants I attempted to produce were in genes encoding for proteins showing 
conserved domains that could exhibit a bacterial phenotype different from the wild 
type when deleted, and potentially important for environmental or clinical adaptation, 
such as the ABC transporter of 20_FIG00471065_hypothetical_protein, the MATE-
like domain of 11_FIG00469626_hypothetical_protein or the LabA-like domain in 
77_FIG00472625_hypothetical_protein. Other genes I attempted to delete encoded 
for hypothetical proteins with domains of unknown functions, such as 
9_FIG00469571_hypothetical_protein, or showing no conserved domains, such as 
27_FIG00470273_hypothetical_protein.  
Six genes targeted for mutation were not successfully deleted. These were the 
mutant strains Dcri, Dhyp25, DparA, Dmate, Dhyp27, and DvirB2. For each of these 
mutants, the DNA construct and the vector for mutation were produced, but once 
transformed into the wild-type strain of C. jejuni, the recombinant strain failed to grow 
on the selective plate. 
 This can be due to several reasons: the construct may have failed to integrate 
in the genome and the substitution of the target gene with the kanamycin cassette 
did not happen; the construct may have integrated in the genome, and the deletion 
of the target gene happened, but the mutation may have disrupted an essential 
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gene, and the resulting strain of C. jejuni may not be able to grow; or the pTet-like 
plasmid that may be carried by the strain Cj1 was lost after the mutation of a gene 
that stopped it from replicating or transmitting to the daughter cells. Regarding the 
latter case, if the HicA/B toxin-antitoxin system function is post-segregational killing, 
and if a plasmid is present in the strain Cj1 and the gene parA function is regulating 
its replication, we may speculate that the mutation of parA was successful, but the 
mutant strain lost the plasmid pTet-like, and this event could not be identified 
because the bacterium is killed as soon as the plasmid is lost either by the HicA/B 
system or by the presence of Kanamycin in the selective plate. In order to 
investigate, the first step should be completing the genome of the strain Cj1, in order 
to understand unequivocally whether it carries a plasmid pTet-like or only a set of 
genes integrated in the chromosome. If this is the case, then it would be necessary 
to understand what is the mechanism regulating its replication, including discovering 
the origin of replication of the plasmid and understanding which proteins regulate its 
replication. These may include the ParA/B system but also the RepA protein 
described in the contig of the genome assembly of the strain Cj1 used to design the 
mutants described in this chapter. 
Further investigation is also required to understand whether one or more of the 
genes targeted for deletion are essential for the growth of C. jejuni, in particular the 
mutants Dhyp25 and Dhyp27, which show no conserved domains, or whether the 
disruption of one of those genes may have facilitated the curing the plasmid pTet-
like. 
In the next chapter, I describe the design and the application of the phenotypic 
tests to the 11 mutants produced. 
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The deletion of the tetracycline resistance gene tet(O) will be used for testing 
the validity of the gene deletion protocol (as the DtetO mutant should be susceptible 
to tetracycline and have a known and identifiable phenotype) and will be used to 
assess the ability of the protocol described in section 2.8 to complement the 
phenotype of the mutant strains. 
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Chapter 6 - Phenotypic analysis of the C. 
jejuni mutations in pTet-like genes 
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The previous chapters described the plasmid pan-genome of C. jejuni, focusing 
on the pTet-like plasmid pan-genome. I described 79 genes present in all of the 
sequenced plasmids of C. jejuni, dividing them into 4 clusters defined according to 
the frequency of each gene in the sequenced strains of C. jejuni to date. The genes 
present in two of these clusters are present in C. jejuni with a higher frequency than 
the others, and I defined the genes belonging to these as “core” genes of the 
plasmid pan genome. I defined the genes in the clusters associated with lower 
frequency “accessory” genes of the pTet-like plasmid pan-genome. I described the 
conserved domains present in the proteins encoded by those 79 genes, and I 
constructed 11 mutants in core and accessory genes. 
In this chapter, I will describe the application of a series of phenotypic assays to 
these mutants, and I will compare their phenotype with the wild-type C. jejuni strain 
Cj1.  
For the mutants that showed a phenotype different from the wild type, I 
complemented the mutation (Jervis et al., 2015), integrating the wild type gene into 
the chromosome of the mutant and under the control of a constitutive promoter. 
This chapter identifies previously undescribed functions for genes associated 
with the pTet-like plasmid. 
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6.1 Growth rate in MH 
The growth rates of the mutants in MH broth were first measured. A 25 ml liquid 
culture was set up for each strain, with a starting OD (600nm) value of 0.1. The 
culture was incubated for 28 hours in microaerophilic conditions, and the OD600 value 
was read at intervals (Figure 6.1). The full protocol is described in Chapter 2.7.1. 
With this test a difference between the WT and the mutant strain Dunk9 was 
identified, in particular the strain Dunk9 grew significantly (p<0.01) more slowly than 
the strain Cj1. 
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Figure 6.1 - Growth rate of each mutant compared to the WT strain Cj1 in 25ml of MH broth 
measured for 28 hours. Each point is the average of three biological replicates; error bars show the 
SD. The growth rate of each mutant is shown in red the growth rate of the wild type is shown in blue. 
Each graph is annotated with the name of each mutant. The graph associated with the mutant Dunk9 
is highlighted in red. * = statistically significant difference. p<0.01 T-test, single tailed, paired. 
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6.2 Motility 
To assess the motility of the different mutant strains of C. jejuni, I used a 
variation of the method described by Reuter et al., in 2013. The full protocol is 
described in Chapter 2.7.5. 
Briefly, 5 l of a C. jejuni suspension was spotted on plates containing MHA 
with 0.4% agar. The MHA plates contained either a full dose or a half dose of 
nutrient. Each plate was photographed and the area covered by the bacterial 
movement was measured with ImageJ software (https://imagej.nih.gov/ij/index.html). 
Figures 6.2 and 6.3 show examples of the plates after 48 hours on MH+0.4% agar 
plates and after 72 hours on MH (half nutrient dose) +0.4% agar plates. Figures 6.4 
to 6.8 shows the percentage of spreading of the colonies compared to the wildtype. 
There was a statistically significant difference (p<0.01) between the mutant 
Dunk9 and the wild type Cj1 strain in the conditions of MH with full nutrients, and 
between the mutant DhicA and the wild type strain Cj1, which moves at a slower rate 
than the wild type both in condition of full nutrients and half nutrients. 
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Figure 6.2 - Example of six motility plates (MH, 0.4% agar). On each plate strain Cj1 WT and one 
or two mutant strains were spotted. Plates were incubated for 48 hours in microaerophilic conditions 
at 37 ̊C. 
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Figure 6.3 - Example of six motility plates (MH half nutrients concentration, 0.4% agar). On 
each plate strain Cj1 WT and one or two mutant strains were spotted. Plates were incubated for 72 
hours in microaerophilic conditions at 37 ̊C. 
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Figure 6.4 - Colony diameter after 24 hours of incubation in microaerophilic conditions at 37 ̊C 
of MH plates 0.4% agar. Each measurement is the average of at least three biological replicates. 
The error bars represent the SD. * = Significantly different from Cj1 WT. p<0.01 One-way ANOVA, 
Tukey’s post-hoc. 
 
 
 
Figure 6.5 - Colony diameter after 48 hours of incubation in microaerophilic conditions at 37  ̊C 
of MH plates 0.4% agar. Each measurement is the average of at least three biological replicates. 
The error bars represent the SD. * = Significantly different from Cj1 WT. p<0.01 One-way ANOVA, 
Tukey’s post-hoc. 
 
 
 
Figure 6.6 - Colony diameter after 48 hours of incubation in microaerophilic conditions at 37  ̊C 
of MH plates, with half the concentration of nutrients, 0.4% agar. Each measurement is the 
average of at least three biological replicates. The error bars represent the SD. * = Significantly 
different from Cj1 WT. p<0.01 One-way ANOVA, Tukey’s post-hoc. 
 
* 
* 
* 
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Figure 6.7 - Colony diameter after 72 hours of incubation in microaerophilic conditions at 37  ̊C 
of MH plates, with half the concentration of nutrients, 0.4% agar. Each measurement is the 
average of at least three biological replicates. The error bars represent the SD. * = Significantly 
different from Cj1 WT. p<0.01 One-way ANOVA, Tukey’s post-hoc. 
 
 
 
Figure 6.8 - Colony diameter after 96 hours of incubation in microaerophilic conditions at 37  ̊C 
of MH plates, with half the concentration of nutrients, 0.4% agar. Each measurement is the 
average of at least three biological replicates. The error bars represent the SD. * = Significantly 
different from Cj1 WT. p<0.01 One-way ANOVA, Tukey’s post-hoc. 
 
 
 
 
 
 
 
 
 
 
* 
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6.3 Biofilm production 
6.3.1 Method design 
The test described by Oh et al. in 2014 was first used to measure biofilm 
production. The test is based on the incubation of a bacterial suspension in MH in a 
96-well plate for 24 hours. After this time, the plate is rinsed with water and stained 
with a crystal violet solution, and de-stained with ethanol. Biofilm is quantified by 
reading the absorbance at 595 nm. This test was characterised by a high degree of 
variability, and I could not repeat the results between experiments (data not shown). 
Therefore, I developed a test on agar plates that provides more repeatable 
results. This test is based on the use of Congo-red, which stains b-(1-*4)-linked D-
glucopyranosyl units, as described in Theather and Wood in 1982, and Coomassie 
blue. Although the main component identified in C. jejuni biofilm is reported to be α-
dextran (Jowila et al., 2015), the Congo-red molecule have been successfully used 
to stain the biofilm of C. jejuni (Reuter et al, 2010): this study showed how the results 
obtained with Congo red staining were confirming the observations made with 
Crystal violet and concluded that C. jejuni biofilms bind Congo red.  
After an optimisation of the duration of the test, temperatures, and 
concentration of agarose in the plates, the test involved a growing step, in which the 
plates were spotted with of 5 l of bacterial suspension (1.0 OD600) and incubated for 
48 hours in microaerophilic conditions, and a biofilm development step, during which 
the plates were incubated in normal aerobic conditions (i.e. atmospheric) for 48 
hours at 37 C. As reported by Reuter et al. in 2010, Campylobacter shows an 
increased ability to produce biofilm when incubated in aerobic conditions, and this 
incubation was necessary to identify the biofilm production in this assay. During the 
growing phase (Figure 6.9 A), bacterial colonies do not develop an identifiable 
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colour. During the biofilm development phase, the colonies develop the colour shown 
in Figure 6.9 B in case of ability of producing biofilm. The final protocol adopted for 
this test is described in Chapter 2.6.7. 
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Figure 6.9 - Biofilm formation in MH plate (0.8% agar) supplemented with Congo Red and 
Coomassie Brilliant Blue (MHA-Congo red). The plate was spotted three times with 5 µl of Cj1 WT 
bacterial suspension (PBS, OD600=1.0). (A) MHA-Congo red plate after 48 hours incubation at 37 ̊C in 
microaerophilic conditions. (B) MHA-Congo red plate from (A) after further 48 hours of incubation at 
37 ̊C with atmospheric oxygen concentration. 
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6.3.2 Biofilm production of the mutant strains and persister cells 
formation 
The biofilm production and the ability for the bacterium to produce persister 
cells are linked in several bacterial species (Wang and Wood, 2011, Wood et al., 
2013); I therefore decided to measure the ability to develop persister cells in the 
strains showing impairment in biofilm formation. Although the association between 
biofilm and persister cells was never shown in C. jejuni, previous unpublished work 
by Champion et al. had shown persisters cells features in the strain 11168 of C. 
jejuni. That data shows how the exposure of strain 11168 to up to 100 MIC of 
Penicillin and Ciprofloxacin for up to 24 hours does not kill the entire bacterial 
population and that the surviving cells remain susceptible to the drug when re-
cultured. 
The protocol applied here to identify the presister cells formation in C. jejuni 
was developed in the University of Exeter’s Molecular Pathogenesis Laboratory 
(Olivia Champion, personal communication). 
 
6.3.2.1 Biofilm production 
10 of the 11 mutant strains showed the same phenotype of the wild-type strain 
Cj1 of C. jejuni, with colonies that diffuse in the MH plate 0.8% agar stained in 
pink/red after 2 days of incubation in microaerophilic conditions at 37 C, followed by 
2 days of incubation in normal atmospheric condition at 37 C. 
The DhicA mutant showed a different phenotype, with bacterial colonies that 
were not stained after the same incubation periods. A picture of the plates is shown 
in Figure 6.10 and a Table 6.1 summarises the results. 
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6.3.2.2 Persister cells formation in the mutant DhicA 
The mutant DhicA was assayed for the ability to form persister cells after 24 
hours of incubation in presence of concentrations of penicillin 10X, 50X, and 100X 
higher than the MIC (256 µg/ml) and concentrations of ciprofloxacin 10X and 20X 
higher than the MIC (32 µg/ml).  
The results of this assay are shown in Figure 6.11: in each condition tested, the 
number of CFUs measured in the mutant strain is not statistically different from the 
number of CFUs measured in the WT Cj1 strain (p<0.01). 
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Table 6.1 - Biofilm production in the 11 mutant strains and in the Cj1 WT strain, evaluated with 
the MH-Congo red plate method. +/- = strain is able or unable to produce biofilm, as identified by 
the colony staining in at least three biological replicates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Strains Congo Red staining
Cj1 WT +
DhicA -
DlabA +
DvapD +
Dcoag +
DparB +
Dabc +
Dcag +
Dunk +
Datr +
DtetO +
DepsG +
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Figure 6.10 - Example of six MH-Congo red plates for the identification of C. jejuni strains able 
to produce biofilm. On each plate strain Cj1 WT and one or two mutant strains were spotted. Plates 
were incubated for 48 hours in microaerophilic conditions at 37 ̊C, followed by 48 hours with normal 
atmospheric concentration at 37 ̊C. 
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Figure 6.11 - Persister cells formation after 24 hours incubation in strain Cj1 WT and strain 
DhicA. Control = MH broth; Pen 10x = MH + penicillin 2.56 mg/ml; Pen 50x = MH + penicillin 12.8 
mg/ml; Pen 100x = MH + penicillin 25.6 mg/ml; Cip 10x = MH + Ciprofloxacin 320 µg/ml; Cip 20x = 
MH + Ciprofloxacin 640 µg/ml. Each measurement is the average of three biological replicates. The 
error bars represent the SD. The mean of each pair (Cj1 WT vs. DhicA) is not significantly different 
(p<0.01 T-test, single tailed, paired). 
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6.4 Survival in water 
The ability to survive in tap water was tested as described in Chapter 2.7.8. 
Briefly, bacteria were grown on CBA+ plate, re-suspended and washed twice in PBS 
buffer. Bacterial were finally re-suspended in 10 ml of filter sterilised tap water, 
adjusting the bacterial concentration to 0.5 OD600. At the beginning of the incubation 
and after 8 days of incubation at 4 C, 100 µL of bacterial suspension was serially 
diluted and bacteria enumerated on agar. 
The results are shown in Figure 6.12. None of the mutants showed a significant 
difference (p<0.01) in survival compared with the wild type. 
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Figure 6.12 - Percent of bacterial survival after 8 days of incubation in water of each mutant 
strain and the strain Cj1 WT. Each measurement is the average of three biological replicates. The 
error bars represent the SD. Each mean is not significantly different from the strain Cj1 WT (p<0.01, 
One-way ANOVA, Tukey’s post-hoc), 
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6.5 Antibiotic resistance 
Antibiotic resistance in the mutant strains was evaluated via MIC quantification 
on microtiter plates, except for the tetracycline resistance in DtetO, for which an e-
strip test (Bio-Merieux) was used. The full protocols are described in Chapter 2.7.2. 
As expected, the mutant DtetO showed susceptibility to tetracycline, with an MIC 
>0.048 g/ml, compared to 48-32 g/ml in strain Cj1. 
The MIC values for the antibiotics erythromycin, ciprofloxacin, penicillin, and 
ceftazidime are reported in Table 6.2. None of the mutants showed a significant 
difference (p<0.01) in MIC compared with the wild type. 
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Table 6.2 - Minimum inhibitory concentrations (MICs) for growth in Erythromycin, Penicillin, 
Ciprofloxacin, and Ceftazidime in each mutant strain and in the strain Cj1 WT. The values were 
measured with the plate dilution method in three biological replicates; values are shown in µg/ml. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Strain Erythromycin MIC Penicillin MIC Cyprofloxacin MIC Ceftazidine MIC
Cj1 WT >0.5 256-128 32-16 32-16
Dabc >0.5 256-128 32-16 32-16
DepsG >0.5 256-128 32-16 32-16
Dcag >0.5 256-128 32-16 32-16
DhicA >0.5 256-128 32-16 32-16
DtetO >0.5 256-128 32-16 32-16
DlabA >0.5 256-128 32-16 32-16
Datr >0.5 256-128 32-16 32-16
DvapD >0.5 256-128 32-16 32-16
Dcoag >0.5 256-128 32-16 32-16
DparB >0.5 256-128 32-16 32-16
DhicA >0.5 256-128 32-16 32-16
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6.6 Acid tolerance 
Acid tolerance was evaluated using a modification of the method described by 
Reid et al., in 2008 (1). Briefly, MH medium was adjusted to pH 3, 4 and 5 using HCl. 
Bacteria grown on CBA plates overnight were used to produce a 0.5 OD600 bacterial 
suspension in MH. One ml of culture was centrifuged and re-suspended in MH 
adjusted to different pH values. The tubes were incubated under microaerophilic 
conditions for 20 minutes and surviving bacteria enumerated on agar. The full 
protocol is described in Chapter 2.7.3. 
The results are showed in Figure 6.13, expressed as percentage of bacteria 
surviving the treatment. None of the mutants showed a significant difference 
(p<0.01) in acid tolerance compared with the wild type. 
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Figure 6.13 - Percent of bacterial survival after 20 minutes of incubation in MH buffered at pH 
3, pH 4 or pH 5 of each mutant strain and the strain Cj1 WT. Each measurement is the average of 
three biological replicates. The error bars represent the SD. Each mean is not significantly different 
from the strain Cj1 WT (p<0.01, One-way ANOVA, Tukey’s post-hoc). 
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6.7 Tolerance to synthetic gastric fluid 
The tolerance to synthetic gastric fluid buffered to pH 4.5 (SGF for the 
simulation of stomach environment, Beumer et al., 1992; Reid et al., in 2008 (2)) was 
evaluated using a similar method to the one described in previous section but using 
synthetic gastric fluid in place of MH medium. The ability to tolerate incubation in 
SGF has been evaluated for 6 hours, preparing 10 ml 0.5 OD600 bacterial suspension 
and enumerating the number of surviving bacteria after 20 minutes, 3 hours, and 6 
hours. The full protocol is described in Chapter 2.7.4. 
The results are reported in Figure 6.14 and Figure 6.15. None of the mutants 
showed a significant difference (p<0.01) in synthetic gastric fluid tolerance compared 
with the wild type. After 6 hours of incubation in SGF no bacteria grew after plating 
samples. 
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Figure 6.14 - Percent of bacterial survival after 20 minutes of incubation in synthetic gastric 
fluid (SGF) buffered at pH 4.5 of each mutant strain and the strain Cj1 WT. Each measurement is 
the average of three biological replicates. The error bars represent the SD. Each mean is not 
significantly different from the strain Cj1 WT (p<0.01, One-way ANOVA, Tukey’s post-hoc). 
 
 
 
Figure 6.15 - Percent of bacterial survival after 3 hours of incubation in synthetic gastric fluid 
(SGF) buffered at pH 4.5 of each mutant strain and the strain Cj1 WT. Each measurement is the 
average of three biological replicates. The error bars represent the SD. Each mean is not significantly 
different from the strain Cj1 WT (p<0.01, One-way ANOVA, Tukey’s post-hoc). 
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6.8 Galleria mellonella larvae infection 
6.8.1 Method design 
In order to evaluate the ability of killing the model organism Galleria mellonella 
larvae, bacteria were injected into the first right foreleg of the larva. 
As with other studies (e.g. Elmi et al., 2012), I was not able to obtain the 
reproducible killing of larvae incubated under aerobic conditions. I optimised the 
technique, incubating the larvae post-injection in different concentrations of oxygen, 
which promoted the growth of Campylobacter, and injecting different bacterial 
concentrations. 
As described in Figure 6.16, when the larvae were injected with 104 to 107 
bacterial cells and incubated for 48 hours at 37 C in normal atmospheric conditions, 
the maximum killing registered was 20% of larvae. If the larvae were injected with 
the same doses of bacteria and then incubated for 48 hours at 37 C in 
microaerophilic conditions, 90-100% of larvae were killed after challenge with 106 or 
107 bacterial cells (Figure 6.17). There was no killing of control larvae injected with 
PBS or in not-injected. 
Therefore, the virulence of the mutants compared to the wild type was 
evaluated injecting 107 bacterial cells and incubating the larvae for 48 hours in 
microaerophilic conditions. The full protocol is described in Chapter 2.7.9. 
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Figure 6.16 - Percent survival of G. mellonella larvae injected with 107, 106, 105, 104 bacterial 
cells (C. jejuni strain Cj1 WT), PBS or not injected (Non-stabbed control NSC). Larvae were 
incubated in normal atmospheric conditions at 37 ̊C for 48 hours post inoculation. Each measurement 
is the result of the injection of 10 larvae. 
 
 
 
Figure 6.17 - Percent survival of G. mellonella larvae injected with 107, 106, 105, 104 bacterial 
cells (C. jejuni strain Cj1 WT), PBS or not injected (Non-stabbed control NSC). Larvae were 
incubated in microaerophilic conditions at 37 ̊C for 48 hours post inoculation. Each measurement is 
the result of the injection of 10 larvae. 
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6.8.2 Infection of larvae 
The results of the injection of at least two groups of 10 larvae per mutant are 
shown in Figure 6.18. The controls (PBS injection and non-injected control) are 
shown in the same graphs, showing 100% survival in every repetition of the 
experiment. None of the mutants showed a significant difference (p<0.01) in killing of 
G. mellonella larvae compared with the wild type. 
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Figure 6.8 - Percent survival of G. mellonella larvae injected with 107 bacterial cells of each 
mutant strain, strain Cj1 WT, PBS or not injected (Non-stabbed control NSC). Larvae were 
incubated in microaerophilic conditions at 37 ̊C for 48 hours post inoculation. Each measurement is 
the average of three independent experiments; in each experiment 10 larvae were injected. The error 
bars represent the SD. Each mean is not significantly different from the strain Cj1 WT (p<0.01, One-
way ANOVA, Tukey’s post-hoc). 
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6.9 Complementation of the mutant strains 
Three mutants exhibited a different phenotype to the wild type in some of the 
experiments described above. The mutant Dunk9 grew significantly slower than the 
wild type in MH in microaerophilic conditions and reached a lower final OD600 (Figure 
6.1); the same mutant Dunk9 was impaired in motility (Figures 6.2.3 and 6.2.4). The 
DhicA mutant showed an impaired ability to produce a biofilm (Figure 6.10 and Table 
6.1) and motility in particular nutrient and agarose concentrations (Figures 6.4 to 
6.8). Finally, the DtetO mutant showed increased susceptibility to tetracycline, 
compared to the wild type. Although this phenotype of the DtetO mutant is not 
surprising given that tet(O) is known to be required for tetracycline resistance (Mazi 
et al., 2008), it was useful to confirm the success of the mutagenesis protocol and 
will be used to confirm the success in the complementation of the phenotypes. 
The strategy used here to complement the mutant strains was described by 
Jervis et al. in 2015 and detailed in Chapter 2.8. 
Briefly, the three mutants were complemented by amplifying the gene of 
interest (hicA, tetO, or unk9) with the primers in Table 6.3. Each primer pair 
introduced a restriction site for the enzymes NcoI and NheI in the 5’ and the 3’ end of 
the PCR product respectively, which were then used to clone the gene in the 
complementation vector. The vectors built for the complementation of the mutants 
are reported in Table 6.4.  
The correct insertion of each wild-type gene was checked by PCR, using 
primers annealing outside the integration site. The PCR product confirming the 
integration of the gene of interest is shown in Figure 6.19. Sanger sequencing 
confirmed the correct integration in each of the complemented mutants. 
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Table 6.3 - PCR primers designed for the complementation of mutants DtetO, DhicA and 
Dunk9. Columns show (from left to right): name of the complemented mutant, name of each primer, 
sequence of each primer, length of the amplified product. 
 
 
 
Table 6.4 - Vectors designed for the complementation of mutants DtetO, DhicA and Dunk9. 
Columns shows (from left to right): plasmid name, length of the plasmid, brief description of the 
plasmid vector, markers present on each plasmid, reference (where available).  
 
 
 
Figure 6.19 - PCR for testing the successful complementation of the mutant strains DtetO,  
Dunk9 and DhicA. Lane 1, 1kb plus ladder (Thermo scientific); lane 2, NTC; lane 3, Cj1 WT; lane 4, 
DtetO; lane 5, DtetO+tetO complemented strain; lane 6, Dunk9; lane 7, Dunk9+unk9 complemented 
strain; lane 8, DhicA; lane 9, DhicA+hicA complemented strain. 
 
 
 
 
 
 
 
Mutant Name Primer Name Primer Sequence PCR product Length
Dunk9+unk9 unk9_complF CATGCCATGGATGAGTGATAAAGAATTAGAA
unk9_complR CTAGCTAGCTCATCTTTTAAACTCCTTATT
DhicA+hicA hicA_complF CATGCCATGGATGCCTGAATTACCAAGATTG
hicA_complR  CTAGCTAGCTTAATCCTTTGCTACTTCTATA
DtetO+tetO tetO_complF  CATGCCATGGATGAAAATAATTAACTTAGGC
tetO_complR    CTAGCTAGCTTAAGCTAACTTGTGGAACAT
576
204
1920
Plasmid Name Length Description Markers
pCJC1 5775 Vector designed for recombination-mediated delivery of genes onto the C. jejuni chromosome. cat, ampR Jervis et al., 2015
pCJC1::tetO 7695 pCJC1 for the complementation of the mutant DtetO cat, ampR This study
pCJC1::unk9 6342 pCJC1 for the complementation of the mutant Dunk9 cat, ampR "
pCJC1::hicA 5979 pCJC1 for the complementation of the mutant DhicA cat, ampR "
500 
1500 
5000 
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6.10 Phenotype of the complemented mutants 
6.10.1 Complementation of the tetO mutant 
The resistance to tetracycline was partially restored in the complemented tetO 
mutant. Figure 6.20 shows the comparison between the strains Cj1, DtetO, and 
DtetO+tetO. 
The MIC of the complemented mutant DtetO+tetO was 1.0-1.5 µg/ml. In 
contrast the MIC was 32-48 µg/ml for the wild type strain and >0.048 µg/ml for the 
DtetO mutant. 
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Figure 6.20 - Measurement of MIC of tetracycline for strains DtetO, Cj1 WT and DtetO+tetO 
(from bottom to top) using Estrips (Biomerieux). 
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6.10.2 Complementation of the hicA mutant 
It was not possible to restore the wild type phenotype to the DhicA mutant by 
complementation. The phenotype of the mutant and the complemented mutant for 
motility and biofilm assays were not statistically different (p<0.01), as shown in 
Figure 6.21 and 6.22. 
A second type of complementation was next attempted by cloning the full hicAB 
operon into the pCJC1 plasmid. This experiment was performed in order to test 
whether both genes of the hicAB operon need to be under the control of the same 
promoter to complement the mutation. The DhicA+hicAB showed the same 
phenotype as the DhicA mutant, as indicated in Figures 6.23 and 6.24. 
Finally, in order to ascertain that during the deletion of the gene hicA no other 
mutations were introduced, the DhicA mutant was genome sequenced (MiSeq, PE 
library 300+300, Illumina Inc.). The alignment between the genome sequence of the 
wild type strain Cj1 and DhicA is shown in Figure 6.25. No other mutation was 
identified in the genome of the mutant strain. 
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Figure 6.21 - Motility of strains Cj1, DhicA, and DhicA+hicA in MH 0.4% agar (half nutrients). (A) 
A plate used to assess the mobility. (B) Average colony diameter and SD (three biological replicates, * 
= significantly different from Cj1 WT. p<0.01 One-way ANOVA, Tukey’s post-hoc). 
 
 
 
Figure 6.22 - Biofilm formation of strains Cj1, DhicA and DhicA+hicA in MH-Congo red 0.8% 
agar.  
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Figure 6.23 - Motility of strains Cj1, DhicA, and DhicA+hicAB in MH 0.4% agar (half nutrients). 
(A) A plate used to assess the mobility. (B) Average colony diameter and SD (three biological 
replicates, * = significantly different from Cj1 WT. p<0.01 One-way ANOVA, Tukey’s post-hoc). 
 
 
 
Figure 6.24 - Biofilm formation of strains Cj1, DhicA and DhicA+hicAB in MH-Congo red 0.8% 
agar. 
 
 
 
Figure 6.25 - Sequence alignment of the region affected by the mutation in the strain Cj1 WT 
and DhicA. Sequence alignment was obtained with MUSCLE software (Edgar, 2004) and visualised 
with CLC Genome Wiewer (Qiagen Inc.). Full pink bars at the bottom of the alignment indicate a 
perfect match. Only the gene DhicA is affected by the mutation. aphA: chloramphenicol resistance 
gene (insertion cassette). 
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6.10.3 Complementation of the unk9 mutant 
The phenotype of the WT strain Cj1 was completely restored in the mutant 
Dunk9 when complemented with the unk9 gene. Figures 6.26 and 6.27 show the 
growth curves of the complemented mutant Dunk9+unk9 compared to the Dunk9 
mutant and the Cj1 strain, and the motility phenotype in the three strains (mutant, 
complemented mutant and wild-type) in MH plates with full concentration of nutrients 
and 0.4% of agarose. 
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Figure 6.26 - Motility of strains Cj1, Dunk9, and Dunk9+unk9 in MH 0.4% agar. (A) An example 
plate used to assess the mobility. (B) Average colony diameter and SD (three biological replicates, * = 
Significantly different from Cj1 WT. p<0.01 One-way ANOVA, Tukey’s post-hoc). 
 
 
 
Figure 6.27 - Growth rate of the mutant Dunk9, the complemented mutant Dunk9 and in the WT 
strain Cj1 in 25ml of MH broth measured for 28 hours. Each point is the average of three 
biological replicate, error bars show the SD. * = Statistically significant difference. p<0.01 T-test, 
single tailed, paired 
 
 
 
 
 
 
 
 
* 
* 
* 
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6.11 Discussion 
In this chapter, I described the phenotypic effects of the 11 mutations I 
introduced into the strain Cj1 of C. jejuni on selected phenotypes related to 
environmental survival and infection. In particular, I assessed the ability to grow in a 
controlled environment, the ability to producing biofilm, the motility of the bacterium 
in 0.4% agar plates with different concentration of nutrients, the survival at low pH, in 
synthetic gastric fluid and in tap water at low temperature, resistance to different 
antibiotics, and the ability to kill G. mellonella.  
Two of these assays needed to be optimised in this study: the measurement of 
biofilm production and killing of G. mellonella.  
I adapted a method that was not applied before to C. jejuni to assess the biofilm 
production on agar plates. Use of Congo Red for bacterial enumeration thanks to its 
interaction with beta-polysaccharides was described for the first time in 1981 
(Teather and Wood, 1981). The method described in this chapter was previously 
applied to other bacterial species to judge the colony morphology and biofilm 
production, including Salmonella (Montiero et al., 2011) and Neisseria (Kyungcheol 
et al., 2007). Other methods for biofilm production evaluation in Campylobacter 
described in the literature are based on the staining with crystal violet of cells 
adhesive to borosilicate or plastic substrates (Oh et al., 2014; Oh et al., 2016; Naito 
et al., 2010). These methods, although quantitative, are, in my experience, laborious 
and give results that are difficult to replicate. Moreover, the application of different 
gas concentrations to a static liquid bacterial suspension requires the tube to be 
prepared in a defined environment (i.e. gas cabinet), with broth that was equilibrated 
to the different oxygen concentrations and needs to be incubated open, which may 
lead to the contamination of the assay. Here, I describe a method that is qualitative, 
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hence it just highlights a positive or a negative phenotype, but it is simple and gives 
repeatable results. 
Congo red was used previously to quantify the biofilm production of C. jejuni 
and the results obtained with this molecule were comparable to the one obtained 
with a less specific stain, such as Crystal violet (Reuter et al, 2010). Although only 
alpha-linked sugars have been identified as components of C. jejuni biofilm (Jowiya 
et al., 2015), given the phenotype identified in this thesis and the previous results 
shown by Reuter et al. in 2010, we observed that Congo red binds with a component 
of the biofilm of C. jejuni. This could be explained with a previously undescribed 
beta-linked polysaccharide secreted by C. jejuni, or with an intereaction of the Congo 
red with the known exopolysaccharides secreted by C. jejuni, and requires further 
investigation.  
In order to apply it to the microaerophilic species C. jejuni, the G. mellonella 
larvae killing assay needed to be optimised. G. mellonella larvae have been used as 
a model organism to evaluate the attenuation in virulence of several pathogenic 
bacteria including Legionella pneumophila, Helicobacter pylori and Escherichia coli 
(Giannouli et al., 2014; Harding et al., 2012; Leuko and Raivio 2012). For C. jejuni, 
the evaluation of virulence in G. mellonella larvae was described by Champion et al. 
in 2010 and Senior et al. in 2011. In both these papers, the larvae were challenged 
injecting 104 to 106 bacterial cells, causing close to 100% killing after two days at 37 
C. I could replicate this percentage of killing only when incubating the injected 
larvae under microaerophilic conditions. This result may be explained with a different 
growth and propagation conditions of the G. mellonella larvae: different pet shop 
suppliers grows the larvae under different conditions, feeding them different 
substrates or even treating them with antibiotics prophylactically to avoid infections 
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(Olivia Champion, personal communication). As shown by the PBS-injected and the 
non-injected groups, the larvae can survive for two days under microaerophilic 
conditions. It is not clear if the killing by C. jejuni is due to the extra stress imposed 
on the animal or it is due to a longer survival of the bacterium in the larvae, allowing 
colonisation. I was not able to recover any bacterial cells after incubation in 
atmospheric conditions, while I was able to count 103 to 104 bacterial cells in the 
haemocoel of the insect after incubation in microaerophilic conditions (data not 
shown). This might indicate that C. jejuni is not able to colonise the larvae in 
presence of atmospheric concentrations of oxygen, although I cannot exclude the 
presence of bacteria colonising the internal organs of the larvae (e.g. the larva’s 
digestive system). The oxygen concentrations used in this study allowed estimating 
the attenuation of Campylobacter virulence, having a baseline of 90-100% killing in 
the wild type. 
The conditions in which the genes of the plasmid pTet are expressed are poorly 
understood. The most valuable work in this area is the complete transcriptome of C. 
jejuni strain 81-176 (Taveirne et al., 2013), showing the expression profiles amongst 
the whole genome of this strain of C. jejuni during stationary and mid-log phase and 
during an in vivo colonisation of chicken. That study highlighted how the genes on 
the plasmid pTet are only expressed during the stationary and mid-log phase of the 
bacterial growth and not during the colonisation of chicken. Even though the 
bacterium is considered to be non-pathogenic in poultry, it is fair to assume that in 
order to colonise the animal, C. jejuni has to resist stresses that are similar to those 
that it encounters when colonising other hosts (e.g. acid tolerance). The mutants 
analysed in this study, did not exhibit any difference in phenotypes associated with 
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acid tolerance, SGF tolerance or virulence in Galleria mellonella larvae, which 
accords with the observations described in the transcriptome analysis.  
Another assay that did not show any difference between wild type and any of 
the mutant strains tested was survival in tap water. C. jejuni has been shown to 
survive up to 64 days in drinking water when incubated at 4 C, while at 25 C the 
number of viable cells drops to zero in the first day of incubation (Cools et al., 2003; 
Trigui et al., 2015). Although Campylobacter may be able to survive for such a long 
time at 4 C, a difference between strains characterised by a different resistance to 
this particular stress can be identified in the first week (Trigui et al., 2015), hence the 
time of incubation of 8 days was selected. 
As far as the assays highlighting a phenotype in some of the mutant strains are 
concerned, the DtetO mutant showed a high level of susceptibility to tetracycline, the 
Dunk9 mutant showed an impaired growth in liquid culture and impaired motility, and 
the DhicA mutant showed impaired motility and an a lack of biofilm production in the 
condition tested in this analysis.  
The tetracycline susceptibility in DtetO is unsurprising, even though it is only 
partially restored by the complementation. Although this test only confirms that the 
tetracycline resistance phenotype is due to the presence of the tetO gene, it is useful 
to confirm that the technique used to produce the mutants works in these conditions. 
The reason why the complementation of tetO is only partial might reside in the 
different promoter that controls the expression of the gene in the complemented 
mutant. It may be useful to test the complementation of DtetO by tetO controlled by 
different promoters (for instance pCJC2, pCJC3, and pCJC4m described in Jervis et 
al., 2015). 
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The Dunk9 mutant showed two interesting phenotypes. They were both fully 
complemented when the unk9 gene was integrated back in the chromosome of the 
mutant strain, a sign that these phenotypes are due solely to the absence of this 
gene. Unfortunately, the predicted gene product did not possess any conserved 
domains that may be associated to the phenotypes identified. The only conserved 
domain identified in the hypothetical protein is part of a superfamily identified in a 
protein involved in the meiotic phase in eukaryotic organism (Meuwissen et al, 2004, 
domain SCP-1, as reported in Section 4.3.6). The unk9 gene expressing the 
hypothetical protein 9_FIG00469571_hypothetical_protein is much shorter than the 
one described in the original paper: the protein SCP1 is 946 amino acids long, while 
unk9 encodes a protein of just 194 amino acids, and the fact that the only domain 
identified here is a partial multi-domain lowers the confidence of function association 
between these two proteins. However, recently an association between DNA 
supercoiling and motility in C. jejuni was described (Shortt et al., 2016). The protein 
SCP1 interacts with chromatin and DNA, and it could be involved in processes that 
might influence DNA-supercoiling and tertiary structure. Certainly, a much deeper 
study of the gene unk9 and its protein product is required to ascertain its cellular 
function. Motility is an extremely important phenotype for C. jejuni, involved in the 
colonisation of the host and in the environmental survival (Young et al, 2007), and 
being involved with this phenotype makes the unk9 gene a candidate for future 
investigation. A follow up of this work should fully characterise the Unk9 protein 
(9_FIG00469571_hypothetical_protein). The protein should be isolated and its 
structure determined in order to gain a better understanding of its function, and the 
conditions in which the protein is produced by the bacterium should be identified.  
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Finally, the DhicA mutant showed a phenotype different from the wild-type but it 
could not be complemented. The gene hicA is part of a toxin-antitoxin system 
encoded by C. jejuni. These systems are formed by a toxin deleterious to the 
bacterial cell and an antitoxin acting like an antidote.  Today, as many as six classes 
of toxin-antitoxin systems are known, characterised by different mechanisms of toxin 
inactivation (Page and Peti, 2016). Plasmid-encoded TA-systems were described 
initially to be involved in the maintenance and stabilisation of the plasmid by post-
segregational killing (PSK), as described in Van Melderen and De Bast in 2009, but 
since then several chromosomal encoded TA-systems were discovered, which are 
not involved in PSK but work to ensure the survival of the bacterial population in 
response to various stresses (Page and Peti, 2016). For instance, in Salmonella, a 
toxin-antitoxin system sehAB was associated with virulence in mice (De La Cruz, et 
al., 2013); in Acidithiobacillus ferrooxidans a series of TA-system were associated 
with the maintenance of integrated genetic elements (Bustamante et al., 2014); in 
Burkolderia pseudomallei the toxin HicA was shown to have a role in persister 
formation (Butt et al., 2014); in Escherichia coli multiple TA-systems were shown to 
influence biofilm formation and fimbriae (Kim et al., 2009). In particular, the study of 
Kim et al. has found that 5 TA systems are involved in the upregulation of biofilm 
formation in the early phases of bacterial growth (8 H) through upregulation of 
fimbriae production (by repressing the expression of a single gene, yjgK, which 
encodes for an uncharachterised protein and has no homologues in C. jejuni) and in 
repression of biofilm production in the late phases of bacterial growth (24 H). 
Although an association between hicA and production of biofilm and motility is 
described C. jejuni for the first time, the phenotypes identified in this study are 
consistent with at least two of the previous works in other bacterial organisms. I 
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recorded impairment in motility and in biofilm production in the mutant DhicA. I also 
evaluated the possibility of forming persister cells in the mutant strain DhicA, 
because TA systems and ability of forming biofilm are linked to the ability of 
producing persister cells in several bacterial species (Xang and Wood, 2011). 
Persister cells are a small fraction of bacterial cells that survive to an antibiotic 
treatment but are not genetically resistant to the antibiotic molecule (Lewis et al., 
2007). I could not identify a difference between the WT strain Cj1 and the mutant 
DhicA in the number of persister cells formed after 24 hours. The impossibility of 
complementing the mutant that I observed applying the methods here described 
undermines the full association between the presence of the hicA gene and the 
phenotypes observed; however, the absence of other mutations in the genome of the 
strain DhicA was ascertained via whole genome sequencing. Several hypotheses 
could be formulated about the impossibility observed here of complementing the 
phenotype of this mutant strain. For instance, according to the mechanism described 
in 1986 for post-segregational killing of plasmid free cells (Gerdes et al, 1986), for 
the TA-system to work the quantity of toxin and antitoxin needs to be finely 
regulated: for the system to work, the quantity of RNAse translated (HicB antitoxin, in 
this case), has to be enough to quickly degrade all the toxin (HicA, in this instance). 
If the two genes are transcribed under the control of different promoters, as in this 
case with the complementation method with pCJC1, this could disrupt the correct 
synergy of the system. Moreover, it is reported that the TA-systems are transcribed 
in an operon, hence a single polycistronic mRNA (Yamaguchi et al., 2011). 
Separating the toxin and the antitoxin gene might have an effect on the correct 
function of the system. Further investigation is required on this novel putative TA-
system of C. jejuni: it is necessary to ascertain the involvement of this system in the 
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phenotypes identified; I suggest producing a mutant lacking for the entire system, 
and measuring its phenotype in the conditions identified in this work, then 
complementing the mutant with hicBA operon. I also suggest evaluating the mRNA 
levels of the toxin and the antitoxin in the complemented mutant via qPCR. 
In conclusion, two genes have been associated with novel phenotypes in this 
mutagenesis analysis: this directly links the plasmids pTet-like to novel functions 
other than the maintenance of tetracycline resistance in a Campylobacter population. 
These functions are directly responsible for a greater fitness of the strains carrying 
those genes (the importance of chemotaxis and biofilm production for 
Campylobacter in the environment and in the pathogenesis was reviewed by Bolton 
in 2015 and by Young et al. in 2007) and may explain at least in part the great 
diffusion of the plasmid pTet, as expected by De Friis in 2007. 
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Concluding remarks 
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The importance of the pTet-like family of plasmids in C. jejuni has been 
neglected for the last 10 years. Since its description in the strain 81-176 of C. jejuni 
in 2000 (Bacon et al., 2000), research has focused on the importance of the plasmid 
pVir, possibly because the plasmid pTet’s function looked clear: the plasmid was 
transferred via the conjugative type four secretion system that it encodes, and it was 
maintained for tetracycline resistance (Batchelor et al., 2004). 
In this work, I studied the importance of this plasmid family through sequence 
analysis and mutagenesis.  
Initially, I determined the sequence of 19 new pTet-like plasmids in C. jejuni. 
These plasmids were between ~37 kbp and ~48 kbp long and showed a high level of 
similarity with the plasmid pTet but also showed some remarkable differences: for 
example, three of them lacked the tetracycline resistance gene, and 10 of them 
lacked for the replication protein described in the pTet plasmid carried by the strain 
81-176 (NC008790.1). I also assessed the presence of the plasmid pTet in a 
database of 4005 strains of C. jejuni, sequenced before February 2016. This study 
showed that the majority of the pTet genes are carried by around 15.4% percent of 
the strains, and of these, 25.3% lack the tetracycline resistance gene. Also, different 
clusters of genes of the plasmid pTet were characterised by different frequencies in 
the C. jejuni strain database. I approached this variability between the plasmids 
pTet-like producing a plasmid pan genome for the plasmids pTet-like that I 
sequenced, together with the ones that are already present in the NCBI database. 
The result of this analysis shows that the pTet-like plasmids are composed of 79 
genes. The majority of them are core genes, which largely encode for maintenance 
and conjugation. The remainders are accessory genes, encoding for disposable 
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phenotypes, such as antibiotic resistance, colicin production, or metabolism of 
particular compounds.  
One strain of C. jejuni tested in this work (strain Cj1) was able to accept foreign 
DNA using a mutagenesis method developed for this bacterium, using a suicide 
plasmid constructed on pGEM-T easy as DNA vector. This strain has a particular 
genomic set-up: it shows the presence of the majority of the pTet-like plasmid pan-
genome genes in a structure that appear to be either a much bigger plasmid, like the 
one present in the strains RM3194 (CP014745.1), or integrated in the chromosome. 
The sequencing experiments applied to this strain were not able definitively to 
ascertain the chromosomal or plasmid location of the pTet-like genes; however, 11 
mutants were produced on this strain in order to study the importance of the pTet-
encoded functions. The production of a further 7 mutants was attempted, but the 
mutant strains were not able to grow on selective plates for screening after 
transformation. Future work is required to understand whether this is due to a 
technical problem in the deletion protocol (and the kanamycin cassette used failed to 
substitute the target gene) or whether one or more of these seven genes are 
essential for the growth of C. jejuni. The genes targeted for mutation successfully 
encoded largely for hypothetical proteins, which contained conserved domains 
associated with several important functions: an acetyl transferase domain (Datr), a 
LabA-like domain associated with a variety of regulatory functions (DlabA), an 
ATPase associated with several cellular activity and a CsbA domain for stress 
response (DepsG), an ABC transporter (Dabc), a domain for nuclease activity and a 
domain for sensing extracellular L-fucose (DparB), a domain associated with a cag 
pathogenicity island in H. pylori (Dcag), a blood coagulase described in S. aureus 
(Dcoag), a conserved domain involved in chromatin structure in eukaryotic cells 
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(Dunk9), and a virulence-associated protein (DvapD). Furthermore, a mutant on the 
toxin protein hicA of the toxin-antitoxin system hicAB identified for the first time on 
the plasmids pTet-like was constructed, together with a mutant on the gene tet(O) 
responsible for tetracycline resistance. 
Nine different phenotypic tests were applied to the 11 mutants produced on the 
strain Cj1. These tests were designed to simulate an array of conditions associated 
with pathogenesis and environmental survival and included a growth curve in 
Mueller-Hinton broth, resistance to different antibiotics, tolerance to low pH, survival 
in Synthetic Gastric Fluid, motility in soft agar, production of biofilm and formation of 
persister cells, survival in water and virulence in the model organism G. mellonella 
larvae. Two of these tests required an optimisation that led to the design of a novel 
protocol for the test of biofilm production in C. jejuni when grown in solid medium and 
a modification of the incubation conditions for testing the virulence in G. mellonella 
larvae.  
Three of the mutants showed a different phenotype when compared to the wild-
type strain in some of the conditions tested: the mutant DtetO exhibited a high 
susceptibility to the antibiotic tetracycline, the mutant DhicA exhibited an impaired 
ability of swimming in soft agar in particular concentrations of nutrients and an 
impaired ability to produce biofilm, the mutant Dunk9 showed a reduced growth rate 
in MHB and an impaired ability of swimming in soft agar in particular concentrations 
of nutrients. If the phenotype of the mutant DtetO is unsurprising, as the gene tet(O) 
is reported to be responsible of the tetracycline resistance phenotype, the 
phenotypes of the other two mutants require a deeper study. 
The hypothetical protein affected by the mutation in the mutant Dunk9 carries a 
conserved domain involved in the interaction with chromatin and DNA in eukaryotic 
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organisms. In Campylobacter, an association between DNA supercoiling and motility 
was described recently (Shortt et al., 2016), and it is certainly interesting that the 
mutant Dunk9 shows a phenotype impaired in motility and growth. 
The mutant DhicA exhibit an interesting phenotype on motility and biofilm 
production: these phenotypes were shown to be associated with a toxin-antitoxin 
system in several bacterial species, such as E. coli (Kim et al., 2009), but never 
before in C. jejuni.  
Complementation of the mutants was performed in order to ascertain the 
association of the genes deleted with the phenotype observed: the phenotype of 
mutant Dunk9 was fully restored to the wild-type, the phenotype of the mutant DtetO 
was partially restored, and finally it was impossible to restore the wild-type 
phenotype in the mutant DhicA. 
The work carried out in this thesis can be further extended both in the 
bioinformatics section and in the functional analysis of the pTet-associated genes. 
In the production of the pTet-like plasmid pan-genome, I used a total of 27 
pTet-like plasmids, present on the NCBI database, or sequenced in-house and 
whose sequence was ascertained using the paired-end information of the Illumina 
sequencing. I have demonstrated how 15.4% percent of the C. jejuni strains 
sequenced to date show at least half of the genes associated with the plasmid pTet. 
A step that can be taken in the direction of extending the knowledge on the variability 
of the plasmids pTet-like could be producing a pTet-like plasmid pan-genome using 
a larger number of plasmids pTet-like. These could be assembled from the strains 
that have been already sequenced, with the help of Bandage (Wick et al., 2015) or a 
newer version of SPAdes software that promises to be plasmid-aware 
(PlasmidSPAdes, Bankevich et al., 2012). A characteristic of pan-genomes is the 
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completeness: adding more genomes in the analysis corresponds to having more 
genes in the pan-genome result. When this growth in the number of genes after 
adding more genomes in the analysis reaches a plateau, the pan-genome is 
complete (Lefébure et al., 2010; Méric et al., 2014). It would be interesting to 
investigate whether the same were true for the pTet-like plasmid pan-genome: the 
79 genes described in this study describe the variability of the 27 pTet-like plasmids I 
used in the pan-genome analysis, but further work is required to ascertain if this is 
the total variability of the plasmid or if new genes can be discovered by adding other 
pTet-like plasmids to the analysis. 
Secondly, other mutants could be produced in order to study the phenotype of 
other genes identified in the pTet-like plasmid pan-genome. An array of hypothetical 
proteins has been identified in several different plasmids pTet-like, and many of them 
show interesting conserved domains that could not be studied in this work. A few 
examples of hypothetical proteins that would require further study are the one 
encoded by “7_FIG00471069_hypothetical_protein”, carrying a conserved domain 
for membrane carbohydrate transport or the one encoded by 
“42_FIG00638667_hypothetical_protein,” which shows a conserved domain 
encoding for a peptidase involved with bacteriocins resistance. Furthermore, several 
hypothetical proteins identified with automated annotation show no putative function 
and no conserved domains (Table 4.1.1), leaving the production of a mutant and a 
thorough phenotypic study the only way to identify their importance. 
The mutants produced in this work were tested with an array of phenotypic 
tests designed to simulate conditions important for bacterial environmental survival 
and host colonisation, but they by no means cover all the possible characteristics of 
C. jejuni. The majority of the mutants did not show a phenotype different from the 
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wild-type, but different phenotypic assays could highlight differences that I was not 
able to identify. In particular, future work could point in the direction of high 
throughput metabolic analysis using Biolog system (Biolog INC., 
http://www.biolog.com/) and host invasion, evaluating the ability to invade the well-
established models for C. jejuni caco-2 or INT407 cell lines. 
The important phenotype shown by the mutant Dunk9 has been fully 
complemented with the system developed by Jervis et al. in 2015. In the future, it is 
necessary to characterise fully the function of the deleted gene and the protein 
produced. As far as the deleted gene is concerned, it would be interesting to 
ascertain possible interactions with other genes and expression patterns in different 
conditions via transcriptomics study. It is also necessary to identify the deleted 
protein, studying its cellular localisation or secretion, structure, and interaction with 
other proteins. 
The phenotype of the mutant DhicA was not complemented; however, the 
absence of mutations different from the expected one was ascertained via whole 
genome sequencing of the mutant strain. The impossibility of restoring the wild-type 
phenotype in this mutant strain could be due to the operon structure of the toxin-
antitoxin system, and future analyses of this mutant could involve the study of the 
expression levels of the toxin and the antitoxin in the complemented strain and 
production of a mutant lacking of the entire system, if possible. I also suggest trying 
to complement the mutant with different pCJC plasmids, containing the gene to 
complement under the control of different promoters (Jervis et al., 2015). 
Overall, in this project, I demonstrated that plasmids pTet-like have a role in the 
lifestyle of C. jejuni other than the tetracycline resistance. I described a variability in 
the plasmids pTet-like and the absence of the tetracycline resistance characteristic 
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from a large set of them. I summarised the variability of the plasmids pTet-like 
describing the pTet-like plasmid pan-genome and a set of core and accessory genes 
for the plasmid pTet. I produced several mutants on pTet-like genes and tested them 
for phenotypes that simulated the environmental survival and host invasion, 
revealing that some of the genes encoded by the plasmids pTet-like are useful in 
previously undescribed conditions, such as the production of biofilm and motility. 
This work could shed new light on the lifestyle of C. jejuni: I showed that a 
common characteristic like the presence of a plasmid pTet-like is not to be ignored. 
A better understanding of the genetic and the lifestyle of C. jejuni, achieved with 
studies of this kind, can lead to the design of better control measures for the 
bacterium, aiming to eliminate it while it colonises the environment and typical 
ecological niches, preventing the attack to the human host. 
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S1 - Strains from Molecular Microbiology Laboratory (Geoffrey Pope building, 
laboratory 401, EX44QD) used in this study. 
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Strain Origin Growth Tet R virD4 mark tet(O) markhel mark hicA/B mark Species
Calf_3 Cow Y N N X X X X
99/118 Cow N X X X X X X
99/194 Cow N X X X X X X
99/201 Cow Y N N X X X X
99/202 Cow Y N N X X X X
C85-4-99-5 Cow Y N N X X X X
C500-1-99-2 Cow Y N N X X X X
C559-3-99-2 Cow Y N N X X X X
KS_Cattle_8 Cow Y N N X X X X
BB1267 Environmental Y N N X X X X
Beach_28766 Environmental Y N N X X X X
EX1182 Environmental Y N N X X X X
47 Goose Y N N X X X X
95 Goose Y N N X X X X
222 Goose Y Y Y Y Y N jejuni
32799 Human Y N N X X X X
33084 Human Y N N X X X X
K1 Human Y N N X X X X
K3 Human Y N N X X X X
K4 Human Y N N X X X X
K5 Human Y Y Y Y Y N coli
K6 Human N X X X X X X
K7 Human Y Y N N N N coli
Jan-43 Human Y N N X X X X
99/97 Human Y N N X X X X
99/188 Human Y N N X X X X
99/189 Human Y N N X X X X
99/197 Human Y N N X X X X
99/212 Human Y N N X X X X
99/216 Human Y N N X X X X
11818 Human Y Y N Y Y Y jejuni
11919 Human Y N N X X X X
11974 Human Y N N X X X X
12241 Human Y N N X X X X
12450 Human N X X X X X X
13305 Human Y N N X X X X
18836 Human Y N N X X X X
30280 Human Y N N X X X X
30328 Human Y N N X X X X
31467 Human Y N N X X X X
31481 Human Y N N X X X X
31485 Human Y N N X X X X
32787 Human Y N N X X X X
33106 Human Y N N X X X X
34007 Human Y N N X X X X
44119 Human Y N N X X X X
47693 Human Y N N X X X X
K2 Human Y Y Y Y Y N jejuni
90843 Human Y N N X X X X
Hi40500471 Human Y N N X X X X
Hi40620300 Human Y Y Y Y Y Y jejuni
Hi40980306 Human Y N N X X X X
Hi80547 Human Y N N X X X X
Hi80554 Human N X X X X X X
Hi80586 Human Y N N X X X X
Hi81006 Human Y Y N Y N N jejuni
Hi81214 Human Y Y N Y N N jejuni
Hi81266 Human Y N N X X X X
K8 Human Y N N X X X X
KSSAPSM6 Human Y N N X X X X
52471 Human N X X X X X X
KSSHPSM4 Human Y N N X X X X
93/372 Unknown Y N Y N Y Y jejuni
PS304 Pig Y Y N Y Y Y coli
PS549.1 Pig Y N N X X X X
PS623 Pig Y Y Y Y Y Y jejuni
PS762 Pig Y Y Y Y Y Y jejuni
PS838 Pig Y N N X X X X
PS843 Pig Y N N X X X X
PS849 Pig Y N N X X X X
PS852 Pig Y N N X X X X
PS857 Pig Y N N X X X X
Chicken_91_B1 Poultry Y N N X X X X
A1.CF.12 Poultry Y Y Y Y N Y jejuni
A6.T2.15 Poultry Y Y Y Y Y Y jejuni
A8/35/15A Poultry Y Y Y Y Y Y jejuni
C1/C/2 Poultry Y Y Y Y Y Y jejuni
C120/2 Poultry Y N N X X X X
C132/1 Poultry Y X X X X X X
C3/T/25col3 Poultry Y Y N Y Y Y jejuni
C5/T2/8 Poultry Y Y Y Y Y Y jejuni
D2/27/3 Poultry Y N N X X X X
D2/T/8 Poultry Y N N X X X X
D2/T/95 Poultry Y N N X X X X
D5-20-9A Poultry Y N N X X X X
EX1286 Poultry Y N N X X X X
MB1 Poultry Y N N X X X X
MB2 Poultry Y N N X X X X
MB3 Poultry Y N Y N Y Y jejuni
MB4 Poultry Y N N X X X X
MB5 Poultry Y N N X X X X
MB6 Poultry Y N N X X X X
MB7 Poultry Y N N X X X X
MB8 Poultry Y Y N Y N N jejuni
MB9 Poultry Y Y Y Y Y Y jejuni
MB10 Poultry Y N N X X X X
MB12 Poultry Y N Y N N Y jejuni
MB13 Poultry Y N N X X X X
MB14 Poultry Y N N X X X X
MB15 Poultry Y N N X X X X
MB16 Poultry Y N N X X X X
MB17 Poultry Y Y N Y N N coli
MB18 Poultry Y Y Y Y Y Y jejuni
94/229 Poultry Y N N X X X X
S39-2-99-3 Sheep Y N N X X X X
S87-4-99-3 Sheep Y N N X X X X
S120-4-99-4 Sheep Y N N X X X X
S216-5-99-1 Sheep Y N N X X X X
S372-5-99-4 Sheep Y N N X X X X
S379-8-99-1 Sheep Y N N X X X X
S435-3-99 Sheep Y N N X X X X
S499-1-99-5 Sheep Y N N X X X X
S585-3-99 Sheep Y N N X X X X
30x2_tag60 Unknown Y N N X X X X
KJSHPFELL_2 Unknown Y N N X X X X
KJSHPM8 Unknown N X X X X X X
Cj1 Human Y Y Y Y Y Y jejuni
Cj2 Human Y Y Y Y Y Y jejuni
Cj3 Human Y Y Y Y Y Y jejuni
Cj4 Human N X X X X X X
Cj5 Human Y N N X X X X
293 
 
S2 - Plasmids maps sequenced in this study. Plasmids maps were obtained with 
BRIG software. Green and Red arrows represent the genes annotated on the 
plasmid, as reported by RAST automated annotation. Inner circles represent C+G % 
and GC skew (C+G % only for pCj3 and pK2). 
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S3 - Annotated genes in the 19 newly sequenced plasmids and in the plasmid pTet 
(NC_008790.1). Plasmids have been linearised at the start of the virB2 gene. Each 
plasmid annotation shows the start nucleotide, the end nucleotide, the gene 
orientation (+/- = sense or antisense), gene name (as reported by RAST automated 
annotation pipeline). 
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S4 - Putative proteins of the pTet-like plasmid pan-genome 
 
This section will provide a summary of the conserved domains identified in the 
pTet-like plasmid pan-genome. The protein names reported in this section refer to 
the pTet-like plasmid pan-genome (Section 3.3.1). For each hypothetical protein, the 
detail of each conserved domain identified is described: this includes the results 
retrieved from NCBI’s CD-Search search engine for each hypothetical protein, 
together with the name, the accession number and the e-value of each conserved 
domain and a brief description of the putative function of each conserved domain 
identified. 
 
S4.1 2_virulence_associated_protein_D_(vapD) 
 
Virulence-associated protein VapD (function unknown) 
CRISPR associated protein Cas2 
Ligand-binding domain - PBP1_NPR_GC_like 
COG3309 
pfam09827 
cd06352 
1-285 
1-252 
79-273  
7.63e-42 
8.48e-07 
1.32e-03 
 
This protein shows a VapD (virulence associated protein) domain. The function 
of this domain is unknown, but it belongs to the “Cas2_I_II_III Superfamily”, a 
CRISPR/Cas system associated domain (cl11442). A CRISPR_Cas2 domain is also 
identified in the same region of the VapD domain. 
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and 
associated Cas proteins comprise a system for heritable host defense by prokaryotic 
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cells against phage and other foreign DNA, this domain is present in most 
CRISP/Cas systems (Barrangou et al., 2007). 
Further, a non-specific hit against a PBP1_NPR_GC_like domain is reported in 
this hypothetical protein (cd06352). This domain is a ligand-binding domain of 
membrane guanylyl-cyclase receptors, and it is found in several mammalian tissues 
(Garbers et al., 2006). 
 
S4.2 3_hypothetical_protein 
 
TIR domain; family of bacterial Toll-like receptors 
aro_clust_Mycop; aromatic cluster surface protein 
Borrelia_orfA 
COG2604; Uncharacterized conserved protein [Function unknown] 
pfam13676 
TIGR04313 
pfam02414 
COG2604 
805-1083 
103-720 
25-414 
16-570 
1.99e-06 
1.95e-05 
2.72e-04 
5.83e-03 
 
The conserved domains shown in this protein suggest a surface expression, 
possibly involved in signal transduction. A domain of superfamily TIR_2 is described 
as a bacterial toll-like receptor (Wu et al., 2012) involved with signal transduction. 
The aro_clust_Mycop, is a domain restricted to Mollicutes, far from gram negative 
bacteria such as C. jejuni, and is associated with a lipoprotein suggesting membrane 
expression. COG2604 is a conserved domain in bacterial proteins with unknown 
function. 
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Borrelia ORF-A is a conserved domain often found in the putative proteins from 
the pTet-like pan-genome and it is derived from plasmid-borne DNA repeats in 
Borrelia species (Zückert et al., 1996). Its putative function is unknown. 
 
S4.3 4_hypothetical_protein 
 
Haemolysin XhlA  
PRK05771 - V-type ATP synthase subunit I 
pfam10779 
PRK05771 
4-132 
3-327 
8.67e-03 
8.00e-04 
 
A partial domain related to XhlA is identified in this protein. This is described as 
a cell-surface haemolysin in an insect pathogen, also able to lyse mammalian horse 
cell (Cowles et al., 2005).  
A multi domain PRK05771 is also identified in this putative protein, associated 
with the subunit 1 of a V-type ATP synthase. 
 
S4.4 6_FIG00469644_hypothetical_protein 
 
Acetyltransf_1  
pfam00583 244-426 2.21e-03 
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In this hypothetical protein a partial acetyl transferase domain is identified. It 
belongs to a NAT_SF superfamily (cl17182), a large superfamily of enzymes that 
catalyses the transfer of an acyl group with several associated functions, from 
histone acylation to antibiotic resistance in bacteria (Neuwald et al., 1997, Cort et al., 
2008). 
 
S4.5 7_FIG00471069_hypothetical_protein 
 
Serpentine type 7TM GPCR chemoreceptor Srd 
Tellurite-resistance/Dicarboxylate Transporter (TDT) family 
pfam10317 
cd09321 
40-114 
7-117 
4.39e-05 
9.73e-04 
 
In this small hypothetical protein two partial non-specific hits are identified: the 
first is far from the bacterial kingdom, associated with a 7 transmembrane domain 
chemoreceptor in Caenorhabditis elegans (Robertson et al., 2006); the second is 
associated with a partial Tellurite-resistance/Dicarboxylate Transporter (TDT). This 
protein family is conserved in all kingdoms of life. In bacteria a member of this family 
has been identified as an uptake channel for C4 carbohydrates (Teramoto et al., 
2008). This may be particularly relevant in Campylobacter, as most Campylobacter 
strains cannot utilise sugars and they rely on the use of amino acids and C4 
carbohydrates for survival and successful colonisation (Guccione et al., 2008; Stahl 
et al., 2011). 
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S4.6 9_FIG00469571_hypothetical_protein 
 
Synaptonemal complex protein 1 (SCP-1) 
pfam05483 4-549 1.77e-03 
 
In this hypothetical protein, the only hit is related to a superfamily that is 
involved with a chromosomal structure that is formed during the meiotic phase in 
eukaryotic cells (Meuwissen et al., 1992). 
 
S4.7 10_hypothetical_protein 
 
Guanylate-binding protein, C-terminal domain 
cd16269 208-468 9.22e-03 
 
The conserved domain GBP_C is the only domain found in this hypothetical 
protein. It is the C-terminal domain of a guanylate-binding protein, a regulative 
protein synthesised in eukaryotic cells after activation with interferons (Vestal et al., 
2011).  
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S4.8 11_FIG00469626_hypothetical_protein 
 
Subfamily multidrug and toxic compound extrusion (MATE) proteins; MATE_like_10 
M. penetrans paralogue family 26; MpPF26 
NADH dehydrogenase subunit 5 - ND5 
oligosaccharide repeat unit polymerase - glyco_rpt_poly 
Membrane protein - RfbX 
Tetraspanin family 
cd13125 
pfam07666 
MTH00095 
TIGR04370 
COG2244 
pfam00335 
10-270 
49-234  
37-408  
10-321 
1-264 
82-261 
8.86e-05 
1.42e-03 
5.71e-04 
1.18e-03 
2.83e-03 
3.90e-03 
 
This hypothetical protein shows several partial domains the majority of which 
seem related to a membrane transporter or a membrane protein. One of the 
conserved domains identified is a MATE-like domain (Putman et al., 2000; Hvorup et 
al., 2003). It encodes for a family of proteins associated with the function of multidrug 
and toxic compound extrusion (MATE), which is involved in exporting metabolites 
across the cell membrane and conferring multi drug resistance to bacteria. 
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Further, it is possible to identify the domain MpPF26, a paralogue of a protein 
family in Mycoplasma penetrans (Sasaki et al., 2002). The domains RfbX and 
glyco_RPT_poly are involved with the synthesis and export of cell walls component. 
The domain ND5 associated with a NADH dehydrogenase subunit and an 
undescribed Tetraspannin family domain associated with eukaryotic membrane 
proteins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
325 
 
S4.9 12_FIG00471537_hypothetical_protein 
 
EpsG family 
S. cerevisiae inner mitochondrial membrane Mg2+ transporters Mfm1p and Mrs2p-like 
AAA domain - AAA_23 
PHA02590 
General stress protein CsbA 
PRK03918 
helix-rich Mycoplasma protein - Mplasa_alph_rch 
pfam14897 
cd12823 
pfam13476 
PHA02590 
COG4897 
PRK03918 
40-276 
46-219 
217-555 
289-546 
40-228 
223-555 
9.78e-05 
1.66e-04 
7.78e-04 
1.71e-03 
4.51e-03 
3.33e-04 
 
In the hypothetical protein 12_FIG00471537_hypothetical_protein, one specific 
hit is identified as AAA protein (ATPase associated with diverse cellular activities; 
Iyer et al., 2004). Other non-specific hits include an EpsG domain, which appears 
often in the plasmidic proteins of C. jejuni: it is related to the EpsG protein of Bacillus 
subtilis, which appears to be involved in the production of exopolysaccharides 
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required for biofilm maintenance (Branda et al., 2004). Moreover, a general stress 
protein CsbA domain is identified, related to a protein of unknown function in Bacillus 
subtilis involved in stress response (Petersohn et al., 2001). 
Finally, this hypothetical protein includes domains associated with viral proteins 
(PHA02590), mitochondrial cation transport (cd12823), chromosome segregation 
(PRK03918), and a membrane protein of unknown function occurring in members of 
Mycoplasma species. 
 
S4.10 13_FIG00469557_hypothetical_protein 
 
Small protein-protein interaction domain - LIM 
Putative ribonucleoprotein zinc-finger pf C4 type - zf-RRPl_C4 
cd08368 
pfam17026 
85-165 
16-183 
2.97e-03 
6.73e-03 
 
The LIM domain found in this protein is identified in several proteins with 
various functions in eukaryotic cells, such as DNA expression regulation and cell 
development (Matthews et al., 2003). The domain contains two zinc finger motifs. 
Furthermore, a domain for a putative ribonucleoprotein is identified. This family 
(zinc finger of C4 type) is largely represented in Microsporidia and carries residues 
(in a pattern of CxxC) that suggest DNA binding (Nakjang et al., 2013). 
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S4.11 15_DNA_topoisomerase_II 
 
endonuclease subunit - 47 
PHA02546 1-165 1.77e-03 
 
This putative protein, annotated as a DNA topoisomerase II carries a viral 
endonuclease domain (Mickelson and Wiberg, 1981). 
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S4.12 16_Tetracycline_resistance_protein_TetO 
 
Tet(M)-like family 
EF-G_domain IV_RPP - Tet_like_IV 
Domain III of Tetracycline resistance protein Tet - Tet_III 
Domain II of ribosomal protection proteins Tet(M) and Tet(O) - Tet_II 
Tet_C: C-terminus of ribosomal protection proteins Tet(M) and Tet(O) 
Translation elongation factor EF-G - FusA 
cd04168 
cd01684 
cd16258 
cd03690 
cd03711 
COG0480 
13-723  
1252-1596  
1030-1242 
736-987 
1609-1839 
1-1875 
3.32e-149 
5.89e-65 
1.34e-35 
1.12e-34 
2.22e-32 
3.25e-137 
 
This putative protein shows all the typical domains of a tetracycline resistance 
protein Tet(O) or Tet(M) (Roberts, 2005; Oggioni et al., 1996). This protein acts 
protecting the ribosome and it is a homologue to the elongation factors EF-Tu and 
EF-G. 
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S4.13 18_FIG00470991_hypothetical_protein 
 
Uncharacterized conserved protein - COG2604 
Pkip-1 protein 
CRISPR/Cas system-associated protein - Cas8a1 
heat shock protein GrpE - PRK14149 
chromosome segregation protein - PRK03918 
DNA repair exonuclease SbcCD 
Autophagy protein Apg6 
COG2604 
pfam06878 
cd09730 
PRK14149 
PRK03918 
COG0419 
pfam04111 
7-279  
49-267  
4-261  
31-219  
7-183  
4-237  
16-276  
1.78e-04 
5.78e-04 
7.02e-04 
8.81e-04 
1.39e-04 
1.50e-04 
5.76e-04 
 
Several conserved domains appear in this protein. 
Pkip-1 is related to viral proteins of unknown function. PRK14149 is a part of 
the GrpE superfamily, including heat-shock proteins and an essential factor for 
bacterial chaperone proteins. Other non-specific domains are mainly involved in 
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eukaryotic cellular processes (PRK03918 and Apg6) (Pijlman et al., 2003; Castanié-
Cornet et al., 2014). 
Cas8a1 domain is associated with CRISPR/Cas proteins (Boyaval et al., 2007). 
 
S4.14 19_FIG00471111_hypothetical_protein 
 
Predicted RNA binding protein YcfA 
HicA toxin of bacterial toxin-antitoxin 
COG1724 
pfam07927 
1-198 
28-174  
8.40e-19 
1.00e-12 
 
This protein shows the conserved domain for YfcA/HicA toxin. The HicA toxin 
acts as an mRNA interferase and is neutralised by the cognate antitoxin HicB, 
usually found in tandem in the sequenced plasmids and described later on in this 
chapter (23_FIG00470952_hypothetical_protein). The HicAB system is often used in 
the bacterial cell for plasmid stabilisation (Makarova et al., 2006; Yamaguchi and 
Inouye, 2011). 
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S4.15 20_FIG00471065_hypothetical_protein 
 
ABC-2 family transporter protein - ABC2_membrane_5 
spore germination protein (amino acid permease) - 2A0309 
solute carrier 6 subfamily - SLC6sbd_Tyt1-Like 
glycopeptide antibiotics resistance protein - VanZ 
hypothetical protein - PRK09609 
oligosaccharide repeat unit polymerase - glyco_rpt_poly 
acyltransferase family - Acyl_transf_3 
membrane protein, O-antigen and teichoic acid export - RfbX 
NADH dehydrogenase subunit 2 - ND2 
pfam13346 
TIGR00912 
cd10336 
COG4767 
PRK09609 
TIGR04370 
pfam01757 
COG2244 
MTH00091 
19-381 
1-366 
1-375 
70-366 
7-366 
13-393 
49-363 
28-390 
112-381 
2.75e-09 
4.17e-06 
1.50e-05 
1.60e-04 
3.38e-04 
1.21e-04 
1.17e-03 
1.69e-03 
2.77e-03 
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This hypothetical protein shows several domains linked with membrane protein 
and transport. In particular, the domain with a lower p-value associated with this 
sequence is an ABC transporter domain, a bacterial system associated with export 
of drugs and carbohydrates (Reizer et al., 1992). Another domain hit associated with 
molecules transport is the solute carrier from Fusobacterium nucleatum Tyt1-like. 
Bacterial variants of this protein family are involved in transport of amino acids 
(Quick et al., 2006). 
Furthermore, a VanZ domain is identified and this is involved in the resistance 
to glycopeptide antibiotics such as vancomicin and teicoplanin (Arthur et al., 1995).  
 
S4.16 21_hypothetical_protein 
 
ParA 
Cellulose biosynthesis protein BcsQ [Cell motility] 
cd02042 
COG1192 
4-333 
1-66 
3.01e-04 
3.29e-03 
 
The conserved domain ParA is recognisable in this hypothetical protein. It is 
part of a ParA-ParB system involved in bacterial chromosome segregation. ParA, in 
particular, appears to have an ATPase activity that promotes the regulation of the 
DNA replication process. It shares similarity with a conserved family of ATPases 
involved in the same processes that includes RepA (Easter and Gober, 2002). 
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S4.17 22_Virulence-associated_protein_2_(vapD) 
 
Virulence-associated protein VapD 
CRISPR/Cas system-associated protein Cas2 superfamily 
COG3309 
cl11442 
13-294 
13-294 
7.41e-12 
7.41e-12 
 
The conserved domain found here is consistent with the automated annotation. 
VapD, is a virulence-associated protein of unknown function, part of a superfamily of 
CRISPR/Cas system-associated protein involved in the protection of the bacterium 
against phages and other foreign DNA (Boyaval et al., 2007; Nam et al., 2012). 
 
S4.18 23_FIG00470952_hypothetical_protein 
 
Predicted nuclease of the RNAse H fold, HicB family 
HicB_like antitoxin of bacterial toxin-antitoxin system - HicB_lk_antitox 
COG1598 
pfam15919 
1-168 
13-192 
2.34e-16 
3.78e-09 
 
This putative protein harbours an HicB domain, antitoxin of the HicAB toxin-
antitoxin system. The conserved domain associated with the cognate toxin is 
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encoded by the “19_FIG00471111_hypothetical_protein” (Yamaguchi and Inouye, 
2011; Makarova et al., 2006). 
 
S4.19 24_Site-specific_recombinase_resolvase 
 
Serine Recombinase (SR) family - SR_ResInv 
Resolvase, N terminal domain 
Resolvase, N terminal domain 
multiple promoter invertase - Mpi 
Site-specific DNA recombinase - PinE 
helix-rich Mycoplasma protein  - Mplasa_alph_rch 
cd03768 
pfam00239 
smart00857 
PRK13413 
COG1961 
TIGR04523 
7-405 
7-435 
7-435 
1-540 
1-495 
31-534 
7.34e-41 
6.13e-38 
4.63e-37 
2.65e-47 
2.87e-28 
1.47e-04 
 
As predicted by the automated annotation, this hypothetical protein contains 
conserved domain associated with a resolvase/inverase of the serine recombinase 
family. This family of proteins catalyses the site-specific recombination of DNA 
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molecules (Hallet and Sherratt, 1997; Smith and Thorpe, 2002). Several catalytic 
features associated with this protein family are also identified in the sequence. 
 
S4.20 26_FIG00470038_hypothetical_protein 
 
Staphylococcus aureus coagulase  
pfam08764 16-309 9.78e-03 
 
The coagulase conserved domain shown here derives from a coagulase protein 
described in Staphylococcus aureus, which initiates blood clotting (Friedrich et al., 
2003). 
 
S4.21 27_FIG00470273_hypothetical_protein 
 
helix-rich Mycoplasma protein 
TIGR04523 328-606 1.51e-04 
 
A partial domain of unknown function is present in this hypothetical protein. It is 
associated with Mycoplasma species, strong amino acid periodicity and it is almost 
completely formed by alpha helices (Sasaki et al., 2002). 
 
S4.22 28_IncQ_plasmid_conjugative_transfer_protein_TraQ 
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TrbM 
conjugal transfer protein TrbM - PRK13893 
pfam07424 
PRK13893 
70-582 
1-327 
1.60e-35 
4.67e-27 
 
The protein family described here is consistent with the automated annotation 
and represents a TrbM protein (homologous with TraQ), involved with DNA conjugal 
transfer (Lessl et al., 1992). 
 
S4.23 29_Coupling_protein_VirD4_ATPase 
 
TraG_VirD4 bacterial conjugation protein 
TraM recognition site of TraD and TraG - TraG-D_C 
ATP/ADP translocase - TlcC 
Type IV secretory system Conjugative DNA transfer - T4SS-DNA_transf 
Type IV secretory pathway, VirD4 
type IV secretion system component VirD4 - PRK13897 
Ti-type conjugative transfer system protein TraG 
cd01126 379-1581 5.96e-82 
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pfam12696 
COG3202 
pfam02534 
COG3505 
PRK13897 
TIGR02767 
1216-1584 
40-315 
274-1704 
109-1758 
61-1674 
187-1650 
5.53e-28 
9.86e-03 
4.98e-104 
6.78e-107 
2.63e-76 
7.79e-15 
 
This hypothetical protein, annotated as VirD4 ATPase, shows conserved 
domain consistent with the function of ATPase providing the energy to the Type IV 
Secretion System (Hofreuter et al., 2001; Kado, 2006). 
 
S4.24 30_VirB8 
 
VirB8 protein 
Type IV secretory pathway, component VirB8 
type IV secretion system protein VirB8 - PRK13865 
pfam04335 
COG3736 
PRK13865 
22-651 
4-651 
40-651 
5.25e-60 
1.89e-57 
8.52e-07 
 
This hypothetical protein, annotated as VirB8, shows a complete conserved 
domain associated with that Type IV Secretion System protein (Kumar and Das, 
2001; Backert et al., 2000). 
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S4.25 31_FIG00471711_hypothetical_protein_NTPase 
 
Borrelia_orfA 
Intein/homing endonuclease - Hop 
putative recombination protein RecB - PRK13909 
pfam02414 
COG1372 
PRK13909 
43-561 
4-603 
34-558 
1.77e-03 
1.25e-03 
1.29e-03 
 
This hypothetical protein shows a conserved domain associated with an ORF of 
unknown function identified in plasmids of Borrelia bugdoferi (Zückert and Meyer, 
1996). 
Two further domains are involved with DNA mobilisation and recombination 
(Marsin et al., 2008). 
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S4.26 32_FIG00469957_hypothetical_protein 
 
Uncharacterized conserved protein - COG1479 
Borrelia_orfA 
two transmembrane protein - mycoplas_twoTM 
Ligand-binding domain of a transcription repressor - PBP1_FucR_like 
F0F1 ATP synthase subunit delta - PRK08474 
helix-rich Mycoplasma protein - Mplasa_alph_rch 
AAA ATPase domain 
DNA polymerase III subunits gamma and tau - PRK07133 
Uncharacterized protein - COG4487 
Spc7 kinetochore protein 
COG1479 
pfam02414 
TIGR04527 
cd06276 
PRK08474 
TIGR04523 
pfam13175 
16-720 
4-453 
4-621 
88-759 
100-387 
7-531 
1-570 
1.39e-05 
2.90e-05 
5.46e-05 
8.66e-05 
5.53e-04 
1.64e-08 
8.69e-06 
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PRK07133 
COG4487 
smart00787 
7-561 
1-447 
76-438 
3.74e-05 
3.11e-03 
6.49e-03 
 
Several domains of different functions are identified in this protein. A partial 
uncharacterised protein domain (COG1479) is present which contains a ParB-like 
nuclease domain, making it a candidate to complete the ParA-ParB nuclease system 
described with the 21_hypothetical_protein (Easter and Gober, 2002). Other 
Domains are consistent with the nuclease activity, such as the AAA-domain 
pfam13175. 
The domain PBP1_FucR_like (cd06276) is also found in this hypothetical 
protein: it is described as a ligand binding domain sensor for L-fucose which function 
as a transcription repressor. The protein FucR, from which this domain family is 
derived, is composed of a helix-turn-helix DNA-binding domain at the N-termius, and 
a C-terminal sugar binding domain, homologous to other sugar binding domain found 
in other membrane transport systems, such as ABC transporters. (Felder et al., 
1999; Nguyen and Saier. 1995). 
 
S4.27 33_cag_pathogenicity_island_protein 
 
Cag pathogenicity island protein Cag12 
pfam13117 37-369 1.05e-22 
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This putative protein shows a Cag12 conserved domain, which is consistent 
with the predicted function of the automated annotation. The protein Cag12 is part of 
the Cag pathogenicity island of Helicobacter pylori. The Cag-PAI encodes for the 
Type IV Secretion System of H. pylori, used by the bacterium to deliver cytotoxins to 
the host cells. Although the function of Cag12 is not clear, it is a component located 
on the outer membrane of the bacterium and it has been proved that it could be used 
to develop a protective immunity against the pathogen (Kim et al., 2006). 
 
S4.28 34_VirB11 
 
P-type DNA transfer ATPase VirB11 
Type IV secretory pathway ATPase VirB11 
Type IV secretion system ATPase VirB11 - PRK13900 
Type IV secretory pathway component VirB11 
Type II/IV secretion system protein - T2SSE 
Type II secretory pathway ATPase GspE/PulE or T4P pilus assembly pathway ATPase PilB - PulE 
plasmid transfer ATPase TraJ 
ATPases associated with a variety of cellular activities - AAA 
AAA-like domain - AAA_10 
ATP-dependent RNA helicase HrpA - PRK11131 
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TIGR02788 
COG0630 
PRK13900 
cd01130 
pfam00437 
COG2804 
TIGR02525 
smart00382 
pfam12846 
PRK11131 
46-975 
37-975 
13-984 
454-972 
46-933 
385-894 
490-957 
478-723 
484-591 
457-525 
3.32e-132 
4.49e-74 
3.35e-67 
5.63e-67 
5.90e-58 
2.11e-12 
4.43e-11 
7.72e-06 
2.79e-04 
1.92e-03 
 
As predicted by the automated annotation, this putative gene encodes for 
conserved domains strictly related to the VirB11 ATPase of the Type Four Secretion 
System (Atmakuri et al., 2004). 
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S4.29 35_VirB2 
 
TrbC/VIRB2 family 
serine transporter - stp 
Subfamily of the multidrug and toxic compound extrusion (MATE) proteins - MATE_like_3 
MFS/sugar transport protein - MSF2 
pfam04956 
TIGR00814 
cd13148 
pfam13347 
7-255  
7-174 
22-258  
7-243 
1.64e-19 
2.21e-03 
7.04e-03 
2.16e-05 
 
Consistent with the automated annotation, the most reliable hit according to the 
p-Value is the TrbC/VirB2 family domain. It is the main structural component of the 
Type IV secretion system (Kalkum et al., 2002; Schulein and Dehio, 2002). 
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S4.30 36_VirB9 
 
P-type conjugative transfer protein VirB9 
Conjugal transfer protein - CagX 
Type IV secretory pathway, VirB9 component 
VirB9/CagX/TrbG, a component of the type IV secretion system - VirB9 
type IV secretion system protein VirB9 - PRK13861 
TIGR02781 
pfam03524 
cd06911 
PRK13861 
10-816  
10-825 
544-813 
25-849 
4.75e-79 
1.73e-34 
2.70e-28 
3.69e-15 
 
The conserved domains identified in this protein are consistent with the 
component VirB9 of the Type IV secretion system. A VirB7 interaction site is also 
identified: the two proteins form a complex when the Type IV secretion system is 
assembled (Anderson et al., 1996; Bayliss et al., 2007). 
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S4.31 37_FIG00470457_hypothetical_protein 
 
Translation initiation factor IF-2, N-terminal region 
vacuolar sorting protein SNF7-like - PTZ00446 
pfam04760 
PTZ00446 
13-150 
16-273 
1.86e-05 
4.96e-03 
 
The N-termini of the IF2 translation initiation factor of E. coli is identified in this 
hypothetical protein. The IF2 factor ensures the binding of the MET-tRNA to the 30S 
ribosomal subunit (Nyengaard et al., 1991; Laursen et al., 2003). 
A non-specific hit is also identified with a superfamily associated with vacuolar 
sorting and transport of membrane protein in eukaryotic cells (Babst et al., 2002). 
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S4.32 39_VirB10 
 
Bacterial conjugation TrbI-like protein 
Type IV secretory pathway, VirB10 
type IV secretion system protein VirB10 - PRK13855 
Protein of unknown function - DUF1510 
pfam03743 
COG2948 
PRK13855 
pfam07423 
577-1119 
76-1149 
223-1140 
61-240 
5.96e-55 
7.49e-54 
1.69e-39 
3.05e-03 
 
The conserved domains identified in this protein are associated with the VirB10 
component of the Type IV secretion system, with the exception of a small domain of 
unknown function (pfam07423) (Ward et al., 1990). 
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S4.33 40_FIG00471323_hypothetical_protein 
 
Nodulin-21 and CCC1-related protein family 
TLC domain - TRAM_LAG1_CLN8 
NADH dehydrogenase subunit 4L - NDL4 
tandem five-transmembrane protein - Gpos_tandem_5TM 
proton-translocating NADH-quinone oxidoreductase - NDH_I_N 
NADH dehydrogenase subunit 5 - ND5 
Uncharacterized membrane protein - COG4984 
cd02434 
pfam03798 
MTH00093 
TIGR01218 
TIGR01770 
MTH00095 
COG4984 
82-207 
1-207  
52-201 
58-198  
52-273 
55-186  
61-216 
2.39e-04 
5.64e-04 
6.01e-04 
1.35e-03 
9.93e-04 
2.04e-03 
8.19e-03 
 
This hypothetical protein includes conserved domains associated with several 
putative functions. A nodulin related protein associated to nitrogen fixation in plants 
and metals transporter in yeast (Delauney et al, 1990; Li et al., 2001); a domain 
associated with lipid sensing in yeast and mammalian cells (Winter and Ponting, 
348 
 
2002); a domain of unknown function present in proteins with five transmembrane 
domains; and domains associated with a NADH dehydrogenase function. A putative 
function is not possible to predict, but the majority of the conserved domains suggest 
that this is likely to be a membrane protein. 
 
S4.34 41_Single-stranded_DNA-binding_protein 
 
SSB_OBF: A subfamily of OB folds similar to the OB fold of ssDNA-binding protein (SSB) 
Single-strand binding protein family - SSB 
single stranded DNA-binding protein - ssb 
single-stranded DNA-binding protein - PRK08763 
Single-stranded DNA-binding protein - Ssb 
single-stranded DNA-binding protein - PRK08486 
cd04496 
pfam00436 
TIGR00621 
PRK08763 
PRK08486 
10-312  
1-312 
4-351  
1-372  
4-396 
4.37e-33 
4.60e-29 
5.91e-24 
7.54e-17 
1.56e-16 
 
The conserved domains identified in this protein suggest the possible function 
of single-strand DNA binding protein. This protein family are known to bind ssDNA in 
order to aid several processes including transcription, replication and recombination. 
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In E. coli this protein is known to form stable homodimer, while in other bacterial 
species (such as Mycobacterium tuberculosis) it forms tetramer. The sequence here 
described shows features for dimer and tetramer interaction, highlighted in the figure 
(Lopper et al., 2004; Saikrishnan et al., 2003; Arcus, 2002). 
 
S4.35 42_FIG00638667_hypothetical_protein 
 
Predicted double-glycine peptidase - COG3271 
Peptidase_C39G 
Peptidase C39 family 
ABC-type bacteriocin/lantibiotic exporters - SunT 
ABC-type bacteriocin transporter - bacteriocin_ABC 
COG3271 
cd02423 
pfam03412 
COG2274 
TIGR01193 
1-537 
103-513 
94-522 
100-570 
121-546 
2.73e-39 
6.64e-38 
2.89e-21 
8.50e-12 
7.79e-06 
 
This hypothetical protein shows several conserved domains associated with the 
C39 peptidase, proteins necessary to process various bacteriocins. These are 
antibiotic proteins produced by bacteria to inhibit the growth of other bacterial 
species. This family of peptidase is usually the N-terminal of an ABC-transporter: the 
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processing of the bacteriocin involves the cleavage of a Glycine-Glycine bond, 
followed by the export of the molecule across the cytoplasmic membrane. The 
putative active site is also identified in the protein sequence (Wu and Tai, 2004; 
Barrett and Rawlings, 2001). 
 
S4.36 44_IncQ_plasmid_conjugative_transfer_TraR_(VirD2) 
 
Relaxase/Mobilization nuclease domain 
Type IV secretory pathway - VirD2 
pfam03432 
COG3843 
406-909 
214-684 
5.24e-08 
2.61e-04 
 
The domains identified in this putative protein are consistent with the 
VirD2/TraR protein. This protein is involved with the mobilisation of DNA during 
conjugational transfer (Meyer, 2000). 
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S4.37 45_Ribbon-helix-helix_protein_copG_family_domain_protein 
 
F0F1 ATP synthase subunit delta - PRK13436 
PAM-interacting domain of CRISPR-associated endonuclease Cas9 - Cas9_PI 
Uncharacterized conserved protein - COG2604 
Proteasome chaperone - Hsm3_like 
aromatic cluster surface protein - aro_clust_Mycop 
helix-rich Mycoplasma protein - Mplasa_alph_rch 
AAA ATPase domain - AAA_15 
reticulocyte binding protein 2-like - PTZ00440 
ATPase/GTPase - AAA15 
PRK13436 
pfam16595 
COG2604 
cd12794 
TIGR04313 
TIGR04523 
pfam13175 
PTZ00440 
COG1106 
1-516  
28-504 
4-345 
97-423 
1-471 
4-513 
16-549 
28-501 
34-549 
1.77e-06 
5.81e-06 
1.52e-04 
3.04e-04 
5.07e-04 
9.72e-07 
1.73e-06 
6.90e-05 
1.48e-04 
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This hypothetical protein presents several domains of different nature. One of 
these is a complete conserved domain associated with the proteasome assembly in 
yeast showing an ATPase function (Park et al., 2010).  
A CRISPR/Cas9 associated protein domain is also identifiable (Boyaval et al., 
2007). 
Other domains are of unknown function, an ATP synthetase and several 
ATPase putative domains. 
 
S4.38 46_DNA_primase_(EC_2.7.7.-) 
 
topoisomerases, DnaG-type primases - TOPRIM 
Toprim domain - Toprim_3 
Topoisomerase-primase - TOPRIM_primases 
Uncharacterized domain associated with phage/plasmid primase COG4643 
helix-rich Mycoplasma protein - Mplasa_alph_rch 
RecF/RecN/SMC N terminal domain - SMC_N 
smart00493 
pfam13362 
cd01029 
COG4643 
799-1026 
808-1122 
799-966 
241-1017 
2.79e-06 
6.89e-06 
7.45e-06 
6.85e-28 
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TIGR04523 
pfam02463 
373-1224 
208-1215 
4.80e-04 
6.07e-03 
 
This protein carries a Topoisomerase/Primase domain. Bacterial primases 
synthesise RNA primer to initiate DNA replication. The reaction is Mg2+ dependent. 
The active site together with the metal binding site are identified in the conserved 
domain (Keck et al., 2000; Aravind et al., 1998). 
 
S4.39 47_IncQ_plasmid_conjugative_transfer_protein_TraG 
 
Murein lipoprotein - PRK15396 
Protein of unknown function - DUF4223 
PRK15396 
pfam13978 
7-222 
1-114 
1.50e-04 
4.78e-03 
 
In this hypothetical protein, annotated as a plasmid conjugative transfer protein, 
it is possible to identify just two conserved domains of unknown function. 
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S4.40 48_FIG00470960_hypothetical_protein 
 
AAA domain, DNA repair proteins - AAA_25  
Hexameric Replicative Helicase - RepA 
DNA repair and recombination protein - recomb_RadB 
Archaellum biogenesis protein - FlaH 
Uncharacterized protein - COG3421 
DNA polymerase III subunits gamma and tau - PRK07133 
RecA-family ATPase 
reticulocyte binding/rhoptry protein - 235kDa-fam 
pfam13481  
cd01125 
TIGR02237 
COG2874 
COG3421 
PRK07133 
COG3598 
TIGR01612 
88-528 
97-717 
88-501 
97-684 
964-1791 
451-1662 
88-525 
589-1785 
1.68e-14 
4.06e-13 
4.06e-05 
1.02e-03 
3.28e-03 
1.20e-06 
1.37e-05 
5.21e-03 
 
This hypothetical protein carries domains for DNA repair and replication. In 
particular, one of the highest p-value is identified for a hexameric replicative protein 
RepA domain including its catalytic and polymerisation sites. The RepA protein is an 
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ATP-dependent helicase encoded by plasmids in gram-negative bacteria, which 
initiates the replication of DNA (Niedenzu et al., 2001). 
The other conserved domains are consistent with the ATPase function of the 
protein RepA, with the exception of 235kDa-fam (TIGR01612), which is usually 
found in plasmodium species. 
 
S4.41 49_VirB4 
 
CagE, TrbE, VirB family, component of type IV transporter - CagE_TrbE_VirB 
Type IV secretory pathway, VirB3-like protein - VirB3 
Type IV secretory pathway - VirB3 
type IV secretion system protein VirB3 - PRK13899 
AAA domain - AAA_23 
type IV secretion/conjugal transfer ATPase, VirB4 - VirB4_CagE 
Type IV secretory pathway - VirB4 
type IV secretion system ATPase VirB4 - PRK13898 
AAA-like domain associated with conjugative transfer protein - AAA_10 
pfam03135 
pfam05101 
COG3702 
PRK13899 
pfam13476 
832-1446 
10-255  
4-294 
1-267 
1642-2103 
4.45e-51 
5.23e-24 
1.86e-15 
5.55e-10 
5.73e-04 
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TIGR00929 
COG3451 
PRK13898 
pfam12846 
340-2700 
331-2763 
331-2760 
1636-2532 
0e+00 
0e+00 
5.71e-134 
4.05e-36 
 
This hypothetical protein annotated as VirB4 shows conserved domains for 
both the protein VirB3 and the protein VirB4 of bacterial Type IV secretion system 
(Christie and Vogel, 2000). These domains might appear together in this hypothetical 
protein because of an error in the automated annotation and CDS prediction 
pipeline.  
 
S4.42 50_Phage_Rha_protein 
 
Phage regulatory protein Rha - Phage_pRha 
phage regulatory protein - phage_pRha 
NADH-quinone oxidoreductase/respiratory complex I - MopB_Res-Cmplx1_Nad11-M 
Phage regulatory protein Rha - pRha 
pfam09669 
TIGR02681 
cd02774 
COG3646 
70-357  
46-372 
91-525 
37-372 
2.24e-40 
3.62e-29 
5.16e-04 
1.89e-26 
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The conserved domains included in this hypothetical protein encode for a 
phage regulatory protein, with the exception of the mitochondrial NADH 
oxidoreductase, which has the highest e value. This protein, found in temperate 
phages and bacterial prophages, interferes with the infection of the bacterial cell 
(Iyer et al., 2002). 
 
S4.43 51_Minor_pilin_of_type_IV_secretion_complex_VirB5 
 
Type IV secretion system proteins - T4SS 
VirB5 protein family - VirB5_like 
P-type DNA transfer protein - VirB5 
Leucine-rich repeats of kinetochore protein Cenp-F/LEK1 - CENP-F_leu_zip 
Flagellin and related hook-associated protein - FlgL 
pfam07996 
cd14262 
TIGR02791 
pfam10473 
COG1344 
289-891 
370-891 
217-891 
676-918 
625-885 
5.48e-30 
9.30e-10 
7.73e-09 
1.81e-03 
2.37e-03 
 
This hypothetical protein is associated with several VirB5-like conserved 
domains. VirB5 is required for the assembly of the Type IV secretion system 
extracellular pilus. It was shown to be involved in protein-protein interaction with 
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VirB2, and coiled-coiled motifs that could explain this interaction are identified in the 
protein sequence (Yeo et al., 2003; Christie, 2004). 
 
S4.44 52_VirB6 
 
TrbL/VirB6 plasmid conjugal transfer protein 
Type IV secretory pathway - VirB6 
Transmembrane subunit (TM) found in Periplasmic Binding Protein - TM_PBP2 
P-type conjugative transfer protein - TrbL_P 
type IV secretion system protein VirB6 - PRK13852 
Permease of the drug/metabolite transporter (DMT) superfamily - RhaT 
NADH:ubiquinone oxidoreductase subunit M - PRK05846 
Tripartite ATP-independent periplasmic transporter - DctM 
Na+/H+ antiporter - NhaC 
pfam04610 
COG3704 
cd06261 
TIGR02783 
PRK13852 
COG0697 
112-753 
1-960 
391-720 
97-945 
316-741 
355-825 
1.14e-49 
1.63e-12 
3.72e-06 
4.13e-06 
7.71e-06 
3.08e-05 
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PRK05846 
pfam06808 
COG1757 
493-819 
376-813 
94-513 
6.14e-05 
7.11e-05 
8.00e-03 
 
The conserved domains in this protein sequence are associated with the 
TrbL/VirB6 protein of the Type IV secretion system (Hapfelmeier et al., 2000). 
 
S4.45 53_DNA_topoisomerase_III_28828-31020_00-0949_pTet 
 
DNA Topoisomerase, subtype IA - TOP1Ac 
Bacterial DNA topoisomerase I DNA-binding domain - TOP1Ac 
Topoisomerase-primase domain - TOPRIM_TopoIA_TopoIII 
Toprim domain 
Topoisomerase DNA binding C4 zinc finger - zf-C4_Topoisom 
Borrelia ORF-A 
DNA topoisomerase III - PRK07727 
DNA topoisomerase III - TopB 
DNA topoisomerase IA - TopA 
DNA topoisomerase - Topoisom_bac 
ssDNA-binding Zn-finger and Zn-ribbon domains of topoisomerase 1 - YrdD 
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DNA topoisomerase I - PRK07219 
cd00186 
smart00437 
cd03362 
pfam01751 
pfam01396 
pfam02414 
PRK07727 
TIGR01056 
COG0550 
pfam01131 
COG0551 
PRK07219 
475-1812 
793-1686 
1-423 
4-402 
1882-1998 
1450-1881 
1-2067 
1-1983 
1-1872 
454-1794 
1843-2130 
1864-2124 
3.76e-86 
8.16e-54 
3.93e-46 
6.58e-07 
2.55e-06 
1.82e-04 
0e+00 
2.64e-173 
6.76e-151 
1.99e-111 
1.28e-10 
3.48e-05 
 
The conserved domains identified in this protein sequence are consistent with 
the automated annotation and they are related to a bacterial topoisomerase. 
Topoisomerases break the single or double stranded DNA and re-join the 
phosphodiester-backbone: these enzymes tune the supercoil state of DNA, 
facilitating interactions with other proteins (Champoux, 2001). 
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S4.46 54_FIG00470281_hypothetical_protein 
 
Outer membrane protein - OMP_w_GlyGly 
Opacity protein and related surface antigens - LomR 
Alkylphosphonate ABC transporter - PhnD 
TIGR04219 
COG3637 
TIGR03431 
7-174 
4-327 
1-123 
1.79e-03 
6.55e-03 
1.85e-03 
 
This hypothetical protein shows hits with conserved domain associated with 
membrane transport. Both OMP_w_GlyGly and LomR are part of a superfamily of 
porins (cl21487), which are non-specific channels for transport of various molecules, 
for instance hydrophilic molecules or various sugars (Nikaido, 2003). 
A further partial conserved domain is involved in the uptake of 
alkylphosphonate in E. coli (Chen et al., 1990). 
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S4.47 55_FIG00470802_hypothetical_protein 
 
aromatic cluster surface protein - aro_clust_Mycop 
Mitochondrial-encoded NADH-quinone oxidoreductase - MopB_Res-Cmplx1_Nad11-M 
Borrelia ORF-A 
Uncharacterized conserved protein - COG1479 
hypothetical protein - PHA03016 
hypothetical protein - PRK07143 
AAA ATPase domain - AAA_15 
Abortive phage infection protein - abortive_AbiA 
Transcriptional antiterminator - BglG 
TIGR04313 
cd02774 
pfam02414 
COG1479 
PHA03016 
PRK07143 
pfam13175 
TIGR04499 
COG3711 
40-858 
31-939 
484-1128 
382-1122 
28-840 
94-918 
1-921 
28-858 
118-915 
1.35e-13 
1.21e-10 
1.29e-09 
2.26e-09 
1.74e-08 
1.09e-06 
4.12e-11 
8.62e-09 
1.84e-07 
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Several conserved domains identified in this hypothetical protein are 
uncharacterised or of unknown function: these include TIGR04313, pfam02414, 
COG1479, PHA03016 (Bawden et al., 2000). 
Other conserved domains are associated with a eukaryotic respiratory complex 
(Mitochondrial-encoded NADH-quinone oxidoreductase, Oudot et al., 1999), a 
protein for phage defence in Lactococcus lactis (Abortive phage infection protein, 
Tangney and Fitzgerald, 2002) and a transcriptional anti-terminator protein (Manival 
et al., 1997). 
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S4.48 56_FIG00470802_hypothetical_protein 
 
Adenine-specific DNA methylase - COG4646 
Adenine-specific DNA methylase - COG4646 
Methyltransferase domain - Methyltransf_26 
helicase superfamily c-terminal domain - HELICc 
Type III restriction enzyme - ResIII 
Helicase conserved C-terminal domain - Helicase_C 
DEAD-like helicases superfamily - DEXDc 
Helicase superfamily c-terminal domain, DEXDc-, DEAD-, and DEAH-box proteins - HELICc 
Borrelia ORF-A - Borrelia_orfA 
putative methyltransferase - PHA03412 
Superfamily II DNA or RNA helicase, SNF2 family - HepA 
Type I restriction-modification system, DNA methylase subunit - HsdM 
N-6 DNA Methylase; Restriction-modification (R-M) systems - N6_Mtase 
SNF2 family N-terminal domain - SNF2_N 
DEAD-like helicases superfamily - DEXDc 
helix-rich Mycoplasma protein - Mplasa_alph_rch 
Glucosyl transferase GtrII - B3:C24 PTZ00440 
type I restriction system adenine methylase (hsdM) - HsdM 
chromosome segregation protein - PRK01156 
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Probable chromatin-re-modeling complex ATPase chain - PLN03142 
Chromosome segregation ATPase - Smc 
AAA ATPase domain - AAA_15 
EpsG family - EpsG 
Glucosyl transferase GtrII - Glucos_trans_IIB2B1:C24B24B3:C24 
COG4646 
COG4646 
pfam13659 
smart00490 
pfam04851 
pfam00271 
cd00046 
cd00079 
pfam02414 
PHA03412 
COG0553 
COG0286 
pfam02384 
pfam00176 
smart00487 
TIGR04523 
PTZ00440 
TIGR00497 
PRK01156 
PLN03142 
1528-3168 
3592-4209 
937-1269 
4498-4752 
2995-3312 
4498-4752 
3049-3723 
4402-4758 
5068-5784 
838-1167 
2041-4887 
784-1494 
853-1494 
3013-3894 
2998-3732 
5026-5784 
91-2343 
757-1419 
4378-5790 
3553-3834 
1.15e-74 
5.07e-44 
1.01e-17 
1.13e-07 
1.32e-06 
2.97e-06 
3.69e-04 
1.03e-03 
1.90e-03 
8.87e-03 
8.16e-13 
5.77e-15 
4.53e-13 
9.04e-12 
4.04e-11 
3.27e-08 
3.51e-06 
8.63e-06 
1.89e-05 
2.97e-04 
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COG1196 
pfam13175 
pfam14897 
pfam14264 
4870-5796 
1846-2538 
5017-5799 
94-828 
8.73e-04 
1.31e-03 
6.00e-07 
2.40e-05 
 
This is the largest predicted hypothetical protein. In total, 24 conserved 
domains are predicted. The lowest E-values are identified in three domains 
associated with an adenine-specific methyl transferase domain, involved in DNA 
protection and repair (Zhang-Akiyama et al., 2009). 
Furthermore, a group of Helicase-associated conserved domains is 
characterised by an E-value between 1.0e-13 and 1.0e-15. This class of proteins is 
associated with the unwinding of supercoiled DNA in order to regulate transcription 
and replication (Muzzin et al., 1998). 
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S4.49 57_FIG00469861_hypothetical_protein 
 
Borrelia ORF-A - Borrelia_orfA 
AAA ATPase domain - AAA_15 
helix-rich Mycoplasma protein - Mplasa_alph_rch 
pfam02414 
pfam13175 
TIGR04523 
4-399 
7-648 
145-570 
1.96E-03 
1.69E-04 
9.48E-04 
 
This hypothetical protein is associated with an uncharacterised domain found in 
plasmid DNA of the spirochete Borrelia (Zückert and Meyer, 1996). 
Other multi-domains family are associated with an ATPase domain and an 
alpha-helix rich uncharacterised domain. 
 
S4.50 58_FIG00471069_hypothetical_protein 
 
CRISPR/Cas system-associated protein Csx1 - Csx1_III-U 
DOmain of unknown function - DUF4883 
cd09728 
pfam16224 
1-177 
31-201 
2.64E-03 
7.03E-03 
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Two domains of different functions are identified in this hypothetical protein: a 
CRISPR/Cas system domain, and a domain of unknown function belonging to the 
superfamily YycH_N_like. This superfamily includes the membrane signal 
transductor of a two component system YycG-YycC in several bacteria, including S. 
aureus (Makarova et al., 2006 (2); Türck and Bierbaum, 2012). 
 
S4.51 59_aminoglycoside_3_phosphotransferase_aph3_HypA 
 
Aminoglycoside 3'-phosphotransferase and Choline Kinase family - APH_ChoK_like 
Predicted kinase, aminoglycoside phosphotransferase (APT) family - YcbJ 
Phosphotransferase enzyme family - APH 
Ser/Thr protein kinase RdoA involved in Cpx stress response - SrkA 
cd05120 
COG3173 
pfam01636 
COG2334 
64-711 
76-705 
76-714 
40-702 
1.15E-25 
4.95E-10 
1.29E-22 
1.49E-09 
 
This putative protein is associated with an aminoglycoside phosphotransferase 
function. The enzyme catalyses the transfer of a phosphate group to a small 
molecule such as an antibiotic belonging to the aminoglycoside or macrolide class in 
order to inactivate it. This protein may also catalyse the transfer of a phosphate 
group to other small molecules, such as choline, ethanolamine, and homoserine, 
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which function as precursors for the synthesis of several biological compounds, like 
phospholipids or amino acids (Kim and Mobashery, 2005). 
 
S4.52 60_hypothetical_protein 
 
Hydrogenase/urease nickel incorporation, metallochaperone - HypA 
Hydrogenase maturation metallochaperone HypA/HybF - HybF 
DNA replicative helicase MCM subunit Mcm2 - Mcm2 
anaerobic ribonucleoside triphosphate reductase - PRK09263 
pfam01155 
COG0375 
COG1241 
PRK09263 
70-153 
70-174 
70-177 
76-171 
3.44E-04 
3.86E-03 
6.19E-04 
1.86E-03 
 
A domain for the incorporation of nichel in Nichel-containing enzyme is 
identified in this protein. This type of protein was identified and described in H. pylori 
(Xia et al., 2009). 
Two further multi-domains are identified, involved with DNA interaction 
(helicase) and with NTP reduction. 
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S4.53 61_hypothetical_protein 
 
AAA domain - AAA_18 
Chloramphenicol (Cm) phosphotransferase (CPT) - CPT 
Cytidylate kinase [Nucleotide transport and metabolism] - CmkB 
AAA domain - AAA_33 
hypothetical protein; Provisional - PRK12338 
cytidylate kinase - cyt_kin_arch 
DNA polymerase III subunits gamma and tau - PRK14961 
pfam13238 
cd00227 
COG1102 
pfam13671 
PRK12338 
TIGR02173 
PRK14961 
46-405 
205-381 
46-534 
46-438 
46-384 
46-393 
16-93 
3.35E-11 
4.85E-03 
6.09E-04 
4.75E-06 
1.41E-03 
3.10E-03 
6.64E-03 
 
The lowest e-value score for this hypothetical protein is associated with an 
ATPase domain associated with a variety of cellular functions, from DNA replication 
to signal transduction and the regulation of gene expression (AAA_18) (Iyer et al., 
2004). 
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A partial conserved domain (CPT, cd00227) of the same superfamily (P-
loop_NTPase) is identified and is associated with resistance to chloramphenicol. 
(Izard, 2001). 
 
S4.54 62_hypothetical_protein 
 
TMPIT-like transmembrane protein 
helix-rich Mycoplasma protein - Mplasa_alph_rch 
Uncharacterized N-terminal domain of peptidoglycan hydrolase CwlO1 
pfam07851 
TIGR04523 
COG3883 
19-249 
10-663 
10-252 
5.76E-04 
1.96E-04 
3.52E-03 
 
The conserved domains associated with this hypothetical protein are 
associated with a membrane localisation but unknown function, and no literature in 
support. 
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S4.55 63_hypothetical_protein 
 
Helix-turn-helix XRE-family like proteins - HTH_XRE 
Helix-turn-helix XRE-family like proteins - HTH_XRE 
Helix-turn-helix - HTH_3 
DNA-binding transcriptional regulator - XRE 
Helix-turn-helix XRE-family like proteins - HTH_XRE 
Helix-turn-helix domain, DNA-binding helix-turn-helix domain - HTH_19 
Archaeal ribosome-binding protein aMBF1 
cd00093 
smart00530 
pfam01381 
COG1476 
cd00093 
pfam12844 
COG1813 
1-111 
1-90 
7-90 
4-90 
268-441 
268-456 
25-162 
6.56E-04 
8.42E-04 
1.63E-03 
2.35E-03 
4.72E-03 
7.53E-03 
3.02E-03 
 
In this hypothetical protei,n several DNA-protein interactions conserved 
domains are identified. The HTH_XRE domain is described as a DNA binding protein 
regulating gene expression in response to xenobiotic compounds (Wintjens and 
Rooman, 1996; Luscombe et al., 2000; Ren et al., 2010). 
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S4.56 64_antirepressor_partial 
 
Phage regulatory protein Rha - Phage_pRha 
phage regulatory protein, rha family [Mobile element, Prophage functions] - phage_pRha 
Phage regulatory protein Rha - pRha 
pfam09669 
TIGR02681 
COG3646 
70-351 
46-366 
31-366 
1.32E-34 
4.23E-24 
2.68E-25 
 
This hypothetical protein is associated with phage regulatory proteins. The 
protein pRha is a phage regulative protein. The presence of this gene interferes with 
infection of bacterial strains without integration host factor (IHF) (Henthorn and 
Friedman, 1995). 
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S4.57 65_peptidase_C15_partial 
 
pyrrolidone-carboxylate peptidase - PRK13197 
Pyrrolidone-carboxylate peptidase - Pcp 
Pyroglutamyl peptidase (PGP) type I, pyrrolidone carboxyl peptidase (pcp) type I - Peptidase_C15 
Pyroglutamyl peptidase - Peptidase_C15 
pyroglutamyl-peptidase I - pyro_pdase 
PRK13197 
COG2039 
cd00501 
pfam01470 
TIGR00504 
1-216 
1-216 
1-216 
1-216 
4-216 
6.35E-38 
1.17E-30 
1.22E-30 
3.46E-30 
8.48E-21 
The conserved domains identified in this protein are consistent with the 
automated annotation: a peptidase associated with the cleavage of C-terminal 
pyroglutamate. The role of this protein in the various species is not fully understood 
(Tanaka et al., 2001; Barrett et al., 2003; Cummins and O’Connor, 1998). 
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S4.58 66_hypothetical_protein 
 
RNA polymerase Rpb4 - RNA_pol_Rpb4 
helix-rich Mycoplasma protein - Mplasa_alph_rch 
reticulocyte binding protein 2-like protein - PTZ00440 
Rhoptry-associated protein 1 (RAP-1) - RAP1 
pfam03874 
TIGR04523 
PTZ00440 
pfam07218 
268-492 
19-639 
160-639 
268-609 
3.62E-05 
1.34E-05 
8.95E-04 
1.02E-03 
 
The partial conserved domain (RNA_pol_Rpb4) is identified in this hypothetical 
protein. It is associated with an essential subunit of the RNA polymerase III.  
Other partial multi-domains families are identified, including a Mycoplasma 
associated-helix rich domain, and two domains associated with immune response in 
mycoplasma (Todone et al., 2001; Sadhale and Woychik, 1994; Galinski et al., 
2000). 
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S4.59 68_TolA_protein 
 
Relaxase/Mobilization nuclease domain - Relaxase 
Sperm histone P2; substitute for histones in the chromatin of sperm - Protamine_P2 
ATP synthase archaeal, H subunit - AhaH 
TolA protein - tolA_full 
MAP7 (E-MAP-115) family; microtubule-stabilizing protein - MAP7 
MAEBL; Provisional - PTZ00121 
Membrane protein involved in colicin uptake [Cell wall/membrane/envelope biogenesis] - TolA 
pfam03432 
pfam00841 
TIGR02926 
TIGR02794 
pfam05672 
PTZ00121 
COG3064 
61-363 
406-642 
463-627 
247-609 
331-660 
331-606 
244-621 
4.10E-07 
2.56E-04 
3.21E-03 
3.81E-06 
7.92E-06 
3.42E-05 
8.51E-05 
 
This protein is annotated as a TolA protein, part of the Tol-Pal complex. It is 
required for maintaining outer membrane integrity and also involved in uptake of 
colicins and filamentous DNA, and implicated in pathogenesis. The TolA and 
tolA_full Multi-domains are identified in this protein, alongside other domains of 
different functions including mobilisation of DNA (pfam03432) and an ATP synthase 
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associated with archaeal organisms (TIGR02926) (Levengood and Webster, 1989; 
Derouiche et al., 1996; Meyer, 2000). 
 
S4.60 70_FIG00469626_hypothetical_protein 
 
Protein of unknown function - DUF1516 
Sugar transporter, SemiSWEET family [Carbohydrate transport and metabolism] - SWEET 
Eukaryotic cytochrome b(561) - Cyt_b561 
sporulation protein YqfD - spore_yqfD 
pfam07457 
COG4095 
cd08554 
TIGR02876 
10-126 
1-150 
10-129 
46-189 
2.55E-04 
4.81E-04 
5.60E-04 
8.06E-03 
 
In this hypothetical protein, three non-specific hits are identified: one of them is 
associated with a sucrose membrane transporter (SWEET), part of a PQ-loop 
superfamily (Xuan et al., 2013). 
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S4.61 72_DNA_topoisomerase_III_TraE_(EC_5.99.1.2) 
 
DNA topoisomerase I/SWI domain fusion protein - PRK06319 
PRK06319 43-123 2.32E-04 
 
This protein is annotated by the automatic pipeline as DNA topoisomerase III, 
and the conserved domain identified in it confirms this.  
 
S4.62 75_FIG00471024_hypothetical_protein 
 
Ras-GTPase Activating Domain of proteins similar to neurofibromin - RasGAP_Neurofibromin_like 
cd05392 25-405 6.91E-05 
 
The partial conserved domain identified in this protein is associated with 
eukaryotic organisms. Ras proteins have been described in yeast and human cells to 
activate the cAMP/protein kinase A (PKA) pathway, controlling metabolism, stress 
resistance, growth, and meiosis (Harrisingh and Lloyd, 2004). 
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S4.63 76_hypothetical_protein 
 
CRISPR/Cas system endoribonuclease Cas6 
COG1583 34-126 8.62E-03 
 
This small hypothetical protein shows the presence of a CRISPR/Cas system 
conserved domain belonging to the Cas6 superfamily. As described in other 
hypothetical proteins, CRISPR/Cas systems are associated with defence from phage 
infection in bacteria (Makarova et al., 2006 (2), Haft et al., 2005). 
 
S4.64 77_FIG00472625_hypothetical_protein 
 
LabA_like proteins 
NYN domain 
Uncharacterized conserved; LabA/DUF88 family [Function unknown] - LabA 
cd06167 
pfam01936 
COG1432 
52-684 
385-627 
304-639 
6.40E-20 
2.09E-08 
2.72E-10 
 
The LabA domain found in the hypothetical protein encoded by this gene has 
no defined function but it is well conserved in all kingdoms of life. In cyanobacteria, it 
is required to regulate the circadian clock system via negative feedback of an 
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autokinase (KaiC). In Pseudomonas putida a protein falling in the “LabA family” is 
involved in the bacterial degradation of nicotine. The hypothetical protein also 
exhibits a putative metal binding site, structurally similar to proteins like YrbI 
phosphatase from Haemophilus influenzae (Taniguchi et al., 2007; Taniguchi et al., 
2010; Tang et al., 2008; Parsons et al., 2002). 
 
S4.65 79_pK2_Serinethreonine_protein_kinase_PrkC2C_regulator_of
_stationary_phase 
 
Catalytic domain of Protein Kinases - PKc 
Kae1-associated kinase Bud32 - arch_bud32 
serine/threonine protein kinase - PRK14879 
tRNA A-37 threonylcarbamoyl transferase component Bud32 - Bud32 
Borrelia ORF-A 
Protein kinase domain - Pkinase 
Serine/Threonine protein kinases, catalytic domain - S_TKc 
Serine/threonine protein kinase [Signal transduction mechanisms] - SPS1 
cyclin-dependent protein kinase - PTZ00024 
helix-rich Mycoplasma protein - Mplasa_alph_rch 
Domain of unknown function; integral membrane proteins - DUF4271 
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cd00180 
TIGR03724 
PRK14879 
COG3642 
pfam02414 
pfam00069 
smart00220 
COG0515 
PTZ00024 
TIGR04523 
pfam14093 
472-1110 
469-885 
463-885 
463-885 
445-1161 
463-1164 
463-1047 
463-1113 
472-885 
493-1170 
382-990 
2.32E-46 
1.44E-10 
1.15E-09 
5.99E-06 
4.91E-05 
5.85E-34 
7.44E-36 
2.43E-30 
3.91E-17 
2.42E-06 
1.67E-07 
 
The conserved domains identified with a solid hit in this hypothetical protein are 
associated with a protein kinase function. Protein kinases in bacteria are often 
involved in signal transduction and response regulation (Kannan et al., 2007; 
Handford et al., 2009; Pérez et al., 2008). 
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